var title_f20_29_20944="Glove finger tourniquet";
var content_f20_29_20944=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85734&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85734&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Glove finger tourniquet",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 298px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_29_20944=[""].join("\n");
var outline_f20_29_20944=null;
var title_f20_29_20945="Patient information: Postconcussion syndrome (The Basics)";
var content_f20_29_20945=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?22/12/22722\">",
"         Patient information: Concussion (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/45/40658\">",
"         Patient information: Head injury in children and adolescents (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?3/31/3570\">",
"         Patient information: Headache (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?40/59/41905\">",
"         Patient information: Vertigo (a type of dizziness) (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Postconcussion syndrome (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/postconcussion-syndrome-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H13955529\">",
"      <span class=\"h1\">",
"       What is postconcussion syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Postconcussion syndrome is a condition that happens after a mild brain injury. A &ldquo;concussion&rdquo; is another word for a mild brain injury.",
"     </p>",
"     <p>",
"      Common causes of mild brain injuries include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Car accidents",
"       </li>",
"       <li>",
"        Falling down and other accidents that can happen from daily activities",
"       </li>",
"       <li>",
"        Injuries from playing sports such as football, ice hockey, soccer, and boxing",
"       </li>",
"       <li>",
"        Injuries that can happen to soldiers during combat. These include injuries from blasts and bullet wounds.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13955544\">",
"      <span class=\"h1\">",
"       What are the symptoms of postconcussion syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Headache",
"       </li>",
"       <li>",
"        Dizziness",
"       </li>",
"       <li>",
"        Feeling very tired",
"       </li>",
"       <li>",
"        Feeling irritable or anxious",
"       </li>",
"       <li>",
"        Memory problems or problems paying attention",
"       </li>",
"       <li>",
"        Problems with sleep",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Being easily bothered by noise",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13955559\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Maybe. Your doctor or nurse should be able to tell if you have postconcussion syndrome by learning about your symptoms and doing an exam.",
"     </p>",
"     <p>",
"      But depending on your symptoms, you might have tests to make sure you do not have a different problem. For example, some people have an imaging test called an MRI that creates pictures of the brain.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13955574\">",
"      <span class=\"h1\">",
"       How is postconcussion syndrome treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The treatments are different depending on which symptoms a person has. &nbsp;There are medicines that can help with headaches, dizziness, and other problems.",
"     </p>",
"     <p>",
"      If you have postconcussion syndrome, your symptoms will probably start to go away after about a week. Most people start to feel better in a week or 2 and are back to normal in 3 months. But a few people have symptoms that last longer.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13955589\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/12/22722?source=see_link\">",
"       Patient information: Concussion (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/45/40658?source=see_link\">",
"       Patient information: Head injury in children and adolescents (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/31/3570?source=see_link\">",
"       Patient information: Headache (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?40/59/41905?source=see_link\">",
"       Patient information: Vertigo (a type of dizziness) (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?20/29/20945?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 17132 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-F35B292492-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_29_20945=[""].join("\n");
var outline_f20_29_20945=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13955529\">",
"      What is postconcussion syndrome?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13955544\">",
"      What are the symptoms of postconcussion syndrome?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13955559\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13955574\">",
"      How is postconcussion syndrome treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13955589\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/12/22722?source=related_link\">",
"      Patient information: Concussion (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/45/40658?source=related_link\">",
"      Patient information: Head injury in children and adolescents (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/31/3570?source=related_link\">",
"      Patient information: Headache (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?40/59/41905?source=related_link\">",
"      Patient information: Vertigo (a type of dizziness) (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_29_20946="Patient information: Restless legs syndrome (The Basics)";
var content_f20_29_20946=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16243\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/24/32142\">",
"         How to stretch the backs of your legs",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?18/53/19281\">",
"         Patient information: Anemia caused by low iron (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?38/4/38978\">",
"         Patient information: Daytime sleepiness (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/58/22434\">",
"         Patient information: Insomnia (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/5/35921\">",
"         Patient information: What is a sleep study? (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?29/49/30484\">",
"         Patient information: Anemia caused by low iron (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?2/16/2306\">",
"         Patient information: Insomnia (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Restless legs syndrome (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/restless-legs-syndrome-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H32680993\">",
"      <span class=\"h1\">",
"       What is restless legs syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Restless legs syndrome (RLS) is a condition that causes strange sensations in your legs. If you have restless legs syndrome, you probably have the urge to kick or move your legs at night. This can wake you up or make it hard to sleep.",
"     </p>",
"     <p>",
"      In some cases, RLS happens on its own and seems to be passed on in families. In other cases, the condition seems to be linked to other medical problems. For instance, a condition called &ldquo;anemia,&rdquo; in which there is too little iron in the blood, seems to increase the risk of RLS. Other conditions that increase the risk of RLS include kidney disease, diabetes, and multiple sclerosis. Pregnancy seems to increase a woman's risk of developing RLS, too.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H32681000\">",
"      <span class=\"h1\">",
"       What are the symptoms of RLS?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People who have RLS get an uncomfortable feeling in their legs when they are at rest. They describe this feeling as crawling, creeping, pulling, or itching. And they say the feeling is deep in the legs&mdash;not on the skin&mdash;usually below the knees. These symptoms usually get worse as the day moves on, and they are worst at night. But people can make the feeling go away temporarily if they kick or move their legs. Some people with RLS find that their legs move on their own while they are asleep. &nbsp;",
"     </p>",
"     <p>",
"      In short, the symptoms:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Happen when you are at rest",
"       </li>",
"       <li>",
"        Go away if you move your legs on purpose",
"       </li>",
"       <li>",
"        Are worst at night",
"       </li>",
"       <li>",
"        Sometimes include the legs moving on their own during sleep",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Together, the symptoms of RLS can make it hard to get a good night&rsquo;s sleep. People with the condition often feel tired during the day.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H32681007\">",
"      <span class=\"h1\">",
"       Is there a test for RLS?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There is a test, but it is not usually necessary. Your doctor or nurse should be able to tell if you have it by asking about your symptoms and doing an exam. Still, it is possible that your doctor or nurse will decide to send you for a &ldquo;sleep study,&rdquo; to be sure of what is happening.",
"     </p>",
"     <p>",
"      For a sleep study, you spend the night in a lab, and you are hooked up to different machines that monitor your movements, heart rate, breathing, and other body functions.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H32681014\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. You might feel better if you:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Do activities that keep your mind alert during the day, such as crossword puzzles.",
"       </li>",
"       <li>",
"        Avoid caffeine, nicotine, and alcohol. These things seem to make RLS worse.",
"       </li>",
"       <li>",
"        Stretch your legs at night before you go to sleep (",
"        <a class=\"graphic graphic_picture graphicRef63450 \" href=\"UTD.htm?31/24/32142\">",
"         picture 1",
"        </a>",
"        ).",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H32681021\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;See your doctor or nurse if your condition bothers you, or if it keeps you from getting a good night&rsquo;s sleep.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H32681028\">",
"      <span class=\"h1\">",
"       How is RLS treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Some people with RLS do not need treatment because they have mild symptoms that don&rsquo;t bother them very often. If treatment is needed, there are several medicines doctors can suggest. Examples include iron supplements,",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?35/4/35908?source=see_link\">",
"       pramipexole",
"      </a>",
"      (brand name: Mirapex&reg;),",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?19/46/20196?source=see_link\">",
"       ropinirole",
"      </a>",
"      (brand name: Requip&reg;), and",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_patient\" href=\"UTD.htm?10/27/10676?source=see_link\">",
"        carbidopa",
"       </a>",
"       /levodopa",
"      </span>",
"      (brand name: Sinemet&reg;).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H32681035\">",
"      <span class=\"h1\">",
"       What if I am pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you are pregnant, you can take iron supplements and try the other tips that do not involve taking prescription medicines. Most of the medicines used to treat RLS are not safe to take during pregnancy. If your symptoms are bad, there are some medicines that might be OK to take. But keep in mind that the condition usually goes away toward the end of pregnancy. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H32681145\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/53/19281?source=see_link\">",
"       Patient information: Anemia caused by low iron (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/58/22434?source=see_link\">",
"       Patient information: Insomnia (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?38/4/38978?source=see_link\">",
"       Patient information: Daytime sleepiness (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/5/35921?source=see_link\">",
"       Patient information: What is a sleep study? (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/16/2306?source=see_link\">",
"       Patient information: Insomnia (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?29/49/30484?source=see_link\">",
"       Patient information: Anemia caused by low iron (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?20/29/20946?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16243 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-17F8E0A872-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_29_20946=[""].join("\n");
var outline_f20_29_20946=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32680993\">",
"      What is restless legs syndrome?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32681000\">",
"      What are the symptoms of RLS?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32681007\">",
"      Is there a test for RLS?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32681014\">",
"      Is there anything I can do on my own to feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32681021\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32681028\">",
"      How is RLS treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32681035\">",
"      What if I am pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32681145\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16243\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/24/32142\">",
"      How to stretch the backs of your legs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/49/30484?source=related_link\">",
"      Patient information: Anemia caused by low iron (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/53/19281?source=related_link\">",
"      Patient information: Anemia caused by low iron (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/4/38978?source=related_link\">",
"      Patient information: Daytime sleepiness (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/16/2306?source=related_link\">",
"      Patient information: Insomnia (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/58/22434?source=related_link\">",
"      Patient information: Insomnia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/5/35921?source=related_link\">",
"      Patient information: What is a sleep study? (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_29_20947="Cauliflower ear deformity from infected piercing";
var content_f20_29_20947=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F86320&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F86320&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cauliflower ear deformity from infected piercing of the fossa trangularis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 342px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn C Isaacson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_29_20947=[""].join("\n");
var outline_f20_29_20947=null;
var title_f20_29_20948="Carboprost tromethamine: Drug information";
var content_f20_29_20948=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Carboprost tromethamine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?40/24/41347?source=see_link\">",
"    see \"Carboprost tromethamine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F146277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Hemabate&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F146278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Hemabate&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F146296\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Abortifacient;",
"     </li>",
"     <li>",
"      Prostaglandin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F146280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Refractory postpartum uterine bleeding:",
"     </b>",
"     I.M.: Initial: 250 mcg; if needed, may repeat at 15- to 90-minute intervals; maximum total dose: 2 mg (8 doses)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Termination of pregnancy:",
"     </b>",
"     I.M.: 250 mcg, then 250 mcg at 1.5- to 3.5-hour intervals, depending on uterine response; a 500 mcg dose may be given if uterine response is not adequate after several 250 mcg doses; do not exceed 12 mg total dose or continuous administration for &gt;2 days",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F146281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15682502\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15682503\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F146266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [strength expressed as base]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hemabate&reg;: 250 mcg/mL (1 mL) [contains benzyl alcohol]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F146253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F146268\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer deep I.M.; rotate site if repeat injections are required. Do not inject I.V.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F146267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Termination of pregnancy during the second trimester between weeks 13 and 20 of gestation; treatment of refractory postpartum hemorrhage due to uterine atony",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F146294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Frequency not defined. Effects due to increased smooth muscle contractility are most common and are generally transient and reversible upon discontinuation of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Chest pain, flushing, hypertension, syncope, palpitation, tachycardia, tightness of chest",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, chills/shivering, dizziness, drowsiness, dystonia, faintness, headache, lethargy, lightheadedness, nervousness, sleep disturbance, temperature elevation (may be drug induced or due to postabortion endometritis), vasovagal syndrome, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Breast tenderness, dysmenorrhea-like pain, endometritis, hot flashes, thyroid storm",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Choking sensation, diarrhea (~",
"     <sup>",
"      2",
"     </sup>",
"     /",
"     <sub>",
"      3",
"     </sub>",
"     patients), dry throat, epigastric pain, gagging/retching, hematemesis, nausea (~",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      3",
"     </sub>",
"     patients), taste alteration, thirst, throat fullness, vomiting (~",
"     <sup>",
"      2",
"     </sup>",
"     /",
"     <sub>",
"      3",
"     </sub>",
"     patients), xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Perforated uterus, posterior cervical perforation, urinary tract infection, uterine bleeding (excessive), uterine rupture, uterine sacculation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Backache, leg cramps, muscular pain, paresthesia, torticollis, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, eye pain, eyelid twitching",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Asthma, cough, bronchospasm, dyspnea, epistaxis, hyperventilation, pulmonary edema, respiratory distress, upper respiratory tract infection, wheezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis, hiccups, retained placental fragment, septic shock",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F146270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to carboprost tromethamine or any component of the formulation; acute pelvic inflammatory disease; active cardiac, pulmonary, renal, or hepatic dysfunction",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F146257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fever: Transient fever may be observed with treatment and is believed to be due to carboprost&rsquo;s effect on hypothalamic thermoregulation; use caution to distinguish between fever induced by the drug and fever associated with postabortion endometritis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertension: Increased blood pressure may be observed with treatment; degree of hypertension observed is generally moderate and does not require treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anemia: Use with caution in patients with anemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Use with caution in patients with a history of asthma; therapy may cause transient bronchoconstriction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease, especially hypotension or hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Compromised uteri: Use oxytocic agents with caution in patients with compromised (scarred) uterus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment, especially jaundice.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizures: Use with caution in patients with a history of seizure disorder.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Antiemetic/antidiarrheals: Pretreatment or concomitant use of antiemetic and antidiarrheal agents is recommended to decrease incidence of GI side effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Potent oxytocic agent:",
"     <b>",
"      [U.S. Boxed Warning] Potent oxytocic agent; use with strict adherence to recommended dosing. Carboprost should be used only by medically-trained personnel in a hospital which can provide immediate intensive care and acute surgical facilities.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F146261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F146263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3198105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Teratogenic effects were not observed in animal reproduction studies. When used for termination of pregnancy, carboprost tromethamine is not considered feticidal, but is used to terminate pregnancy due to its ability to stimulate uterine contractions; use is not indicated if the fetus has reached a stage of viability",
"     <i>",
"      in utero",
"     </i>",
"     . Complete termination of pregnancy may not be induced in ~20% of cases and should therefore be completed in another way.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F146284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16117666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if carboprost tromethamine is excreted in breast milk.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Hemabate Intramuscular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mcg/mL (1 mL): $165.07",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F16117992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Termination of pregnancy: Confirmation of fetal death; cervical exam after termination of pregnancy",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F146271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Hemabate (CL, GB, SG, TW);",
"     </li>",
"     <li>",
"      Prostin 15m (BE, BG, CZ, HN, NL, NZ);",
"     </li>",
"     <li>",
"      Prostin/15M (HR, LU);",
"     </li>",
"     <li>",
"      Prostinfenem (DK, NO, SE);",
"     </li>",
"     <li>",
"      Prostodin (IN)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F146256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Carboprost tromethamine is a tromethamine salt analog of naturally occurring prostaglandin F",
"     <sub>",
"      2",
"     </sub>",
"     alpha (dinoprost) except for the addition of a methyl group at the C-15 position. This substitution produces longer duration of activity than dinoprost; carboprost stimulates uterine contractility which usually results in expulsion of the products of conception and is used to induce abortion between 13-20 weeks of pregnancy. When used postpartum, hemostasis at the placentation site is achieved through the myometrial contractions produced by carboprost.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F2929990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: I.M.: 30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Ippoliti C, Przepiorka D, Mehra R, et al, &ldquo;Intravesicular Carboprost for the Treatment of Hemorrhagic Cystitis After Marrow Transplantation,&rdquo;",
"      <i>",
"       Urology",
"      </i>",
"      , 1995, 46(6):811-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/29/20948/abstract-text/7502421/pubmed\" id=\"7502421\" target=\"_blank\">",
"        7502421",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levine LA and Jarrard DF, &ldquo;Treatment of Cyclophosphamide-Induced Hemorrhagic Cystitis With Intravesical Carboprost Tromethamine,&rdquo;",
"      <i>",
"       J Urol",
"      </i>",
"      , 1993, 149(4):719-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/29/20948/abstract-text/8455230/pubmed\" id=\"8455230\" target=\"_blank\">",
"        8455230",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      West NJ, &ldquo;Prevention and Treatment of Hemorrhagic Cystitis,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1997, 17(4):696-706.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/29/20948/abstract-text/9250547/pubmed\" id=\"9250547\" target=\"_blank\">",
"        9250547",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9203 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-08BE826B45-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_29_20948=[""].join("\n");
var outline_f20_29_20948=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708653\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146277\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146278\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146296\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146280\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146281\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682502\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682503\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146266\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146253\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146268\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146267\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146294\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146270\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146257\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298974\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146261\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146263\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3198105\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146284\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16117666\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323042\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16117992\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146271\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146256\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2929990\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9203\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9203|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/24/41347?source=related_link\">",
"      Carboprost tromethamine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_29_20949="Tiagabine: Patient drug information";
var content_f20_29_20949=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Tiagabine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/22/26982?source=see_link\">",
"     see \"Tiagabine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/40/39558?source=see_link\">",
"     see \"Tiagabine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F227535\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Gabitril&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10017269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10017271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691482",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or control seizures.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10017270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703028",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to tiagabine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10017275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696966",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow laws about driving with a seizure problem.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have an eye exam every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696900",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take St John's wort with this drug. This drug may not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10017276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698011",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble moving around.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698166",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       More hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shakiness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698230",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may rarely cause seizures in patients who do not have them.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10017278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698512",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If seizures are worse or not the same after starting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If the drug is being used to treat something other than seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699084",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight or in the way you see color.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10017273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10017274\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10017279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10017280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11279 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.69.132.100-7288C09AE7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_29_20949=[""].join("\n");
var outline_f20_29_20949=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227535\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017269\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017271\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017270\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017275\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017276\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017278\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017273\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017274\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017279\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017280\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/22/26982?source=related_link\">",
"      Tiagabine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/40/39558?source=related_link\">",
"      Tiagabine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_29_20950="Hyphae candida albicans";
var content_f20_29_20950=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F79879%7EPC%2F50344&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F79879%7EPC%2F50344&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Candida albicans",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 423px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hyphae of",
"    <em>",
"     Candida albicans",
"    </em>",
"    seen on KOH prep with light microscopy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Eva Rawlings Parker, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Candida albicans",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 327px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Candida albicans on a culture plate.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Eva Rawlings Parker, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_29_20950=[""].join("\n");
var outline_f20_29_20950=null;
var title_f20_29_20951="Sexual dysfunction in uremic men";
var content_f20_29_20951=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Sexual dysfunction in uremic men",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/29/20951/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/29/20951/contributors\">",
"     Biff F Palmer, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/29/20951/contributors\">",
"     William L Henrich, MD, MACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/29/20951/contributors\">",
"     Peter J Snyder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/29/20951/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/29/20951/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/29/20951/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/29/20951/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/29/20951/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disturbances in sexual function are a common feature of chronic renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20951/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Over 50 percent of uremic men complain of symptoms that include erectile dysfunction, decreased libido, and marked declines in the frequency of intercourse [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20951/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. These problems may improve but rarely normalize with the institution of maintenance dialysis, commonly resulting in a decreased quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20951/abstract/2,3,5\">",
"     2,3,5",
"    </a>",
"    ]. By comparison, a well-functioning renal transplant is much more likely to restore sexual activity; however, some features of reproductive function may remain impaired, particularly reduced libido and erectile dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20951/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sexual dysfunction in uremia is primarily organic in nature, as demonstrated by abnormal nocturnal penile tumescence [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20951/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/44/42696?source=see_link\">",
"     \"Overview of male sexual dysfunction\"",
"    </a>",
"    .) It is presumed that the uremic milieu plays an important role in the genesis of this problem. Other organic (and not necessarily uremic) factors that may contribute to erectile dysfunction include peripheral neuropathy, autonomic dysfunction, peripheral vascular disease, and pharmacologic therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     STRESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychologic and physical stresses that may contribute to disturbances in sexual function are also commonly present in patients with chronic renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20951/abstract/2,6-8\">",
"     2,6-8",
"    </a>",
"    ]. One study surveyed a randomly selected group of 68 patients treated with chronic peritoneal dialysis about their actual and desired level of sexual function [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20951/abstract/7\">",
"     7",
"    </a>",
"    ]. The following results were obtained:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      63 percent reported never having intercourse.",
"     </li>",
"     <li>",
"      19 percent had intercourse less than or equal to two times per month.",
"     </li>",
"     <li>",
"      18 percent had intercourse more than two times per month.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There was no difference among the three groups with respect to age, the amount of dialysis received, or the serum albumin concentration. Standard psychologic questionnaires indicated that the patients who never had intercourse were more depressed and anxious, and assessed their overall quality of life at a level that was significantly lower than that of the other two groups. Similar observations have been made in patients on maintenance hemodialysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     HYPOTHALAMIC-PITUITARY-TESTICULAR FUNCTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Spermatogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic renal failure is associated with impaired spermatogenesis and testicular damage, often leading to infertility [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20951/abstract/2,9\">",
"     2,9",
"    </a>",
"    ]. Semen analysis typically shows a decreased volume of ejaculate, oligo- or complete azoospermia, and a low percentage of motile sperm. Testicular histology shows decreased spermatogenic activity varying from reduced numbers of mature spermatocytes to complete aplasia of germinal elements. Other findings include damage to the seminiferous tubules, atrophy of Sertoli cells, and interstitial fibrosis and calcifications.",
"   </p>",
"   <p>",
"    The factors responsible for testicular damage in uremia are not well understood. It is possible that plasticizers in dialysis tubing, such as phthalate, may play a role in patients undergoing maintenance hemodialysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Testosterone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uremia also impairs gonadal steroidogenesis. The serum total and free testosterone concentrations are typically reduced, although the binding capacity and concentration of sex hormone-binding globulin are normal [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20951/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. Low serum testosterone levels are associated with increased mortality in dialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20951/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another manifestation of diminished testosterone secretory capacity is the subnormal and delayed testosterone response to the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/60/26564?source=see_link\">",
"     human chorionic gonadotropin",
"    </a>",
"    (HCG), a compound with luteinizing hormone-like actions [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20951/abstract/14\">",
"     14",
"    </a>",
"    ]. By comparison, although the total plasma estrogen concentration is frequently elevated, the serum estradiol concentration is typically normal [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20951/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Gonadotropins",
"    </span>",
"    &nbsp;&mdash;&nbsp;The serum concentration of luteinizing hormone (LH) is elevated in uremic men [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20951/abstract/12\">",
"     12",
"    </a>",
"    ]; this is due to diminished testosterone feedback.",
"   </p>",
"   <p>",
"    Follicle stimulating hormone (FSH) secretion is also elevated, although to a more variable degree [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20951/abstract/2,9\">",
"     2,9",
"    </a>",
"    ]. Elevated FSH levels are probably the result of decreased testosterone and inhibin, a Sertoli cell product. The plasma FSH concentration tends to be highest in those uremic patients with the most severe damage to seminiferous tubules and presumably the lowest levels of inhibin. It has been suggested that increased FSH levels may portend a poor prognosis for recovery of spermatogenic function after renal transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Gonadotropin reserve",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gonadotropin reserve is generally intact. The acute infusion of gonadotropin-releasing hormone (GnRH) increases the serum LH concentration to the same degree as in normals, but the peak value and return to baseline may be delayed [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20951/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Since the kidney contributes importantly to the clearance of GnRH and LH, decreased metabolism of these hormones may explain the observed variations. The appropriate increases in FSH and LH in response to the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20951/abstract/12\">",
"     12",
"    </a>",
"    ] also indicate a normal gonadotropin reserve.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Prolactin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevated plasma prolactin concentrations are found in the majority of dialyzed men [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20951/abstract/17\">",
"     17",
"    </a>",
"    ], due to a three-fold increase in prolactin production. The metabolic clearance rate of prolactin is also decreased, but only by 33 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20951/abstract/18\">",
"     18",
"    </a>",
"    ]. In addition, the control of prolactin is abnormal. As an example, dopamine infusion or the administration of oral L-dopa fails to decrease basal prolactin levels. On the other hand, procedures which normally increase prolactin secretion &mdash; such as arginine infusion, insulin-induced hypoglycemia, or thyrotropin-releasing hormone infusion &mdash; elicit no or only a blunted response [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20951/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical significance of enhanced prolactin release in uremic men is incompletely understood. In men who have normal renal function, hyperprolactinemia tends to cause a decrease in LH and consequently in testosterone, independently causing impotence. In men with renal failure, however, LH is higher than normal. When",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/40/8840?source=see_link\">",
"     bromocriptine",
"    </a>",
"    is administered to men with renal failure, it lowers prolactin levels to near normal, but the effect on libido and potency is inconsistent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20951/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]; the incidence of side effects, particularly hypotension, is high [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20951/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Gynecomastia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gynecomastia occurs in approximately 30 percent of men on maintenance hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20951/abstract/23\">",
"     23",
"    </a>",
"    ]. This problem most often develops during the initial months of dialysis and then tends to regress as dialysis continues. The pathogenesis of gynecomastia in this setting is unclear. Although elevated prolactin levels and an increased estrogen-to-androgen ratio seem attractive possibilities, most data fail to support a primary role for abnormal hormonal function [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20951/abstract/24\">",
"     24",
"    </a>",
"    ]. Alternatively, a mechanism similar to that responsible for gynecomastia following refeeding of malnourished patients may be involved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thorough history and physical examination are essential first steps in the evaluation of the uremic male with sexual dysfunction. The principal complaint is impotence, which occurs in approximately 80 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20951/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Among such individuals, the following findings may suggest a particular cause:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a history of normal erectile function prior to the onset of renal disease may have a secondary cause, such as a neuropathy or peripheral vascular disease. The presence of a neurogenic bladder suggests an underlying neuropathy, while findings of peripheral vascular disease point toward inadequate penile blood flow.",
"     </li>",
"     <li>",
"      The lack of secondary sexual characteristics combined with small soft testicles suggests hypogonadism.",
"     </li>",
"     <li>",
"      The ingestion of a number of medications, such as beta blockers and tricyclic antidepressants, may be a cause of erectile dysfunction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among those without an obvious cause of impotence after an initial evaluation, consideration should be given to a psychologic difficulty, such as stress (as above) or depression. The administration of a nocturnal penile tumescence test may help distinguish between an organic and a psychologic disorder; the absence of an erection during sleep suggests underlying organic dysfunction. A positive test, however, does not exclude a physical cause. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32533?source=see_link\">",
"     \"Evaluation of male sexual dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many different tests may be performed to help discriminate between a neurogenic or vascular cause; however, such examinations are now principally performed in men who do not respond to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    (see below) and who may therefore be considered for a penile prosthesis. As previously mentioned, the measurement of serum luteinizing hormone, follicle stimulating hormone, testosterone, and prolactin may also be helpful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of uremic men with sexual dysfunction begins by maximizing the delivered dose of dialysis, discontinuing culprit medications (if possible), and correcting the anemia of chronic renal disease. As an example, the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/48/2825?source=see_link\">",
"     recombinant human erythropoietin",
"    </a>",
"    to raise the hematocrit to 33 to 36 percent may enhance sexual function [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20951/abstract/27\">",
"     27",
"    </a>",
"    ]. It is likely that the associated improvement in well-being probably plays an important role in this response (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33496?source=see_link\">",
"     \"Erythropoietin for the anemia of chronic kidney disease among predialysis and peritoneal dialysis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5626?source=see_link\">",
"     \"Erythropoietin for the anemia of chronic kidney disease in hemodialysis patients\"",
"    </a>",
"    ), but there is also evidence of normalization of the pituitary gonadal feedback mechanism: testosterone levels are increased, along with reductions toward normal in the serum concentrations of LH, FSH, and prolactin [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20951/abstract/28-30\">",
"     28-30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subsequent treatment is based upon findings from the history, physical examination, and possibly laboratory studies (",
"    <a class=\"graphic graphic_algorithm graphicRef74246 \" href=\"UTD.htm?19/28/19919\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Phosphodiesterase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     Sildenafil",
"    </a>",
"    , a phosphodiesterase inhibitor, is effective therapy for erectile dysfunction in both hemodialysis and peritoneal dialysis patients (as well as kidney transplant patients) and is often used as first-line therapy for psychologic, vascular, or neurogenic causes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20951/abstract/25,31-38\">",
"     25,31-38",
"    </a>",
"    ]. As an example, a systematic review of five trials that included 181 patients found that, compared with placebo, phosphodiesterase-5 inhibitors significantly improved erectile function in patients with chronic kidney disease [48]. In the largest placebo-controlled study in hemodialysis patients, sildenafil was highly effective (85 versus 9.5 percent improvement for placebo) and well tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20951/abstract/34\">",
"     34",
"    </a>",
"    ]. However, a large number of individuals were excluded from this study, including those older than 70 years of age or taking nitrates,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    patients with cirrhosis, diabetes, angina, severe anemia, a recent stroke or myocardial infarction, or an anatomically abnormal penis. Furthermore, in a study examining the pharmacokinetics of sildenafil, the drug was not cleared by hemodialysis. In addition, intradialytic hypotension did not occur when a single 50 mg dose was given to 15 men prior to hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20951/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other phosphodiesterase inhibitors are available for clinical use but have not been adequately studied in patients undergoing renal replacement therapy.",
"   </p>",
"   <p>",
"    To limit the possibility of hypotension among hemodialysis patients, some clinicians recommend the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    on non-dialysis days [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20951/abstract/39\">",
"     39",
"    </a>",
"    ], although (as previously mentioned) one small study found that sildenafil did not promote intradialytic hypotension [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20951/abstract/35\">",
"     35",
"    </a>",
"    ]. Concurrent use of sildenafil and nitrates in any form, regularly or intermittently, is contraindicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30282?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of male sexual dysfunction\", section on 'Sildenafil'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/15/8442?source=see_link&amp;anchor=H18#H18\">",
"     \"Sexual activity in patients with heart disease\", section on 'Sildenafil'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Psychotherapy and/or psychoactive medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among those with normal nocturnal penile tumescence testing, a psychologic cause should be investigated and, if found, psychotherapy may be warranted. The effectiveness of such therapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    antidepressant medications in uremic men is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Dopamine agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/40/8840?source=see_link\">",
"     Bromocriptine",
"    </a>",
"    has shown some efficacy in improving sexual function in men with increased serum prolactin. However, its usefulness has been limited in some but not all studies by a relatively high frequency of side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20951/abstract/22,40,41\">",
"     22,40,41",
"    </a>",
"    ]. Thus,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7206?source=see_link\">",
"     cabergoline",
"    </a>",
"    , which causes nausea much less often than does bromocriptine and is at least as effective in treating hyperprolactinemia, should therefore be tried first. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31561?source=see_link\">",
"     \"Treatment of hyperprolactinemia due to lactotroph adenoma and other causes\"",
"    </a>",
"    .) Other dopaminergic agonists, such as lisuride, also seem to be better tolerated than bromocriptine but have only been used in small, short-term studies [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20951/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Testosterone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Correcting the deficit in circulating testosterone levels generally results in clinical improvement in other forms of gonadal failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1545?source=see_link\">",
"     \"Testosterone treatment of male hypogonadism\"",
"    </a>",
"    .) By contrast, the administration of testosterone to uremic men usually fails to restore libido or potency, despite normalized serum testosterone and reduced release of LH and FSH [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20951/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. Nevertheless, a trial of testosterone therapy may be performed in the patient with low serum testosterone who is primarily suffering from decreased libido.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Vacuum tumescence device",
"    </span>",
"    &nbsp;&mdash;&nbsp;A vacuum tumescence device may be effective in restoring potency in uremic impotent males unresponsive to medical therapy. In a review of the experience of one renal impotence clinic, vacuum tumescence devices were utilized in 26 impotent patients, all of whom had a normal pituitary-gonadal axis or hypogonadism corrected with testosterone replacement [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20951/abstract/46\">",
"     46",
"    </a>",
"    ]. The device completely corrected penile dysfunction in 19 individuals (73 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Alprostadil",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraurethral administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40966?source=see_link\">",
"     alprostadil",
"    </a>",
"    (prostaglandin E1, MUSE) provides the delivery of prostaglandin to the corpus cavernosum, resulting in an erection sufficient for intercourse [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20951/abstract/47\">",
"     47",
"    </a>",
"    ]. It is supplied in an applicator that is inserted in the urethra. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30282?source=see_link\">",
"     \"Treatment of male sexual dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40966?source=see_link\">",
"     Alprostadil",
"    </a>",
"    can also be injected into the penis shaft, resulting in vasodilatation and inhibition of platelet aggregation. The major side effects of intrapenile alprostadil therapy are penile pain, priapism, and bleeding. Given the presence of platelet dysfunction with uremia, intracavernosal injections should be used with",
"    <strong>",
"     caution",
"    </strong>",
"    in patients with end-stage renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20951/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Zinc",
"    </span>",
"    &nbsp;&mdash;&nbsp;Zinc deficiency has also been suggested as a cause of gonadal failure. Uremic patients are often deficient in zinc, probably due to reduced dietary intake, zinc malabsorption,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    possible leaching of zinc by dialysis equipment. In a controlled trial, supplemental zinc resulted in significant increases in the plasma testosterone concentration and sperm counts, as well as significant declines in LH and FSH levels as compared to a control group [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20951/abstract/48\">",
"     48",
"    </a>",
"    ]. Potency, libido, and frequency of intercourse also improved in patients given zinc. Thus, the aggregate data suggest that the administration of zinc in a zinc-deficient man is a reasonable therapeutic option.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Renal transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although reproductive function remains poor with maintenance hemodialysis, it appears to improve in men with a well-functioning renal transplant. This improvement occurs in association with normalization of the serum testosterone concentration and, in many patients, an increase in sperm count [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20951/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H645172\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Disturbances in sexual function are a common feature of chronic kidney disease. Over 50 percent of uremic men complain of symptoms that include erectile dysfunction, decreased libido, and marked declines in the frequency of intercourse. These problems may improve but rarely normalize with the institution of maintenance dialysis. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chronic kidney disease is associated with impaired spermatogenesis, decreases in testosterone concentrations and increases in serum luteinizing hormone (LH), follicle stimulating hormone (FSH) and prolactin levels. The gonadotropin reserve is generally intact. Gynecomastia occurs in approximately 30 percent of men on maintenance hemodialysis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Hypothalamic-pituitary-testicular function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The principal complaint of the uremic male with sexual dysfunction is usually impotence. Specific causes may be suggested by the history or physical. Among those without an obvious cause of impotence after an initial evaluation, consideration should be given to a psychologic difficulty, such as stress or depression. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of uremic men with sexual dysfunction includes maximizing the delivered dose of dialysis, discontinuing culprit medications (if possible), and correcting the anemia of chronic renal disease.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"       Sildenafil",
"      </a>",
"      may be effective for erectile dysfunction and is often used as first-line therapy for psychologic, vascular, or neurogenic causes.",
"      <br/>",
"      <br/>",
"      To limit the possibility of hypotension among hemodialysis patients, some clinicians recommend the use of sildenafil on non-dialysis days. Concurrent use of sildenafil and nitrates in any form, regularly or intermittently, is contraindicated. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Phosphodiesterase inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other interventions that may be effective include pharmacologically treating the hyperprolactinemia and correcting the deficit in circulating testosterone levels. A vacuum tumescence device or administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40966?source=see_link\">",
"       alprostadil",
"      </a>",
"      (prostaglandin E1, MUSE) may be effective in selected patients. The administration of zinc may treat gonadal failure and improve potency and libido and is a reasonable therapeutic option. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Dopamine agonists'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Testosterone'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Vacuum tumescence device'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Alprostadil'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Zinc'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Reproductive function improves in men with a well-functioning renal transplant in association with normalization of the serum testosterone concentration and an increase in sperm count. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Renal transplantation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20951/abstract/1\">",
"      Palmer, BF. Sexual dysfunction in men and women with chronic kidney disease and end-stage kidney disease. Adv Renal Rep Therapy; 2003; 10:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20951/abstract/2\">",
"      Holdsworth SR, de Kretser DM, Atkins RC. A comparison of hemodialysis and transplantation in reversing the uremic disturbance of male reproductive function. Clin Nephrol 1978; 10:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20951/abstract/3\">",
"      Diemont WL, Vruggink PA, Meuleman EJ, et al. Sexual dysfunction after renal replacement therapy. Am J Kidney Dis 2000; 35:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20951/abstract/4\">",
"      Finkelstein FO, Shirani S, Wuerth D, Finkelstein SH. Therapy Insight: sexual dysfunction in patients with chronic kidney disease. Nat Clin Pract Nephrol 2007; 3:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20951/abstract/5\">",
"      Rosas SE, Joffe M, Franklin E, et al. Association of decreased quality of life and erectile dysfunction in hemodialysis patients. Kidney Int 2003; 64:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20951/abstract/6\">",
"      Charney, D, Walton, D, Cheung, A. Impotence: II. Semin Dial 1994; 7:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20951/abstract/7\">",
"      Steele TE, Wuerth D, Finkelstein S, et al. Sexual experience of the chronic peritoneal dialysis patient. J Am Soc Nephrol 1996; 7:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20951/abstract/8\">",
"      Toorians AW, Janssen E, Laan E, et al. Chronic renal failure and sexual functioning: clinical status versus objectively assessed sexual response. Nephrol Dial Transplant 1997; 12:2654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20951/abstract/9\">",
"      Holdsworth S, Atkins RC, de Kretser DM. The pituitary-testicular axis in men with chronic renal failure. N Engl J Med 1977; 296:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20951/abstract/10\">",
"      de Vries CP, Gooren LJ, Oe PL. Haemodialysis and testicular function. Int J Androl 1984; 7:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20951/abstract/11\">",
"      Levitan D, Moser SA, Goldstein DA, et al. Disturbances in the hypothalamic-pituitary-gonadal axis in male patients with acute renal failure. Am J Nephrol 1984; 4:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20951/abstract/12\">",
"      Lim VS, Fang VS. Restoration of plasma testosterone levels in uremic men with clomiphene citrate. J Clin Endocrinol Metab 1976; 43:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20951/abstract/13\">",
"      Carrero JJ, Qureshi AR, Parini P, et al. Low serum testosterone increases mortality risk among male dialysis patients. J Am Soc Nephrol 2009; 20:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20951/abstract/14\">",
"      Stewart-Bentley M, Gans D, Horton R. Regulation of gonadal function in uremia. Metabolism 1974; 23:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20951/abstract/15\">",
"      Schalch DS, Gonzalez-Barcena D, Kastin AJ, et al. Plasma gonadotropins after administration of LH-releasing hormone in patients with renal or hepatic failure. J Clin Endocrinol Metab 1975; 41:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20951/abstract/16\">",
"      LeRoith D, Danovitz G, Trestian S, Spitz IM. Dissociation of pituitary glycoprotein response to releasing hormones in chronic renal failure. Acta Endocrinol (Copenh) 1980; 93:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20951/abstract/17\">",
"      Foulks CJ, Cushner HM. Sexual dysfunction in the male dialysis patient: pathogenesis, evaluation, and therapy. Am J Kidney Dis 1986; 8:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20951/abstract/18\">",
"      Sievertsen GD, Lim VS, Nakawatase C, Frohman LA. Metabolic clearance and secretion rates of human prolactin in normal subjects and in patients with chronic renal failure. J Clin Endocrinol Metab 1980; 50:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20951/abstract/19\">",
"      Schmitz O, M&oslash;ller J. Impaired prolactin response to arginine infusion and insulin hypoglycaemia in chronic renal failure. Acta Endocrinol (Copenh) 1983; 102:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20951/abstract/20\">",
"      Hochstetler LA, Flanigan MJ, Lim VS. Abnormal endocrine tests in a hemodialysis patient. J Am Soc Nephrol 1994; 4:1754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20951/abstract/21\">",
"      G&oacute;mez F, de la Cueva R, Wauters JP, Lemarchand-B&eacute;raud T. Endocrine abnormalities in patients undergoing long-term hemodialysis. The role of prolactin. Am J Med 1980; 68:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20951/abstract/22\">",
"      Bommer J, Ritz E, del Pozo E, Bommer G. Improved sexual function in male haemodialysis patients on bromocriptine. Lancet 1979; 2:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20951/abstract/23\">",
"      Lim VS, Kathpalia SC, Henriquez C. Endocrine abnormalities associated with chronic renal failure. Med Clin North Am 1978; 62:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20951/abstract/24\">",
"      Sawin CT, Longcope C, Schmitt GW, Ryan RJ. Blood levels of gonadotropins and gonadal hormones in gynecomastia associated with chronic hemodialysis. J Clin Endocrinol Metab 1973; 36:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20951/abstract/25\">",
"      Palmer BF. Sexual dysfunction in uremia. J Am Soc Nephrol 1999; 10:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20951/abstract/26\">",
"      Rosas SE, Joffe M, Franklin E, et al. Prevalence and determinants of erectile dysfunction in hemodialysis patients. Kidney Int 2001; 59:2259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20951/abstract/27\">",
"      Delano BG. Improvements in quality of life following treatment with r-HuEPO in anemic hemodialysis patients. Am J Kidney Dis 1989; 14:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20951/abstract/28\">",
"      Evans RW, Rader B, Manninen DL. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. Cooperative Multicenter EPO Clinical Trial Group. JAMA 1990; 263:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20951/abstract/29\">",
"      Kokot F, Wiecek A, Grzeszczak W, Klin M. Influence of erythropoietin treatment on follitropin and lutropin response to luliberin and plasma testosterone levels in haemodialyzed patients. Nephron 1990; 56:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20951/abstract/30\">",
"      Schaefer RM, Kokot F, Wernze H, et al. Improved sexual function in hemodialysis patients on recombinant erythropoietin: a possible role for prolactin. Clin Nephrol 1989; 31:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20951/abstract/31\">",
"      Ifudu O. Care of patients undergoing hemodialysis. N Engl J Med 1998; 339:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20951/abstract/32\">",
"      Rosas SE, Wasserstein A, Kobrin S, Feldman HI. Preliminary observations of sildenafil treatment for erectile dysfunction in dialysis patients. Am J Kidney Dis 2001; 37:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20951/abstract/33\">",
"      T&uuml;rk S, Karalezli G, Tonbul HZ, et al. Erectile dysfunction and the effects of sildenafil treatment in patients on haemodialysis and continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 2001; 16:1818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20951/abstract/34\">",
"      Seibel I, Poli De Figueiredo CE, Tel&ouml;ken C, Moraes JF. Efficacy of oral sildenafil in hemodialysis patients with erectile dysfunction. J Am Soc Nephrol 2002; 13:2770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20951/abstract/35\">",
"      Grossman EB, Swan SK, Muirhead GJ, et al. The pharmacokinetics and hemodynamics of sildenafil citrate in male hemodialysis patients. Kidney Int 2004; 66:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20951/abstract/36\">",
"      Bellinghieri G, Savica V, Santoro D. Vascular erectile dysfunction in chronic renal failure. Semin Nephrol 2006; 26:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20951/abstract/37\">",
"      Sharma RK, Prasad N, Gupta A, Kapoor R. Treatment of erectile dysfunction with sildenafil citrate in renal allograft recipients: a randomized, double-blind, placebo-controlled, crossover trial. Am J Kidney Dis 2006; 48:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20951/abstract/38\">",
"      Vecchio M, Navaneethan SD, Johnson DW, et al. Treatment options for sexual dysfunction in patients with chronic kidney disease: a systematic review of randomized controlled trials. Clin J Am Soc Nephrol 2010; 5:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20951/abstract/39\">",
"      Mohamed EA, MacDowall P, Coward RA. Timing of sildenafil therapy in dialysis patients-lessons following an episode of hypotension. Nephrol Dial Transplant 2000; 15:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20951/abstract/40\">",
"      Muir JW, Besser GM, Edwards CR, et al. Bromocriptine improves reduced libido and potency in men receiving maintenance hemodialysis. Clin Nephrol 1983; 20:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20951/abstract/41\">",
"      Ermolenko VM, Kukhtevich AV, Dedov II, et al. Parlodel treatment of uremic hypogonadism in men. Nephron 1986; 42:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20951/abstract/42\">",
"      Ruilope L, Garcia-Robles R, Paya C, et al. Influence of lisuride, a dopaminergic agonist, on the sexual function of male patients with chronic renal failure. Am J Kidney Dis 1985; 5:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20951/abstract/43\">",
"      Barton CH, Mirahmadi MK, Vaziri ND. Effects of long-term testosterone administration on pituitary-testicular axis in end-stage renal failure. Nephron 1982; 31:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20951/abstract/44\">",
"      van Coevorden A, Stolear JC, Dhaene M, et al. Effect of chronic oral testosterone undecanoate administration on the pituitary-testicular axes of hemodialyzed male patients. Clin Nephrol 1986; 26:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20951/abstract/45\">",
"      Singh AB, Norris K, Modi N, et al. Pharmacokinetics of a transdermal testosterone system in men with end stage renal disease receiving maintenance hemodialysis and healthy hypogonadal men. J Clin Endocrinol Metab 2001; 86:2437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20951/abstract/46\">",
"      Lawrence IG, Price DE, Howlett TA, et al. Correcting impotence in the male dialysis patient: experience with testosterone replacement and vacuum tumescence therapy. Am J Kidney Dis 1998; 31:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20951/abstract/47\">",
"      Ayub W, Fletcher S. End-stage renal disease and erectile dysfunction. Is there any hope? Nephrol Dial Transplant 2000; 15:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20951/abstract/48\">",
"      Mahajan SK, Abbasi AA, Prasad AS, et al. Effect of oral zinc therapy on gonadal function in hemodialysis patients. A double-blind study. Ann Intern Med 1982; 97:357.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1978 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-183.1.191.153-340D2F8564-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_29_20951=[""].join("\n");
var outline_f20_29_20951=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H645172\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      STRESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      HYPOTHALAMIC-PITUITARY-TESTICULAR FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Spermatogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Testosterone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Gonadotropins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Gonadotropin reserve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Prolactin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Gynecomastia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Phosphodiesterase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Psychotherapy and/or psychoactive medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Dopamine agonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Testosterone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Vacuum tumescence device",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Alprostadil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Zinc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H645172\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/1978\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1978|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?19/28/19919\" title=\"algorithm 1\">",
"      Rx sexual dys in uremic men",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33496?source=related_link\">",
"      Erythropoietin for the anemia of chronic kidney disease among predialysis and peritoneal dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5626?source=related_link\">",
"      Erythropoietin for the anemia of chronic kidney disease in hemodialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32533?source=related_link\">",
"      Evaluation of male sexual dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/44/42696?source=related_link\">",
"      Overview of male sexual dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/15/8442?source=related_link\">",
"      Sexual activity in patients with heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1545?source=related_link\">",
"      Testosterone treatment of male hypogonadism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31561?source=related_link\">",
"      Treatment of hyperprolactinemia due to lactotroph adenoma and other causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30282?source=related_link\">",
"      Treatment of male sexual dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_29_20952="Lichen sclerosus perianal";
var content_f20_29_20952=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F62753%7EOBGYN%2F59461&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F62753%7EOBGYN%2F59461&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Perianal lichen sclerosus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 258px; height: 396px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGMAQIDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD3a+jzLuQL1+ZVOSfTp39gKjigkER3pyAcNnAq2C0rEyO7p97AG388np71UG6OQFIRsb+83T/PtUPQ9pXasMcpnd0PBAOeMDFVr1gI49hG45GSe3+eKsF4zlXKrhTgEBQeOmaiZdsyqVGCPUdcdajbY0tYoLlJTLkD15xn1HFOvJ4muinABUZAB4HtT51CuwLqUBxgH1HWqhTek43HJwSrZB49KzmtLGkEnqQXQIikkDcryFPU/r6VRSCWTbICPJOeCcZ98+tXY7Z59/mBhkHIQf09ayXuZXdbdWOIR8oK5AbnI9OlYy8zohC6aRJe7rWcMVRg3zPt5OP/ANVV3nikMjI0JIJUA9T9B2FWdz3FwxmChAoAbPr6isjUE8m0aJzIEOCGKFe/OD3x6VlJ9tjSlC7s9yHVLCBHnt7aSaKUlWYMwC7SBkLjpyBWObaJWkE12UnwFKeVndjtk/d4Pua0VtmMTSujbc7A6AMQSOOCeR9KwNSv5Jr+GKQh0VCzOccc45H0FZz096x30Iyk+VMtX3kR2bbsLsAkXau6TvxnPAOetc6jSoTG5lRXIYqrbQSMdR3rWnH2kTKsrHeuwsCBu54HHY8U2Gxl2w/2jb4Td+7cYIIH49R+dZ/GrdTrjanGz/r0JYJoLaJGt2a5leMeahjKhDznA9uOfrVm/umtrK3uHkZh52xVC5KZGWJ9yMY7Dk9ap29t5dzJFM0sRyfKYxHdIpPBwOcfj+dS2d3tjQXLeYlwx3bcKeuMD8q1jU5XZ6Gc4LdaixXsN3amTykjkjHkIwHDqCOW7ZA4Hrk+lQ3DyxWMYO5EZA5UrkPgnnOOnJ5pNPV3luLGIYgjGHWMZBI6nHr1GfSrhSa5eO0R1KptQCQlgCem0AHn2FKpJyWm5PKovy3+Q22QWUCFflEygoFIPDdQce/Y1MvnICSjiIJtyvAGDn5vT/61Z0LmO5MTpvMRwpCkbn57ev8AhW1e3st55LSRweYI1DiFdoAx1x059aySSv8AkTKLUlpuW9NnMMkaNHuHUlgduD1XjsQeMdO1Plla7lfAVC7bIyo4I749OMVVubaW0uYzsZC2GAZCOB2A7DPetyGOKHTXLYIZwNpHAJ7ADnv2OK66abTg+hy1LRkprW4632vmKOAq5UIkMY8xmyB1b72eM+np6VrpdGWdEHlu4yjtj5VIIAAVc7j7Z471Bpqpbxz7wnlxgrId/U9jkDBA44rQs1X7Gse9oyp/1ZwrNkZJwvT/AArsp3tqcFaS7FiITpPISjFiuHMmCnBySF/kPxp6PcG58oqZXPzbWH3cg9+np06fpU0cQDo8RIwgRSxyEI5+XHf+nrVgwiEhNzKAhIH3s556dv8A6+M1rZtnLKaKFtbOkLGWEqytwynBH93k9eO5+tCbZWKxtjLBmcjnGOAPTJzz1ovZlaJ1jZYV25dw4bb8uCuScDr+tV3uYYgRAxCZKsynDMQOFHdfzpOxUU5akUsX3w3lqysEVdxIX1zjuT/7N+ClpW2qhdJE+ZnY4yxI6k9+R09PapBKIcyXGxVG0hycdOeMdsn/AOvTT5k7F3LfZ1ZiA3LMxHLEDjOOPpxjrUtItX6iPK8rM7OzLIpAA4DJzhiO2f0GST3pHyEQKqeax3biwOxfVj6Ywdvrj1p9/JiQjzGDMmcLggA9QSOox1J6elSswQujIJBt5ZRgK3XOfxpPQL22CO3Zo1ZonyQCd1yc/jx1oqX7HB/0xPuYxk0V1qrUS/4b/Iz5vP8AP/M6cyFlxHvKbfm+boT2pjs4jWNNqFsNgjoPU4+tWI03y7QHIJ4AYAY4x/kVHKm2PhTGQ23I9frWXQ501exk3gJ/ebSeclVXAH596LkfuC54ZlztXng9f6VJK24q7BtqqQdpzz69M1XkLgKqP1GORk8ngCs0dGtkZ8cRkRgPl2/rnmlaECOIq3mMrbiCPbFWJkQW6uvzEtg/730/rVR0MbnAYK2AAeg+n41lJWNIu5B9sMMxRo1VMEgA9Px71Tv2XczbuE5G09QP50+eGRZHZ1ONp2Ej7xB5AHr/AIVWkVBbbkLqxQpjORk9AfT61jd7M6VFLVFefJELR7nHQL/EOM56VXuorh7q2WXEcRXdnqDk/wDjvNV7yZ4gjFiVjO/aDyB6EdfeoLzUJrhkaOJYIpOhwMkdRz1PJ4NZyijqp05bobe3VrJa+VhVzyQR9zjOB3FYVpFGZtskm+NlIQg5yM/nj/PerU9tM52584FgMHG5eMZB7cYwKBFc2ZkEUqMWxGVkO08g46gA/p0rB3vdo66cVBNJ7mPcSwjzJ7QofLJXBTB+pGT/APWxWe7O11JFOwwQSWDZDemPU8VZv7iUXU0d6symcHbvG1o2/h/DsfUVmtFcPbC4Ij2qcEfxZxzWbXWJ6EIWs2dAxle+hLvKskKqBIhycAjAB7dc1P8AZka5ja1UTQRM05bJPyj7x+gY547H2NUNMiV4VuJHVVXCo7EcHsWHccc46VNBqMv2fEPmfNEVw3UMpBJ9unQdfxrSm/5jmqRktI9DaW2jsgpUhWKfOyuSWfcQzHH8LdcVGt5Hb31vJFv3lsAjKtnpxjkDtx1zV6x09TCk9xGYmEMaon3QFKj+fJ/GsbWLDMwco4D428Hgeq9u1XWk42kkcdLlm2pMsR3NvFqCT3Ctj5o8LjKOCQ3446HuCcdKg3td3v2e0cRF2WMHGABkAHP40kEYgl2tC8iudqRZxn0P4cde9aWpWtrAm2zu3n3pvZAvCyYGRn69/aso+8rmicYysuv3D7a7mW5hj1GQySKFKyKSSwI4yTznJxxXSQ3FubGYLKjAnc+AQGwAAq9/U9ulco0LW7ec03mXH3SzMSygjnHBHGK29JBJcTIN2QX3NwxH8LZ7dc/nXXSm7tM5a8It8yNCBUWFirfvNu5SMqG4+Ucc5zyf5Vq2C4iZlBjjjQHy9xy7jnJ9Scnj260yySJYI2hZElVyNyggKvYbuvfAxTwyecABK0qZGGXYp7FF64yCc9664LlOGq3I1Yj5Lovn4ABJOD8xI4AH6f8A6qhnkik/dpvYs3K7SNuOx7Hg+opkUrRvJ50kbMuFZ2BO5sdhjp1xUMs5aEzQNIYMkyuh2M/IACkdhnkgDcB1rRswcHuSm1RtxZImlRcnzDhIzjgle5GOme3aqSyoMgKikDbFGXJJOchuBhiRVhhOrLFCoSUlv3IO1Yx2J/PuRmoJnHmssrKyxthgF+8Rjdj6EY+g9zSfcuCutSvLk3IZSoL4O0nPydAccYJ6hR+NWpbfbMFgiVHVQMEAKuB245PHSozcStO2DiXcWA7D3J6YAxnrjgU+aQrGPKBaRtvKqHKKPp3JxUuy1GrvQf5aRuRl2Ykqx25Lg9P8afAjbS2NiLhivUtxkkdsHtSRR7IY3O/zHYEM5yxwOSfbp+XpUz3Bhgk3YZMEg8k47579On1pS0Rnrew4reZOwDZ2xjpRVMRykZaKHceu6TB/EUVopR/mf4/5Bb0/r5nbSRNsO1nBU52oQMgnt9e9Q+Sg3eWpO/5c5LHP16fpUxZVBXLJwQFHyrg+/U1UAKKqkyiM9GDYBwPQc1ejORNlW6VjJ5cyBUVeG3E4NKUjNtGw2F1GGKNu/wAmpzCGj3PnKj5skknnqcjpUEw8qNU24zknOBz0zWdu+xtzbJFBk3PtOWO7joPw4qGdXWUrkjBGOeaUbw5VeMHnjrmich5lyFyy8j09qzbVjaG5X1VIZIhI6dBtz1Jz1GR71jXDLEQpGNqnbzySPatiWMh5Ak2AMKxP+fSsB/317IImRlRcHaO5zkeuQP5isamjujpoar0KusXEUnkh0Voo8BzGemejcAZx3zVexsXu7Nim0txjBxwO2aTUj/oSFSqxoczMx+XblQB1zznp78VT07Uv7NWa1IKIQDb+Yd33j047jP6VjL3tWd9OEvZ2hvciu7dxcSC1meKVyCucdPRh/Osi5aWYlriSWVgcYcl1yvQZJ6c9OPxq60yTFpZ5pRcblVpE+UhjwevXPHXvT4tMMkfljczFgCw3EBsdwPwrBy5tjrTVL4jL1OwkNgkqRvNHEMySKpYqnGM+gBOKriS1Xw/P5kcn2uZwozL8oOcbiMcev41auBNGZARksDwDjB74H3eefWse3sZL6WW1cTPcEgxqxO4egHYk+/pSjJrRLVnQtY+89ncSwa5aWK1tmZy3SJVyVPXGPTjNbekoz3RSGNjfojvHhMBmGc9ueCa5+wiVb1zD8jgbY5Ecgq3rkd8cenNdfpSnNxNCxElsI4g74UsGUgggHrxwwOCPQ06Kd9dxYuXLF6GnaW8i2MZMzyKFGcclec/T86zG1GUokTu4SJ/3LYyFGTnOOTyfet29uVi091ihBYoGyvAYDv8AzrIW1S5zkyEMoAKL8zZXjI+vGf0zU1YtNRizzaMlJOU0ZrXDN52yQ+an7vgnOPp2HHpVxba7t7mJZld2UKChICoDzyw6cnPc1VvbR4bzesqKz8MduCp6Zx68GrOmXBjVt3MRQhSFxuYnpj29e9TTV/d2OmUrq8DXI8+C5jMQWfzQWkTAHA5A/wAOKktISzoHlSNHO9h1AycAH646e9QWKiJwTGpRxhOTlmIxyeMDP8q0USGxieG4LQmL5ShABPPX+f8AOuuD5n/XyON+67I1rBWWKMIBzncsuSVOeCPbpzjFTvbTSRy3M0wCIDnaRwoPG3I2jPXj9aIZ2a2xb25bzwEEYG0EY5bpnpj161G7llQgiR1TbvdC0WVbAYc8jgL3zj8K7Y2RwSvzXNCBvNDzzOxtyA6xnI2jsX4AH05p0t1BBHND5asWI2MByM/d9gMj6+1JaPJchVeQsj84G3gHg4AJB5zyTTVlaZN6M8Ic5dmbYigdPT5ce3TtVc1tEZNXZWie5E4J++2CSnzH35z1P6frTrjasbpGqLu/cggHcMk5A546d+vNMRpd8pSOTywN6hflGDxnk5xg+wx2qQCSRWVo9o2j7/8AGcgDn0HB4xkn0qb6aGiD7OypwIV3YRNj7sH04GDt5P19afJbtHdby4DvhW2DBAx0z29vU8U874pWiKoCpCKVUAs3UY9Rnin20oefcm5izFpGA7jtx/nPFMi73RAImgYvcFt/OI0biMZ43ex4zT2UCQRCVneR8OTk5xznJ6evvwKddlVIeRd5chtpOHG7pn2OQAD0HvRbiRmaU5SMORjkZI4HHpyMDvSauK/UvpGwUBWVRjgFen6UU0TmMBDDGCvHI54/GiteSXb8zHlZvmNZW3uxYEddhz9Oe1RvHHEAVIZMfw4FSmTew2hypGfmBHPT0pk7y9t3oAi5wew54qrqxhZ3IpZ5NgAPy4+YEk8dx6VVuFErJtblzwpXaPw5q3kyW4fB8wc4zjcBnms+6dkeNLiUeW+eN+Mdwc9Kho1iuxUhXzJmDM2M8LkZP41HeqUG5dpAzuyc4z70N8qxzQOuR1ZepB9arakZHX93gbQGIP8AFzjH86xnojenG7Mu5WSNWA35LBmYHt3z6CsC9uzHc5VAnm/Kh3Y8w9OPTp1PpXUNcxxEyyRK0aqNwYDPPHTPrXHeKb6ObasMK7AxBiWMgZBOBnr/AErByVj1cJFzlytF2+uhd2CQvJbR+YOQw24YcZB5A7jJHfNY2qNHd2kiJPjC+dFL5f3wCcEEe4INZ80zSrAk5a4VmDOx4Kkc43dAO3PpxVuLUHiMkkShJYwWw+MADbkY7hu49qwclLRnbToey1iPtjJdRreTqfMbDTHIZ1Ix+8K9ce/49K2LfENtIHkuYbobkxEVOT1H+PHrXI29xb/2lL8zIJSsi7RtB3DGDzxg1qTW0cXlrbMEuFIzg9j1z65qOaK1Qq1JOVmyveyiNnjlZJnID+WBiRSefvY6DuSelZmow3DGC4t4pGliQrJIxyDxn5j24zge1aRt1S1kMeFAZgAR8xY87sev9KqWtnLNZzzh9+0bZIRLjJzgHGe2On+NRFOW50RlGK5kyjFi1nuo9khLdx0I4JyB7YrV0YXQgVl4tZGUbgANw5AYE9epqkhfTri2mukaMtGCuPlLoe6kdq6/wLbrc2UjSwCWbO5JZW4Ubjwg7cdz1ralDmdiMXV5KXNa60NG9tvLs45oWSVHcRggcjb0Pv68Vl3EUlviQStHLH88bb8FRz0HvW/qBit5mMsas6qThsgPzwB6Hqa5jUHMt1HJGyeWEMmxgCGOeOc+vapxDtPQ8zDc01qIlutwYJZJFxKd7qAcr25J6Zxn8aJ0itbqJIkkOx9zMTu3cghQexx6etaRZo44okJeSRuJC2VG7so6/jWl4Yt4bm9VJUKofvsAFBJJ/Xsa0p0lJ8vUp1uROb2Rz+pN5V7bTMsg2FX25wR0Oec9vT1+taBmheTbcRuZizOUwdynOcEnknnr+dXvE9vbW0lpclWBidWLIqs+AegLcfnxWTZ3Rlne9kEUIuHIHzYB55C+vuR3rZ0nTlyig/axUkjftDNGiICqhxlASGAX/az154p81zNbpGZUQThBiAthCOgDbQT3PAwMDpVvTohNtUxSRk4JkY7Sintjt9ck+1IzWkVynmCRI1zLhMBnPO1nd+FXPP4V0JWW5yTd3sOinlitJXiRixjKqSuC2ehGSc8EfpxUBkjcMiNGxCqGJYkxjHIz0Oe/WpZLtJFPlqrPvDvKxPBA9MZx+XvRfyW9urQWYEe5cHamAAcZ59z0AqJyt1ISd9tR0NwrH7wLKpBkZ8Y4yAF7nt+NJGHR2mLiQwrhVCnBkI2kHIxwM/TPeqNzM7XLJC7tskzNKy7ihA6Ln+I9MkcfhWiUbeqwlQkS8qpDEZ6E/XNO7YlGy9RIyhmlmlxLlNvLnlicZHtn8PzosICIt4XH/LRmZgpPJzgZ9SfyoklWQ7wkSRRDCBvuPJ6k49ew6YqWJWkZpIwu44IwmFbj72M8559hjuab1ehN2kSNHnKyBEKMrs7DsOQMDrRHK5kVB5iCLkSb8FRyR19c5/rUPmLGqMQnlxjAB/jOR/iKi5TaV4LgEKuAxB5H1J647e5pc3QXL3NsSSgAKxCjoMDj9KKxxPIAA9yqv3ATIB9Mk0U+f+rk+xO3O1WZjJ83bnI+mM1UuFEgYgEoxBAOQFPPPWrDJgksN2PvY5H6GmGXaql/unHzDOcfU9K306nIr3uinNILcFoT5ir8pOWzz369agaKB7QETOzbcDORwPTPv61LdxFtxRo9wOcZOD+I5rLDSWtwzIEdAOVI3Dvwc9//AK1Sn3OlK6umSXMLZyU3AuSR6/Tp61ma15UVjvRZMfL8pOc89/Sp5SzEkjMZ6kNwBnsDVXU9twY1jklEO5XYKBnr6+lYVnozejGzVzNjura7sgs5AfkFduSD75rA1C4nJdUt4mZ8hHddzHuCB61p+IVgjvyUlTIGW3blx35496yLxYPLh/fSGQtnauBgevPr7Vx1dNj1cNFfEluUNMNrPLLFdI25gDuHBc+o9/rVPylaQxsyjy5FBVMsrjpvHfBAHTvUmsLClxFLZiRo9qhkdVVWOTk7geD9R27Vc0zT2aMSt5iGNiEkWT5x0P4Edaj49EjtTULzb3KZ0Zgn2wA4ikxu2ZVkI9/fBxUF1cW893Huc7ARuJG3qOc1s3nicx6Q8Ekay3E2HZnGCefUdz/Wuda3ErF4gQkjsoAOSO4GfbjtSnCCa5GKk5ybdVW7GkL5be427iICRG0jKHXbjBPPXHXGe1Zt43kvPbYVbgTFZNp4YLx26g9c+9DWKOoAJUKoYoxLZPQgD6c1oNDBDqcRMyXMEQWKRvujcFDIfXAHyk/7IqYqUtEVLkg9O35GM1jdPG0rK7Iruqd/L78D05P516t4R0eS0sIdnyGYqNrDkEnn6daydNssTw+TIJzOSxCgE+WMb22g7iOMZ7Y612WqXBnVjHHtlZcBnbkN68dB/wDrr1aFGNNOR5WYYt1VGnHY5PxPcRm+uIVYXAiOximSA2fun/PY1krDEUXO8OxPlBgV3Kpx0/z1qT7BPBMsszYV/nZ+gB5BOP1x7064lha0aFGbz1QRQnC5bGSRnqeSST715kvfk5y0NKSUYqMHcp+XNNFvCmOIjK452KD2PtW3p+rxWCzidV24baCN20sOGI4z9KqaLBJdy5mijGSDsXhV9wO54rQ1bQfMhVim8I2dgJXcD1JP5H8D61rTjUjHniTUlTcvZ1CvrV5HfaPEbsLDGoLMqkks+Tge/BHXH86ydKa8gd7O4s7+LfH8rSIBJtyRgf3R1HvW3Y20X2SYNIrTx4YMvCrzj8j/APXqtpGrDTreSykiRLmSQF5C+SWDAMefQEDHQCulpySnJhCXLGUIK+p19jJcWcMrmGCKEAOCTuJOM/d7n6HrWdNDJN58l2bl0bDuu7HmNt+VMEHcQT1P3dvGc1btfsv9nySzPvllTYpbhASehPUkdfSs95Uv5BHbrHFJIXUBpNn3cHzDn+LkgAcAEnnNdFtEmcKV5MurbWgtWmmlV0Dl2eQkZ5Ibk9fmz9c8Csae+a4lfCzRxr8q4jzuXGfl54J7nOR2FbDxG9l81mR2t1PmFx8kZ7Adm/DNUbhopDIUnI2KkIQN80ncnAGT3PGPrWFRNsunZb6lK0mSJ0jRtnlYkRWc7SSOuQTnr69fWtm3JCyoykO4ULHwCDnq3oTxj61hwYWSIbJGzMwj8td3J57nAPAyeMc966Lct2iSSoroyiQFcrkA5P4dR7ULRDq2QxkxNBbuQPlx93Byec56EgZGe9WbeeJbNZMYdx5S7+dgwOw6/hVeZJfspIKrG4LNKccqPvL7gggVThmuG1GNkZXRD5jErxk9MeoPBz3249afNbQ54x5upLIouAHYOfMBSMMMMq5wWPoTzj0/CrkJhxscBJlBCJt5XGfw44/QCp1gKQoVkZ55Mhiec+gOPryfqKPKjkdkU/JGOASPlz1+ueCfc0+RomVS+gwNCRksCTyTuxmirYmhQbX8lWHBG3ofw4ordcv8y+4jml2N1gJCXyULEbtpx+pqpOXZyF3JGxIw4yGH681c2u8TGQK2eGZu/wCX/wBbpVDPltk5Vi2cGQKD9M1TimZRepXvGkBR28vIwAobBPHUkct9KglmTAJtwxYZI6nHscjFGp7xhCAq7sghs4x6H1+tVmmaeGVpmQODhj8vP0A5HTvXPs7HSotpMq6m+6MXNkUMeQSGICsQOgOcVSS5jltMMPJZxuCMduOp28evvipryFFHmKwcEhQhO3OfwrCnMsrO00b7dpCBeT78/Tj1rKo7a2OyjFSjZkd5epJC5kdmMoKgABiM+44xWBcq88arHuZ9pGQedw6Dntiuji8iO8dJBNkMRvbkg9+Gx3z+dZ2tQi11KRZGZYHXhkI5Pdfz5P1rnqLm2PQoTUXyo5me4ulWW0ladInlBaNclEbOAxx16kDvWnY+IjaL5MsW0sQkgOCDngNz2BApjC1vLdU3fZipMRlwzKSclN3XHIIyOnFYeoxbJWuOEij2MozuG8thVz6YBP0HvWUpOC0f9dTsjGFX3Jok1BY5ZGG7fLLJtBU8DHJ60liUaXypyFYgDdLnGe2TV3So7VoZvtYmkuo0YJtIwmAdu4YySTzx261lyI7yCRjtcEEgKBjI/QZqXTekr7msWpNw7HWeGraN5pY5EAOD95scdSCe1U9dtDa3TEogt5gyZVgQvIKtn/e7dua2NCikks0lVUjkXClWZiX2jOWHfkfT8a2L2x+0SWwuYFjaU5UlgDyOpJ4xyOD0+prshQ54WR5Vav7OtdnP+D4bmO3R1AS7n+SDG4yCHueBgAng8nPp3r0yCLEcYkKfLyXI3DIFZ+k6fFYWgEUa74jtCAH5uSC2ffpj3rVEe+NQHBAAz8vDAZxn16/416FGn7NHk43Ee1nzLY5vXr22njv/AClKwRLscdSMjGM/ieelcK9xFFcRmZGhCrlCxz2HJH05963vFEVxDOXRmBkGzDEDcM9CB9PpWNZeG725KzSNtjLEYz8x6fpXkV5SqVLW1PVwcadOleUtGbnhfULWNZd5Yxl9iAj+HGR8x6V2VvcB7EMTtXeAsqvuBU8ng968s1VhpL/ZbfDOG3AE5CkdB6Vo6bpeqalEjy3e1SQFCEg49sfnW1DEzg+TlOfEYWE37VysmXL6KW91gx6ZISDIAQo+43qx6AD/ADis240qaCUysd745nlAURvnG4k9z079etdnpmnR6XHsaclmXLOGwXHoT3FX7qOzlG9VieOPMpL4CqyjAGO+Sa6o4dSXNPRmaxvJK0dUYOjWRkle3u7wXEm/Mjy7gCFH3SFx8o4ABx3ODV2PT4ZCSsYMsbtGpZNyIORuAGAu7px7UpXyLUrLJGkcxY+amQHcZzjjJzzx3rV8NW8lwu/7K6RLFnEilQW3ZB55OQW5FdFOnFaGVas0nO5HcWsn2NMyTBFAKhsAE+vHesY6J++SfcwMhLMzFizA4yBz0wK666I2xru52lNo+YgNwWx7ZqverHb27MrljFvQ7s46ZHPvSnh4Sd2YQryitOpxzafeLcbixZYsBU3YCqec4GP/ANdaCzra3DfvdzRIpxnj5gTz7bcfiasPL/aV0qKQqwhWcKf9Z14Genr361kQbjcPHOAyNc7yu7GUwAq5/XNcs48sk49Tqi3UXv8AQ1LtzIJ4gghjypG1+Qo5ZsdBycY/KnRlZFdShactvKKDwrEbQfTnjnk1lrcwvKJIjizhYgKuQZARwemCM9D3PPpVu1mvFnMgOPORXUKuxQ2QDwc42gqADx1NLmMlDl0NY7kmdonw5b76c5JOGPPHsPzpLfcbligJjTcVZ2AGMZBz/Ealt0cD7PnODhm6kDGOOenI6eoqJ/3SlfJKqAAM8tnPP0J6VXmc99bGlGInjVsSnIB4AxRUKRyFFJlUHHIJwfyorpUXb4fxIt5mtJmMFZPkGMZVRn2znr+BqrdBSuwKH3DBDJk/h79+KS9u3wo2szlgM5HT6/d/DFVDNL8xUyBMZEcg28n1wcj6jtWLlbRFxg73HMVkV4ySTnG5fmOPcdyPWqLxxC522yEsFDAD73BPORyT3q/Fds1s5OQvHBVjsboeeh+tU0KAu8wuIpcgg9do7EfnjrUpp2sbK6vdGVfrM9uoUFgOuORgHINVTcNAIXXMixY8wKCCc9898VqtJIuZAqNGAQdqY2E/zB/Ss+eIncTCqh2xuReSvXAGQAf51nJdtzopT0sylqEtrdETDMYL7CrcDcehx781hyySXEV6kMoXcu1I3G7B/u59GAIrauZLa6sZYHXypplZ1IOfmUghsY4xg/nXPXebO3QFg9woDJIrAhj2zjoevFclTmWp6GHV1br0JrHw+slr51xJIkL7Sfm27SuT830Ap/iCy+yaTbL5RZXlMjAEGRBkYJHY7QB+NRnWpY4Ps92IxA0kbtkcEY+ZTz1zz64+tamn3dnqeo3MsMZWNDt2EmRTzy2TjgnsRnFdFONKUeVbkuVaMueeqRjaTaQGW2RrcmHzCWmUZJU+3rnH4VdvvDS3U6F1kiGCrDOeMdRjr9K27WO2tr5/tKGKGH5mwcHr0X3J9e1a0Eg8i4vbiJUCjYAG54656g4rrWHjKPKznqYycanND+rlTTtNOnWvl26GSeQbl82Rf4RyT6cAZo0dftOoRXN3OiWsjL8v8RODjJPGM8/lmqcWpWtzcNvXczOpV+cMMYAz6HkfXFaNwZZGt7ixdcqCWJXBDZwF2gfezkYrWm4pe70OaspX9/d9Tp7JoI7ULJnD/Nhs5B3HnPYYNPle3huMQsjRt8+Fbv7en09aqRTk2D287bDGoB3NjuOua5PxVeXNtFFJbysQ3YD5uv6CqrVvZLmOKnh3Wly3NLUYrfUdRVndQhOFDZLE+3+FGpR2FtbTPJOsflJhhGdxUjpwATjPv+FY7T28EEZsrS4lbzER3Cbi3HLEuQAT0AHYZrG8a+IYzaOrYFzj5LeGJWIXHUyKflII+6Oo5rglNRUpPdnfToSk4xTdjjJroXmrOMu6NL8jucZHqRXo2l67p8FnBaGS3klT5dqOx2seMZ4Gf8OteMpIsmprFNN5BZsmSQkDpn9a9R8J6BbRMqXF9BL5hUkx8gDjjcOv0Fc2EjO7cY/M9XGxouK529OxHrU93rM6i2nnZUOwRqoAxnqf9rPH9a6bTtOmttMVrliXQnzC79Dt9e+c9q0Y7JIo2EEaLjIyo4x2PXIqyAjw7JASqLuZsHAye/4dK7qeGs3OTu2ePVxaklTgrJFKGYzXzKJJI+rh2X5Rgn7pzhevTHPfrWt9tkg05xby5uQu2CMvuXoCSwHK9xk/0rJulha3M0UWSZGbBY9ApBB7E4XNXdAu0VpZZwjykhg6DamSMZxgE46DrXXBva5jUjdc1tiS2mklZbuW1MaovlpkdJHGMEjGcZ5x1oBuLi2Zri4RkaQgMVIzgdTn9MVejt0M9o6Z8wNuKscrgZGcdj17VJMiFn3H7p3gkcEH0p8rW5nKonsc6zmJ1SIIkSglsj5hzx+ef0rBvVa+uUso2faCXmZlyI13H5AexPPPocd66O+szIVHysSxiXB4zjdyPQAE/lSiy+xW7Nvk81yN74y3PzbiT74xXJVg3p0OinVUFdbme9iInCRCJNqhIs/ITgbseuOOP93FXLOQNEmELSFDKS+NzL3wD+JJ7fpVbUJnKtu5MrrGDsGc8ZJyMZAzyP60XOI2D9COucDevbgenUgYHt3rKduhKvL4i8tz/oquI2IbnIwMqPTvjPHbpVhSsqMFIZTsACgDaOpAx3H9cZzWfaomRIsWXZs/MD90cAE59egq1DKizEgo7BieRgAnJP4A0uZ2VzOSV9DTYHccyHOecf8A66KkiuT5SYtrphtHzIg2n3HHSiu1Onbd/wBfMx1IpJPNiDwyI0ITcxHzEY45U8d+tZ9q00auksMcicEhHySM8HaeRx6ZqaeO5S5EqbRKOvmxblGOcKSM4I56n2qs0pg3SbdgchzuTPlsRyMNjv24OK472Wp2RXRGjc3BYYXacE5cp1Hv3ODnORWasqy25S6DIcn7q7kOO4cdOvQ+lQtqTG5RIvJaY5ZynA4Gep7Y6+mKRphcSeZhlUj/AFoc7Tx7cHAqOe+tyvZuKs0LB5ZmUEedEzbGCcsFP+H6U95oFtY2QMVCncvB56fzqDUrR4DHJ5kcivypVgGYjnNVfttm8jERN5jnLouBuyOSpPU546Hmm5cjtLQcY8yutSprVuPtLP1cIQ5U7uoJXI9evPsKqT6PHI4mMLpbxsHEKnO7HAA9yen1rfs7GNts8Wx5CDuXPOMg7QfbGPz4wasGTMzOE3xoCMd9/Qn8M4+p9qcaPM+aXU1WKlBcsOhy9zoge3CsFDb1Z0JPJyFIA9MEL9AK1NJ0KO2lQwI4i4yYSeWIwFx1/wAcUb4UkCXMsnlsCoh5LHp8wUckjirb3Ba3a0vVkgtQ58yE8SSZ6Alc7VI6gHPPUcitqcIp3ZLr1HHlucvqU8cqXrxMzLHEUiQP80smQC5H8Shcgf7TE9ga7G3jQadawkcynufkwVJ+YdugOaw72P7dq1xdJFIJDblVQgqIscKcL1HTA6cCiwvZrzWbCG0hEbOjI+5SikjcS/J6/wA8VUXytp9S5r2kVy9NX9w/+xpo5RNbysLcjBDPjaSSQPbGMgdK3YNNmhDrO8sqXAGSJNu18YVwR37fUL61de9Ooxq0My5IZZFVcKTj0HrVm2s1uLYWkhdCowTnO09uf8K2jSipXicdfETatPQzmtZPJVFuFkSQ8nJ55zgr68fSp7ixuPkS3itURANzyEsD6HPH5ZqK8iv7DYYUSTzBucK2Fz3565747VyHjLUZWt2CWrouSsifeKY53EgDA7e9E5Rim2aUqMqzSgy7r1xoNkha6D6ldsRhElCxKcjk7ei84J/CuL8TLJPcwm1SOGSG0Msm3bEkSAsDg7jxhsZySSelU7Nvtd6s120aoh3+X2PsFBFas+nM+rsbmNXVoHlEbNgyYB2pz/tbeD6GvPqSdTZaHsQw6w1veu/P8kee6synylmUZJPoVIPb696seHNbm0S9iZHcW+eUHK+3B78mp/FVslvc7P3ZO1UlEUbptIGMgMT19qwSI4NTkicSO0KxtzjgHJGPxHf1xXFFyjO8eh0ys0m/tH0ho+t2xtBFdgR3DRt94cFsZAOeR2p5mDMPLkU/M20uRnaV4zjg+o+teJ6Lq0c17bi6f5vMDs4Y4IP16HtgcYr1vS/sxhaW2gkkl2lVdlwN/ZR+H4V7VOsqqujwsRhI0JX7mokypZQQt5RRmDjbnBBHze+QeffPtSafJDDEJVIZVbnnCnnHpkEYyORVI3cXnwxpagRqMlmI+QAbc4HJPJqGzvVntbqRIpEQzNGdvHQ9M+gGOcVSnZ2MJU3Y7H5VhZVPypnoMsQAST+bdax/OAkSVYWXzW3OQcZxkgkfpVrTS1zZmRtjxywNllJVRzgc9WPA6ccUmowi1h8yRhNOR/DwCenP14/M1pJtq6OdJR917kNvMXmL8hBHgK2OP7549MY/A1p30aizZyeVbklgMk9ao2EBt41SN+QnJYjGOSSf1PPrWdrl2t1FGpbdbhsgEY+0EEk++zg+m76dcpS5I67iUeeS5TAke5e8tfsjEq8v7tyOGAY5wf7pO7nqcema1reOK4vXS6aNpfLWT5UwFQLuA68DG04Hrzmqbvdu0s2dvnOy7zggZHzYA6AAkZ96nZFESRyzMJplDMDxhMYBwPbp9R6VxW5TtfvaGjczCGRRAWOchOPlA/iI9Tk4B7cntSOYWmEEOdu1UAcAFsHr9OB9Sajji8udsqxmYDKAYC46Kc+mfbnOadHMpkMizQPKcSZ6cZI3A46c5H5U5O61MOW2xsxm0CKGmnVgBkA8D9aKhWGPaOIjx1aQ5/GivSi9Pgl/XyMbLuJeo0cQ8oXSgcfvVAXn+ENu79gfWsmSSS4yyvewNnKK6BgwxnBI68559O/FbN0qfu2eKQjYAypgtntz/EB05rGv1ltykyY+yLwq8gJg5ABGcZ54PGa8ua69DsotN26iwzwM7+bCsqjaUUKBg88AZ47cg1j34OnwNPG8nliTEi7MHa2Tkg91I+pyPWoNZLSutyVMzqrARoQpKHggMOOM5B55GD1xUVhcuzt57/6MCpdi+5WC4yxHUHHUDjI6CsG76M7FTsuf7y19rN6RgxplA7eWnVcdjyBxznj61cTTEuIwZdxO7bCMcsPUj19v8ar2S28WokoxCbmZA/ykk4+92wOyn610F1+9g/fhSjDhFBGT7nOcc+wraFNNNy1sc9SpytKGhj2IdZC1p5ysSfMkQg4AyCoyPmPuen1p91eSwN5cPELbVGwFMDqO24Z4Oc81rWpgII2qi/dBTkZ9OOmMU++tWmV1ZlIT5cydvb6ZrSMG17rMXVV/eRhPC8DXDx28eZV3lVGzPB+bjIYd+fSp3vIFkaKQSRsFVTG0ZUOVHTIyMfQmp/LdNPjQSPjmIBSCRkHkH0OMY7VDqhitbWcSOzKA0gIb5Ux1z9cdvrWivF3Q6bUnYbpM0ZndIIY5mnAXeGwy85456ZAxmo/EEBgvmjtMfvBjc/JHfOc4z1p3h6R4Y3keKNGaNVGcZCgZUkdCcnJPWtx7J2Y/aFLS5DZJ4556/wBa3lGU6fmOU/ZVrmbp1jJYabaSGScTT5YscBM9gR3+tb1vM0EEb9+Cy4zkD8QCKdFbCS4VWZXKrlM5IGOeKPtaPCYWVg0bdeu0Dg1pTjyGFap7V6lHWdUjispJmSQNF/rJVXf5SDPXnnJ49OetcbrmoQPbq4cG1lVN4VPMkUHdj5SBvBYYPXb+FdfJpcVxdQzMpMiEbGJ+SInOG9j6Gozp8H26WUw+a6DBnHzMeevP1qJKcnY7aVWjSV93/X9fpvfgdA8OR3UZlmE0YLo4YsD5cYwcAnqSeOfoM1Q1W6nXW7qQTSJcy5jXnlV/u+x7Z9a9UuVSHEdzApmYNKQv8WSMdPdSfrXIeInsIdSiZYI3uYycyliF/wAM8/erkqx5djpo4x1pNyV77HDX+k3i3ttcxyfbLYRrMrkZ2w5xhh7cg471nePNNSK5tLlVEcmPIwh5ZCGYD3xjP4/SvUIJtPKQo08LxSyiFlUA7XbgHJ42E8ZHpmuI8T2hvG022dXjnNyXY54CBTuwT06genSuWcFG8u5pTryrSSmtjkNOsGkv4LSE+YbiZU2wjLOvU7R36d69VTWINMhe1kkfdDF5il2w6jdjYFPJOMnOMjBrzeWEWtzbx2zj5pUbaWxhgSO3I6849M10c9jNe2c948u+9+0BJJGJ3EHaFPPbB6+x9KqjUcYvk3HWhGc0pvQ7CHVY7jdGjrBIECeZs3Enk7gfX0z3ra063gW0lM8SmMqQsbDkckFvxIrA8MyQR2K7tpZohvj4+YEDqPpUlrcXdm2Inikikld0wMgKp46847/Wu6nK1pS1PNrRu3CGljs7GNvs6+YpW3fPloCSQdvPPYZGePcU+ZF/cgsyLDICVYYwu04zWfoWrNqOnvKkcyxQNgibhQerc/Xn2/Grhuvt8xmZlMUTbliIyxPCrn8TwO1dClFxujjnGcW79CV1YxOZIQIxgiI/8tHOAN/8wvtk+lUprJzL553SSt8iKV3bMkZPHXnH+c1suzquQd7s3GcHLYGW/Uj8Kqzyor3BCMIogyDnlscY+p5/M1M6ab1Mqc2tjmZJDiOGX5icvLtOMx5GTj1PA/4FSWxmle4vrlUVvMH7oDhVPzKAe5xt6dAfenQ3EcdxcXRVnu3cs0QAG4k/dH0BP/66bbNJKI4gIlbYxZQM+WCRkkDksSfbr7V58ntb+ux6EVo9P66in7RtciUFXG48neF7rj1P8vrVmPO5YYlWOIYYlnHPfBGO34+gpZh9m3ecfnz9zcvLEH5Ce+MHJ7c+1WbNcxEkxq7LjCc7T1aixDkaEcc7IreS/IB44/QLRVY20ZJIjZ8/xM4Un3IzxRXoqc7by/Aysv6/4cW+uQS7JOIyu1yyblGegznp3qlHeMZ+GiVmPIBIIOejD0x2xUt3G0TPNHhxsIZQpDbs8q3YHBz26VlfaUkYRBGkCleD0yScbhgEHgjjr7V5cpanTTp32Luo2qyIRPsCAdXfcASfvKTjHUd/wNcnJYoslwZctGWzkg8HuTjg59a66LctssJRmcqVIGWXnjvyKjhswi4eIFJgu185YHHJJ7jPQdqPZ+0aLhWdK6M3S4/JjVLhVkIARonbcVx3VuuD15roGcEAxqwUfNtlUsMfh0FRi1SzEbSKpxIN7p8ysvTOPbvjmtIsgc+WdhA+Xa2Rn29iK66VNx905q9RSd0ZqyxRqHZoopmwPv8A7uRfcnp6Z4p7pHIGeHzYGAztJ4PpnsRT7uyV5Q7wqjOu1nBzvwcjP51QktJUiaGxkdNi+WIpMlTk5ytDi4vYmNmr3CGR7ZhJJKjRhSX6cj0Pv0x6U3Vp4bHTRJPA8qSsfLDDKkkbl4xgEkHHvx3rFXWJEvvsWqjyi20himEbjAKsOo65HWrmqIpuZILeFTBn95A4/wBbGx/iHBDA5KnscHmpUuZe4bwpNTXP6l3SLdRpihkBaX5zNKCgTB+6FJ6Hj3zxWvH589shaVskZBxkMPY/hWBpllIkby2ak2jIEVJOHRjg5PsQMcfWr8OoDT7cLexyI4GGYLvXGTjkdPyrpjK0VfYmcXKb5dXc0pxJDaksxjOd7OSflx0OPQ+vNcJqUurabeSeVqFwJ3wDaqMll5OQwBUEAZGR0NeiNN5sW7YLtSMeWgJUZ7Z4z9BWXdaHayxnNnIQw2AFSM88lc8D0yaJwbV0y8NiI0pe+t/I5XQ/E+o397HH83kO4YfaGUGQ85b5RyAB9AfyrtLKW4mRZJrtJ8kNu4CkD7o47DtXOp4Ue3uC935bWznMm/g4HATgDjODjjkdOK6vS7KOKArEIxG5JRlA+gH0qKXO9JGmYVMO1ekl8g8lprqSRydzDG5u5A/lXF+J7QyfaLnFsjIojXzR+7wwIZyOTu6YI6da7lkKpcqxVmKlcq3YkdPwrjPFi2zO9teZEEbqJFV9jEBghwcdRnd9B+NZ1YqxjgpPnVjzu9mWbWDZWMxezmkxEZXwANowM+xyAe+BXY6WiaprCSXMiI1tbx2j7hgbygY45PXAGfXNeZa3btaXlwkEqzGOQhHj6NtOQw68dxW/od5Lc3FkU879+sd0yKAzNhgW2jJ64JAPTPavPUmnJNdUe3iqKcU4voaOp6AreIrayjjkMKyiYGP77J/Fyf4gMnmn3KT2o1HTLicSwR7YBNInzbXbcGbHoCcn2rpUgmvdSjnuree3QM+w7xu5Hynj3rP8RQmK6ndTcESRojx7BhsZ5LVSShByj3f3HmxqudRRl2/G5StLeQ3rIkgNndKz2sw6MgY5UcfwA9OuCDWpqV1b20cYEDl1DDyouWDA4DZ6AZI4PpWFpcsL+HjC7yr/AKtk8s7mSVpguVBIHTg8jgZqx4dtJBqbacGWR4S0c9yAQGdSPkIJypGc9xzkZBrqoyctI9QrJKTcnt+J3Oi232W2RCkaqoAZh8oZvpz1/PHSroMsEUSxr8yjaG4OB/j71Y+wTRwBgIyMZj2c9eGb3Jx1I6ACpnjT7HveJgkMZ2j3zgD6k5rutY82c01fcfHdSPcD50UJGWfYNoRcZ2jPfvWLrt3HbaUgkLRiZ15VclQeh9s/yFPu32IY0YhJnwhHLMR1cjsMD8yBT5YI755LaS3WSCUbN5+6CPUdfTmubETck4rcVGMYtSexlakIEtPIsCsiuMGbO1cnq+e/1P8AOlt7iS3sZHKrGJPnRQMEgEYyf4mJ/AVtraJJDHbWiYt0+4Ao3NjvUE/kwKPMaN55Mhd3zbsDkgdh79ayqU2ve/I3hUTXLa5TUJK6vMmZBIH3PjHqcdgBx+NS20kbM7f8s2+YOnO8Dvjpg8fzqBoiQHctukVSsbAHlTj5umOen65xSwp5b+ZdbQrkhYgxJ2k8Dn8MYHrWd/IbSbNVRdFQfJmbI6+aef1ophlmJysBwemZCD/OivVjVqWWkvuZny+n9fMyL7UvMuILeOCe+kcqXkWdPMjA/vo2G4PPXv8AhSSRBZmR4sXH3WBBLr1OSO4wetauoWG6VC0YEuf+WjAsAOeCOce4/EVnXqveFkvohO8fQZxL07Feo78c/WvIlFrWTOmEotrl/r+vkPinUKfP2w84E0T+YnPXcD8y0sF2IAFkdZABtCZznjg4OOfpVFoTBGp82Rdo27wcMOMgbhySfRgcis+WeMRuySK+zBAtwMZJwThvlVvwH4VcakktxukpbHQTXqW/2gJGWgeNjJG7ckY6oTwGFXViimJa0l34TLAjjOO46+tc5Z3c0oaJ5FnhxhxOMMeQcY6HpzjNO3Je3BW2Y/aI8sI92109cfX8quFS5EqPR6G6G8pFMoKOXDRhgRuGOoPcf41fx5wXCMJJMltxwfYj0+tYsF2PLFtehZo42wzxgjYfcfzxVyMxwIWjH2y0JJ3LLloweCD6jp9K2jUa1Zzzhoc9qtoLlPJe2EsRDEkykKo4BcnHBOVAxyevABrnbO8aL7L9rkd7a34EjkByUk3AOe5Csc/Su1lglFyjIrCJ2EeGPyjGcnH41j+JtFtriC4e1BDOdqoAMg8E5J6dDk9wazmrPmR14WtH4J7P8DsLaeK5Lt5kaMQQHSThwec8ConaOEKtw4kBAEY2ABueQOp5649c1heFrv7JZQx3FpL9jVsKAhYgA5wR1IGT0rpzHa38QNlJBIHBYA/KR6MPTp61235o+Zxyp+yqNPYlgh8kBRbYRhyCcAcccf0q1aMokxGjrzklGOBjtipLWGCAoMPvC8BQTz9akjUqh3ENk5Bbt7U1Gxz1JpsmcBlDNESh+8Sc8VQuGgs2Uq0bRN8oXOM579K1oVViCpwF9OxqrfRJLIQ0jD+EcZpO+6ITWzKeCuXCAnOc4yDXA+KdOe9v1AkwoOQMZwep/Piu8VljQogLOPunGCcdhWX/AGety90koaORQSWORywwB784P9a5q657RR24Wr7F854p400qfSXs5VIZJYlliYHPGSCCPZhir0cVppFpZ6vpKBGRYxcqi4RxIDk+7AkDcMZ9Kf48V5fsoAnACjzjIcKHzghAOg/n1qrolylx4R12xkdQ6xs0I77sggZPbIGMd/zrzWk5yjHTTT1SPoPenQhOWvf0eh6xfSWU0kEsDo7AboRjnGP8PxrlNfmRcyTeWodtkhUnC8rkn8CK1vhtd/2h4LsYhKDKpOVY5wA3A9segpfEehtPBqDFtyZCLkY3SLggj1HrV11KcFOPXX8DxqKjSrOnN7O34nFKBHpsN8YxHEbmRY4COI4yfMVD69M57c103w5jS+Gp38a+V9s1CWaZiAF2IdqLn+PjJ44+bFcd4ouTa+H444h5jM0YaLB+QAkh8/wjLEEn1rrPAV1BB4M0y0DmW8XdlRwMbzj8ff07V0YGS5vkbY2HuNrdu3y3O7mvRKzzQy4tUBjaWQcg5GQB6YH61BqBeZ0ACbEbzQhJLM56Zz1wBn8RT0t2SIMRGIxko3CgluSdvXrng80bmMCpkLJcljI+OQOMsfQYwB713N33PM0S90pSrGkksUayGSOEhHXuc/M2T/nGKkg8yKSCOQt5vl7WlAbkY4Ueg7Z781fhQSSK4TJHyxqTwo9ff1plxE6Xpt3kZI1UFn68ei1z+yk5c1y1NNWZHNMkcTIoHmBfnZAcDNZ0qrFaiZwPmI5QZkKjlR75OePqakkiD7WuHEcbvtWLruHoc9uPqSc1FfrJsiYhXuXxIm4bhEvPIH04A981FaTki6SSdkVIpPL2AxhPN+by5nzgZGS2D3ycD3zVqzmNzLkxNFHny8EcDH056j8x7VTuLfdexL5D+bnBIPCLjuD1xz1/StLRzaySEwiRozhcDALDGCAD90Z4/OsIO7sazatzF1JrLYuY5G46jof0oq0YZCcpIQvYCLPH1orvVSdv+B/9sc/Mu/4sddLIbholZ2Dnc6L1XHdc+nfjNZtxZSRbtwMkakBZFGyRR3APQ844OPrzW1fmMxqJMshKtkA+YhA6A1UijmWOSTep4ILKcn2yOh9D35rla7hTk1qc1ND50pWV1Ys/L48t8qcbW64IJBHHP61i6s8VvqQQ3B88gqkoJ2yoezZyDzzjFdJeIHaSaaKYqmFSSJsNjGDvAOW47jsOlc3fCeJZTMWngUrmX/WFQOmRwcckbhWTSS0PSovmepQjuFs4/mgeJB826DlWYcEsrZGPdfSku5vtUS+Q+yVAGMsALIx4I46j9R7VfhgyiLps0ZU5ZI5/nWVT/cPt0xS2diy27RiJVVX3Mq5wWx2/DtUKDeiN5Sive6mfpl/cG6BSdkmUg4mThieoYcfLnOD2rqPNk8xpTA0LyHEyk4HpyB1HPBrnZ9P86NbwSGSOJ2Yggblzn5cHn8DwauW+qJEttbXcayK2fJMqBWCg9FbOG69Dz6ZrSF0uWTMq0FNXh/X9blyRRZz+cVeeCMrvII3xgjIDL+Awffn0ptlfJd6xdKJl2JOVQSpzkgfwntzintG8M3mRkAN8is5PI5+Q+zDP6VTv4livra5gjZ5lYAI5BJQkYZfQKwA/GtFFwepzU7O9+x0Tm3sWiE6NHExwrLwDn7oYfwt246/jWnbi3S5ZpgqhcYmGSFPOQR6d6xby+W5jaK7jKyStsxKCfMHuO3p+NQW015YmNf30ttjIRjl19cZ/ya7L2OeNOU+up2sWnOvmAzStuGVAf5aktVyogmJBPQlv61m6ZeQR2cBt3XyMYMaD5kPcbew9q04JYpsHcrI3JIPT3FX6HLUUk3c0TEYGUnJU8E9aLi23yp5nyg8H69jUP2iW1JWb5oscHjkGor2ctaYhlG7IKM5x0/nxxxSTsZOMm0OlhitlEgbcwU5b09/p3rj4tZ8zUSgUM7D5jg5LgnPP4Uuraq6SeUZPMGOQp6//AKjj9K5K4EkGtGZo5ts0vnxjfl03fNjOMZyeeBzxXJVq+9daJHqYXCXg+fexd+JtsH0VJhHFHC8gc4XBdiOuR05xxXktojx3zgHYV2Nznn1/WvYPFhmuNONoUk2eT5sjMNoXHOD/AJ7V5bYxJPfXsyBtixBUUDJYkjH09a4cTH95/XY9rK5Ww7izo/h3rq2Gs6tpCW1xNtuDNAI8AIhGSST+HSvY1ge60hXZFEhXIfdnj6dv618++B76K2+JziZlPmoUBIyA5zj88Yz2r6NgMMdk7pu27QyqeMjGa6cNdxd9jxcxXJVTS1Z83fE6WayvodPR5BBHIzOcYDN1w3POO3pj15rtfhdpsg0qC9vzJGWU+WS+3CNnnp1O3jNcL8UYn/4Si0e8DEypLII8c8SAdfoR9Oa9n0m3cWscLxRxxRN8wIYfKp+XGep549T14qcHG03LsdmMqP2Siuv+WpshhE2wFmlMRPzghVXn8h19+KhkILspV3lYpj5DyvRQO3PLevTpVqKCSS6xcckYlmXoEUfcT3Zic/RafeESBJFkVUU4K7c5PHQ9h0Hviu9XlqeQ9CeKNkWTygTjAOQAQR2Hv/hVZjm48vzNu35nMg+7x096fLdrFEqCNFYfMvqT7/TrUL+bJC+4FA5Iwed7H1/z0+tVLR6BCLtdmNNcmW782JVWOI4R8/MDgjj86sCLzkIncxKY1cFVw4HXAxjbxgY9yaqo3mCYQxoEQrgqSods8L16HqT7UiOyXO9wJGLNGTu5bngknOxeMY9Cc9a8+bf3nVGPREt+489k8tRG7FTt7YHKknHXg+496ejTiZkgB4O6aThSozgbevHtjHPGetNVDK0YUm5ywDAAZb1/Pp9M1ZSAqvlWzoVQMdm35Vbuzfnx79M0JN7C0WhbF1cYH7qM+/2gn/2SikSOZlVmuJ0YjJX5fl9ulFehGnWa0f5Gdo/1ctyIXlABZTyAOi+oI9COxpJbhoLp0bdgqPm2AK5PTI7ngc1AIrhbloWXchfK887sZx7+uf8ACpiWXEEpC5G4Z59sZ9//AK9culr7By623M29CXFw2xRBK4/5ZthmxzlfYHn8PaqVxg2a3FwVmjCglm2qw45J9PoQe9XNUgkgUoqoSAR8x+6Qc5yOBx3HuDUc8QjiQmVduQI2J2sjntkdcnkZqLXbN00rWOVtoCYxFGypDvJWJkx2zxzyO4H5E1ALme0f9/DIGwpV1G75M45HUjjvmtS8to0R+DJGrK6N9515+XOOvc57EEd6y7ie+hSR4ZpMZJkBcEFT1wOufYelYv3Wj0F75M14sqKI2jjm4H7wkqeuRz0OOx/Csm+uklnhtsbyrHa4YvsBGAV6cfqMVJb28Vy8wOChYMTyDu9wecfWoLmwDgli1vhi4aKEkr2xnuvqPTmndy3NYQhDc07K7uPsMkM/76JMx7ySGVx0GT3OOAePfpTrq/Nrc6Wb2JIvODSRFmGAG+Uxv6K3HP8Aex6VkWKyw+VcqGlcybJ/MAaO4Q8A49R2z/Ste6t49RsXt7aGd2UOYvlBwxHOQecdQfUHNaXdrrocs4RjLXY1pLgTrHbqJUuCrI6MnIwTx+GMfhTrcmRFeeSRwP8AVuvp/tZ7fSsPw5eDV7VoJnH220AWUkF/NQHCuDxyOh65AB5wa3JbWBLBzO3lOU3q245bBxkeo9uK7FNTipo5+VU5cj3G3kbNJ8srJIoyH3c5+tW7S/vbBw8iLLF8o+VxucnqMcZ9awtPl1K4upYIbSedlIYvtCIBjjJP8q34NMuZ1jeea3tGRTvEfz7846E9Pwp07NXRddKFozt/X4nVaXq9pexAQSYx8vlv95fUYPUe9Qa6tySjW/lbh8yAMF5/Hj8K5K+0xbFftEN3MBguCkoByeoxjP8AKsC78d6jp8Dx+Vb6jEqkFJl8t+P4hjGR+FVKUdmYwwM5vno6rzN2eFoXeaaCYS7gXGOAc5PPAwfSql3qUd5csAm0KCFZORnvnpWZYfEuyvka0NrctIx27IMShhjnAOCPx471cjv9Uv8AzJfJsbOLrGQpeUgeo4UH6AiuWVFy1jszripR+NfiHiLU/tGgTwws0sXlbZHAPyKeu4n8uufSvNJdXtLC0vprpxCjEsBnI9gP9r/Gu+lsYNSdE1K6kntg4YxsxjXJ77AAPpXI/ELwzp6QgQQI1tuyk2D5iH1z2+lYVqMk+eTO3CWjF04L3nqu39fI47wb59xrg1KaNg7Sbiq9h0A/KvpPQ9TWTSFaRsI3y89Vb09+1eC/CGG4u9UayeGJpoGKgEkEkNg8d+1e52thJKoilTEh+ULGNuD3ya1oxfK7Hm4qpTlyw6rU898QWk2sfEO2LW7XVjZIqvtUbS5O4oTkDJIX6Yr03Srm5mZB5EjSKx2gKSFAHr7H8K0H8Oabo9tGY0JujHk28YwCOp98Z5yafAXmgS2ghNujqPmDZwPUjv1HX8K2oUnTjvqzjr4iNVJRWiLSRRqg3yqWHJIIbB7nPdu3T6VK8Me1GdGIQ4QnrnrnHeo0tlSIbiZJc4RQPvH/AApl0WaZE+dY41yDnoTzkn0x6VvHQ5Ju+iZVYo1w/wBoUbR2x936+lUtV8y7tP3sm3ALKFOAuDxn3/nxVq2G+YoyBoVGS2OWPYAelUbwySLKfNKOWGyR8bcdwo7n+eK5qz0d+p10VqvIZZL5q4umEaYPmKR8ygc7BnjJ659M9abNCs0QGdrSB5Qi8A8cYPcdePWrVtb/ALmFiS8rg58wH5wCcEn/AAqDb5mGdlAJ3HYwJAPBGP4ew9OfWuao9FcuMtXZjLIRxSncxwDlUABLHHJz2XOOfbFXwhyFMkUrPtIwpHTrxnrjsfr1rPdBbONzYnj+V9z7RJg5AyOwOBj3NTW6XEePMSSeCfB4PyMc8Fuc4Jzx0GOQacbJCa1vc14b6DyUxeuo2j5fJJx7daKb9lB5YuxPUgMc/rRXpJq3xf8Akv8AwTFxj/Vv8i1dh0AdmXyyCT1OPb/69QBmkTESctkFGP3j7dx9e9XLl8MSqZIIBXJBI9qrwqBGGnIKg5C7emO2fUVxzQQehnPbhC3ml4wMHgcjHOfrVZMS7oZ4/MGCiSA/N64I6H29K2rxSkqywyb2OQyE449jnkVizWwWRpoN0bBclV6cDP5DHSsrWNoS5tznb22t1uXntyY2Z1lwDgNGeCNv94EdO4qsIpJlaS08sSZzviOxd2fckYIzx2JrciQT3DNdxu6kFCYwMhn+YcnqD09u3pWRq8wtZj5Fq21huDiRiyjuSBgEAev41ha3vPY74zbtHqYk1wsjqWk2yqdjbmyT9alluoJrVtwmDYIAhkIJPTp6HHNVrm0mid3aSR4nYBnjUKy5Hpn9KfAwTCpIJIy3zDqW9DnriojKS3OtqPKnElt4TNBNEbhUjYh/JYEDccjjtjuefemwvJBqqtHLtuoE2RLLGz+YWBUoRkZ68HPFaV9bw2ameASqAQWRl84J3Lkd1xWRPPFNB5iSmBoRvTdIDvLHadq9dv8AKt5e67HLB86b6Mg0wT6SH1OGVppw22eFowpRcNgp1JIwcgZyOO1dV4d1C21QNPBvuVuMNGR92MHjHPQZHf8AnXFWd5HDfsj7lW4hMcTvkokwAPJ4Ibd+HzV0Xg2JFkmtIrqKHypfJCux2JjByO+OcEcDI4qsLJ35ehOIja8pb/p/wD0JIVhxtfZvXJjzkN3wD/X2qV2kSH91GjPk5ymAMe/SoY7W5Mjq4ACJwy45H97mi1ZkV4zIDJu6EcEV6idtLHkOzd73Kd1p1rdzO13OMMBujhYvnI7cYH596wL7w/DLMTBpwumQlxJdL8kaDrjPU/pXWSvLBDMJH8xGILvGMZ9Bil067V7iEwoZE7fP/LPWsNG7M741qkI3jqvwPObjw7au6ymzit7hpAu+zQRs4HqAQCB71bZZrK2WONVaXpJMFyzMCckZ+7nI6fXvXWeITbi+F4wYEExMFXnBIxx35H61jawQ32SMQsIZJRCVHVs9Qo7n+tJrkvY66VZ1IxutDJtGZb2FHi2FwcO2SWwfU9frXPeOJjHqot97eS0YBz0z349a17i7ZWyjMLSWYpBDI/3WU43AdQf4T68+lcVrEhur1jGZHV3OzJ5xngVzVKl1yo9XBUm5872sVfhlftpvxASdGIFyGyQBySp49ucHNfRaSwR28JVD+8UvuHfpwvuD618zacjW/jKxjR9q+YfnYdOxB9/avp3wzaF4IwkYGMfvnPI75A9frV4K/JL1PCzWEadRS/r+tSUL5iqYY4o32n5csc+756+wpkVqsPmXMx3ZYtIzNgH/AD0roLuNbezkKKXYqfcsfUn61yOtSyefE884WGBk3RxLlpDkKODxjLDof8K6JzVNX6nkQk6jstEbEE4cxyK24KfLG0cHPA2/gKragRCjS+W77/lSMZJYnjH1HX8KSO/tltvMEhz5vIbqhH3gRwQR6GqOoXDzTK8ay7BlQpdULsemCfr098U4yVt9TRQd+yJbPBUwAFndQ7uDyozyfr6e3NZmpRebq6bnUQR/Mi7cjr+VWLK8jBliuy8Ko+ZpM9Bj1/DAPSmyRi7t5pnjmKtuHABGeihT0IGeawrNNWR0QTi7szrq9laEFMKsh4YcsFzjJGehHT60+3tTdTIsCMoVGyCcYHXr3wQOOmQfSkvCUgUW0KyysoCsoIyBy20H0685rR095I4myj5KgiMj5XYdct36GuaVpSszW/LG8SF9kELSXeJHCbvKiGR1wFwepPJPsc1a0+1eWOVAzIhHmbXw4VT6FQODg8+w5oj2SXL3D7Q7E4YdQCOMDv1xVmJ2hDiZiQxBV2A7D7p6ZwMYHrWsVoc8pO9luaEcsUcaoLqRAoAC+mO1FVQ7AY3w/wDAgSfx4ordVZW+L8P+CY8i/r/hi4yedMNuAo+6Vbrz2P8ASmeU4+VZFMgO7cTwT2zile1FsjfP5UZGQ/Zv8PrQIikZkJBQjaGjcdM+nc1m/MpPXRlMYVzmPy0ThOMEde/9faqF3GA291jKuA+CNw4/l1zWpdxuA3VZGJKAgEdMkZPv1HvWZc7luA+0pxt4HH0I9OvNQ7bG9N3dzMu1iljuFt59pCksSTjrkcdslevSs27txcxjcVjlkBwx4XnH3SO/Pf3rdSNGlbdGsT7iAxUMnuM+mD0rNu7eaNVt4SsibioLKGOM5wOmRzj27Vk43OpSs9DmJdPljtTIrCYY+dvvMCG6jHfn0qpYTQx3RYnzCpaN42XByTwdvb+hIrpHlWSSWGJZpIhEu4ooBVV+XOe47Y61y2qZ80XVtuBXMcgAOWUc59yOn0rmlaDTR30pOacZGxZ3XmOFUERtzG237meqnPWsrW9OhZXZAkZH71/UDcFOOO2QSPQ57VY0ieM3qOshkhJG35WY9BkknAz2rf1TYbE7xI4OF2Bcs6kEEY78fyrWK9pFu+xhzOlUVjgtQtvtL+YCJBcOFBiJXa4Iwdv+0AK09Fk8u0s5LSJcRSf6RFC+7epbGHBwQyEjqv8AEeaqW0TXENvLJKViJdYZGU4Q5Pyk/wB3gc9B61nzMJIEDLHHIAVDA4k+Y4698HoevvUp295HRKLn7nY9h0fXku7eN28mNGUlX5IUe3NaMUkQ8v8AeAEYBDJkH0Bx09c+9cB4dupry0tpZ3LPEGjl/hPmDcrkgfdPzA89ea67RpZWjKyG5KjAYoNwGPl6++Bg17FKfNFM8WtRjCTLtxaGWEFDkt98I+WXnjrVeJNxWBlaVRwSEzIDnofUe/atiCKWKJz5sfljgs65JPp/9aluBCyAuoEi8h0JBz+PSm4a3F7XSxmXF5cXMrWxTdbIRtZx8x/HHAHT8KoahoUcCC5kUSgfPg+qjKrnrg+vvXQWk8LKqz7FYkgFun5jpU+pQxXWmzxvEFR1IKk7t+fQ/pUyjzXZcK7pWUVZHhh1Mz+J5nj2g5fc0fQMHPKnp6/map3WlTW91ZxTvCq3Ep+cPgA57kj5QBzn612yaRb2d9NMY+Yg0QDL2AGfY+n4Vc0e3t77z2nVdgjlgafaAHLbWwO5+7t46Z964VRcnZvX+rnu/XYw96C0scnougRx6tLKtuxudKunZGkAPmqwA3D1G7K7snBxXsOiaij6eJAhiRkDquMOBx27HkVwGmQpZXtvbMCXEbbFXkjHVmJ/WujTT47SOJbJ3iLkynym5DHrtJycH1HAxx0rpg5QXuo8rGRjVl7zN28vBc3MkT3Nwsca7WjiOCz55UHBPAKg8jnjPBrJuLCK7jb55yjqykvK/wAvQ4+Ynvg46cCrNmUiELrBIskcbKoJyDx0A6g9Oev50tsWljWQHcud7bh91e4/TFNxc1ae5wNezfulSO2uYMXDSOs8rlXYpgO398kjkcdfSqmsSM+8WkkKwRAM3mjgL0J+p+nv6Vs2k0j6RGUkcF3CykHIZhywI6Y7E+nFVNXgVIlE8TSMU+byEUM2R0ZSdp7EYwOO1Ry+7oaqVpe8Y+l3dzcOYriJfLJ+SKRxhFYjpxkcDkA+ta804itrf7LbSoJX2YCY3gdSAD2HQcZrN0zQrhN8KXSvIUyX+6X54cLz7jj39aSTUETUbUdZEJgkXfuVCFAU4PY8kZ659q55SkleRvJRm/c6FqKWALEpRvOZ1jijdG/hBxjPBPQ5960rxiWWJI8iVSBzjuO30Dcnjis60Kyq800RZAgbLrxkZPy+w6exqxboUHlOSQMIfm3gfLnbk46DrVdLdzHlV79iLeHiJW2DqPubYvmGM4X245/nV6FLbCuQUXZufBYncc4H1H8z6UXEjSwq6E7hGrfKAxYnAGc9GJA69hmkiuXnjb90YjgZUsCAD1C44bJzg+3tVKK2Id2XxFJgYkYD0br+Py9aKjill8tNglCYGAGbAFFdSlpu/uMuVmrdgPiPjyiMkHv9R2qg6SyOFiAHy8A4wOO3/wCutBgskjNNIylQRyf0NVXeNVQxcRrgdcnr0x6c9K55pPVk07oryzttQTI+V4GTgDA7VXOZGjYnbtBG4cdevH5Zq7exDyx543lurA7s+gPcelQOoMe07QCQPM2fd+vt/jUu5aavoZ86NC7qRMoUFcKfuHr/AJz0rOlt5llZCXHAcse479cD2981rMlwWcQOQVfGMfMDj36/Ws12MzqqkI0bt82eOPT0HT8azdjpTZmajb20Cyeb80iqCsiEgDPOD39PyrAdrdXO8EWV3busgZt3zEcFc9DuwR7E+ldNqdq7W0m9FZ1jJ2uCN544XHfHasK0tysdxbSPGTJ8wZE+ViRlcj+8P69e1YSvzbHbSfuXbOb0qynmh8wOw2AhWX5egJwR0J4rTGvXNtZL5wHmKu9DjAQHjIPf14NVr2xfS5p5neNrcPu2hslcsM565OeSPxrOvbmKS2klmw5iO5UOQUBxtbbjG5jz9AMd6w5uTRaM7VFVdWrofpNxJFc71d3gaD96jHKjOecZ4559qS8sYoIV+1vcizONkaECQg9QAeOOvOBn61XaQRxxyLECWX98wwSCRyCB1Gc9eKtaalxqCXcdzIJrlpBJFIcfNIThQT05OFx6kdhWsWnFLqNpqXPshmnymKZJluftD237wSSAJ5sRAxnJ54Oe+CK9J067iktz+/kK7zghvmVSOhxya88vIBJawXNmrQCNJ42BXgK/Owg8gZYrj0deeK0fCV7G7XFnKUSaPBjLP/yz9z34wf8AJrvw8+WXI+pwYqlzx5u3+Z6/aoj20bxTScKWLSAdPakYxSRiKT5QoOxsEg+pqHS5XntI1DKpUAqQdw9+DjP0rSFvuQo22Rj3B6fh2/CvQseJKVtzMe3NuhdJtny5BkO5WPtxXIeILm9FypEkoViEaJYzGv1yMZ7V2jKNpe23SQhsFThsnHVR6e9Zl3ZwXdsr5Mqx/NgDIjIOSGHPHHWsKkedWO/DVFB3krnE2gudbjug1yIIbd1RmRCfMyfujd930PXvXWizm3LBKlvBBAMRxxpgKDzhR27UyzjWMxQtHHGkWWklK8ZzwAO5Pp7VBq2s5maG2nkLMcPM2N0fTKjtu9+3HeosorU6G5VZcsFoRf2fbHUkmaOSeWNQrgAFVyehORyfTPQVdS2H2mWfMkNxIcF5Fxu7ADtgDgAdB2qLTIZJbwAhktgoGXOFzj379PrzXQx28E0H2ZMPKTnDcAEdvwpxp6XMa1VwlZsgTa1uiyyBZFUE7sHnsM+3enWsZkglJyikHnPTI7D1zzj3p11brbrDFHg+adowdrg/3Qe+fWpY41h2IhLkg84yBj+IitUtNThnJPVFQyR2cQhfP7xUQ4G0RyAAZJ9Dj8xVa5nCIAcgoSGyMfj65omfdewtcMPLV9iRkffGQzkgf8B5/wAao3sUj3jHz1REI2BjlQ+Rk+pxxwT3rCUrLQ6OXa5ZRfORVuGKKCWJT5ZISByUI5yPy+tc1rYni1OSWKAfbQiJG6nYbh1PGBwMqrZIPU8it+ASWIBMYk2qysC2CEODnJHPJrn9Zv5WSCQwqyJB5ku6TcBJ5hQE9P8AnmWHIPzDpXHVSa95nRQundbbG/CryRFrSQsQQu7GAzYGVA6Hnt696njlYW6tGofBKu0ybSh64xknPGfp9aydDaI24s4pmS1WRlCPlRs4G5ckkN246AkAZzW3MpZfOGxwN37oE9yPxB9uMU5aK5lbllYIreSJFaQlZGfC/uxjk5/OrUEaGGTIQFTvGE5yD94k8A/14pkTGNYQC7Engoeeeh+uM/TirtnAJNy9VTnBUfKPStYK6sjCcrO7KIQ4GGlI7HyetFarQ2+47yxbPJ34yaK7Vh9Phf3/APAD2q7D5y7lgVEij5h6/TH41C0bSSDIUgNnOP1q/doHZx5SkH0fbke1RwxnhoDubb80cgwSOcFfSuSUb6MzhOyuVNTlxp0zRqHkA3bD0cdMGsrTJpJot8jyKxyodeQCP4T68Y/Op9U/16YbO3BcdSPRM9iT9OAaoxWrRny4pBG5ySA24E+hHb61lKTudEIrlsXpgjI5knYSAcEDoAMcYPasu3mjSGaPySzP8ozwGzwG68VYcFLWdZjIysQU/dndnnnjtVOLzViURiI7xy64Klsfe9jjr+oqebW5qo6PUbcsVMUNy5cZRt4JAA6fhj8+Kw7mzuGvJ/JiMmRuDqdxTPG4Y7dQfrV3WJpGjYzrHGA23fyxAxxx6fpVLULO63rJ5kJVmUrk7EEnTqvIDdPqRWO7fkdMFZX7mTqEuy3O6MeWHU7ZVQNtyThW6HPTODxwelc5qEBntrBvmW1dSAw45BJIOf4fTsK6K4h3xmCMeXKWcOCoIIz0U85GD+BHvUMWnXENisMkatAwICOctEeRux1GcVlP3nZnbRmqav1uc/qdu9nb2couTJ5gLFNoOzPbd6deD6Vn2Nw73CqX8tGAUNkgKe3Hbt+FbVzbSm3aWRDkBhIv9zaeuew5HY9R0rLWCVLqQ2xUSAbmjK5VwBnHGeeKiTaZ10mpRaZ0msh75IbjdFDNcK6zJnjf/GoPQ4OHUdcMPSubhn8u9a5JWSNysbCMMoOQRnp2OfcEYrS0DcslzbI4LSN5sSJLu8uZRlTk4PK7h+VN1e3TUbY3UEogkglKzMzYVHIy/T+FsBvrurpU3K0upypezlyPb+v+GPWfCd40Oixi9xuyrecpGAG4Gccg57da2bW9vb13W3thBbLkqbgMrTY6nb1256ZwT9K8u8IapJYW9va6hIkRceZFJAQ6SJjhgwJBweDk5HQ85Fd9peozPJ84kIbksx6gg969anL2iR4uKocsnJGik8yX6O8ryR7WMjINvGOeRyMH9KrXQa/YSwOIdoBDkEmReh+904PU89OBVqOcO0cal8xcEoehPIBP6/pWgRbTwx7ygHOF6Mp6/wCe1XypmPPyJOxybWVkieTtWYzyggPIzmM9WJJ7gdPrVqKx0+QPM9pGZC+YwiDCc/nz+pNXdTgRIoXIVUjLDcuOT/P1oE8cKgywO7OOo+Xbx29T9cVk4LmtY6IVJSjdN/eQeWVcNboybugbp7itK2QWw87DHkgYGQp/w5oSZSkTpwqgLtA7e+f51HdxvNLMyqPJVRG3zY+bkh19Rzj9e1Vaxg3zOzHrMt1MF8rcinIBBBPpz6Z596e8jCEyb2MkmDyOgzkD6AfnVOwljtLe7uuRGsWMs3Vsck+p5/WleUm3bYApKdM84A4+meR60XInC0rLYxtanbS7r7RcjMZQxiTOVRixILdxu/oKpaff2l7btPHLCzk+UQzqcNyWwPT3P8q1pl+1yKy+YwJFyQB8zEgFV9uvP0rPvNMtLe/W5WztzdtksCoCue2QOvA68dK4ZqXNpsdvNHl5XuVNbvdsE32eRZZ1ITDFmXb03swzjrnHsMDpU725+yQ2keZ0eQGXdHgSbhjIHr1AA6DHfJqENcX12WaVoViiV42RQSxP8OMfd3AEn0xThcXJuiJ0JuNhdkViCeww3bg/e98YrLRyZok1FJdB9k4uVikgEawcIBHy7kEgqT0AGOntnit15YYSvzk/uzyV6t2Gfr/M1jWVqIY3EBiDCTfkpyyMck47ZJI4+mBWm0JhjAKMkgZmTc3JA4b2Dc/pRdpGMrOWj0LkSSF1aQCPYCqAkEjjqT/ntUypGp8yWQwwkcbMguF9fU5xWczu6Ki7UGG3jrgdQP8AE06GPFg096DhlVlOCPmzwcDj14raL00MHFtkzmRmLbX5OeetFSG0kY7v3xzzkmiu1Odt/wCvuK5l3Ogu9ka5kkRSORu5BJ9DUEl5iPKEsuzq44+nv7VZS3toZNhjjVHzhhyOP5c1HLFsVsbCFzj1Fc8rnHC3UwCiRzLu3FiTjcOXOOSffjt6U2UCP5/K+cj5toJDDPGVNWLtEUkR/I3Tc5O0+x9DTleJ9MkRl3spJJfjYOoP/wCqsOXRo6ubZlO5uizQmN0dI8SAZI496zdQmZJABAI4XYNJzn5gCCSB6nGevtV63WXzGnUeXISGUOoy2Oq+5P8AKqN5HGzGVNh3/u2RlIPrnr+v61HNJxNkop2MeW4b7QrSyRtFFxzkDrgYPQggkflWVqVwEmS3hV4zvzHFLgsg4wQR1PGMHg1vOlm8jtI5jLpuCj5wxH8Jz6jPIrHY2sJnjWJvs3LBNuWi5GGDdce1c0r3Wx6FNrexVRnTzY50KuwPzoW4YYIOex7/AP6qs3ZnuLVZHh3eWquduFOwJkkEHkHnI7Ggoltcldqy2MzKFkjB+Rj0Y/UnHpnHTu3XpBFKke7zI4XwQRyePmx2+nbIqW3FN/1/XUa96SRjSxeUA6Fd7KZI1Hzbc9VB78fzzWVq8ItTNJbSnY43NCxAZT2Ixyw7HpXQapBJE8TWYkmtEYsVjABj7nAHQ45x07Dism9c3MhnjK7g4MZjT7vOOfwoktLHRRn7yfQ5x/NinWe0VlkRQwPT5xyP1xxXXShpb65kiEam4jEgUKMsjKrrkDglW4913e9YOrLLZ4kx5sG0yIGBwVJwfr3wR06VcSeFDYW07rFMY4ovNVtpiA/2u2S23GOAKqmktGa1fes/Ug0e8Sze4gljIti4v1VxwAPllx68MG46+XmvRtE1COIGS1uJiyZJG0BSByQR3zxXnV3d+VrMcQ2tJb3DIWK8ncAChP8AdIJUjkc5rW0G5Wwt3tbreZ4XMLhj9zbwQT06bfzNduGq29058TR51e256rp90vlr9pWIPIx37HAzx6fnSxW0q+TcGZpVQYdQuEYg9Q2f5elReH47KMJIwLblJwp3HkcCta6Ux2a7/mdR91DnaOw9zjOa70mtzxpTUXyxW5Vu5baSUJKysojMhfGO4xx2PGCPektZ/tcaglFXOASCQD6H2/lXLazOJ9cntFAUFShJGRHnn/8AV9a6LR4UFq1urkQoSiA89qUZNyZs6Cp0kzWgjEKIwRWZv3ZTpz9aivSikgy4OGyoPsP6D/OKmvJZSFZIyM9CD8xx6D161mTSRPIdkgk3AR5AwOeOvc96uVjjpxvK7JZYYl09SMgyYIAOQBkY/E8Vk3LSwRTNIhMigFSf4sn684wR+FapDiD5sfKFCjoDgjA9hxWDdXQgurZmLkoB525cAjcOOecZ54rnraK9zakryatcnt7v7LeyuCoXfuIDYZmIA+g61Q1i4i+1Yvx5CkmRyu5tgK/Kp4zu4J6AE+grY8K2tvc3E80m3zFIKHqGGeCPw4qj4iDR3MyhGRC+xW3DjHt/Ef8AIrklGUYXN7w9py21MmKKFpYCgDMHWIHcdxBBIK8nIBKnPsa0tTtWiVnh86SWYqxcuN20D5uf72Pn9Mj3rNcXXnyRlxDcCIiM5IaIBepHUfKAPX2q/BrCyP5N3Hl1OPLj5Dbhjg9wMtn0yOlZJxV1sbTUrJx1LPmwNcJFaQjzBGMS49twIH0Oe+OauwuJjDMIW8sgBm3cKcnI+n/1vSsjS76BrKN4ZhISzKcjkAHAA74IHXHPatm1ZcyKrrGqjMhH3eTwi+hySPz9KpNSa1OaUXG6sSSFFgAkURwNkkuAMrnOAevt9aNKTzYA29jbw7Sqkg5yBwR9Sef8KgvZ5EhV4yskjSBQgHKgHkj0HNMtVCTsI9iIxUOxcMSQOi8np7Vqn1M1HQlkMjyM4uWG4k4J6UVehn2QxqVgyFA5iYmiq9zq1+P+ZF7dDfLNyrEgD+925/lUcj74ArL8yrk9yPx7inZMi+XMMgnA55Bzxio3iJfcZmwPvYHKn++oHQ+taSucsbdTP1G2It0kjZXQjn29Qw7+1Z6q0Em53Mci9pTkDtwfStKeQyOygKQ33mTGH6d6olpJVJVAwQAEsfu/j/nNZSab0OmkmlqVflFvLDKqkbixVfnZfRl9cH+dZM0lxC58rbcKeeDh8j36EHHsRWzbN5Urs8paDb8rBQMgjB+h9vSsqUeTcSSKZBHG6lGjbJwfXj16+9YvZanVHd6FeOWykil+2RSCONAwxHyxyfu47dc561zy3ULSyTRpIPlGwGNvmIPUHnnttPY10hjCWk22QiJyCcHCqWOc/TAxWWvkwtcKyF23gGHftYrjJGOQQR0PqKynFtpHVBpJspCQMgieA7NySsssbbh/Eq7RwQT0zz0+lNublZZ1zCEWIKWRXHPoePQHBx6c0mpXaK6fZpHe3O1IpNu148PlVlb+LHZj09qhW708K8skjSTSqfmjHmEsQQQx9dpB4zzWb067GsI3V7Eljq6WzJFcPDGGVkZkUnDfdR0I6oTjOehzkGsCVGi1GOBY1xIf3RYbFO5vmVgBjOSCPTuBVu322kwVoZBDOrnJcHcSScoO4IOWXByMH3pdNCme5t7yDyg7KIs4bYSPlO1uCp6Z9xzSblKy6mkIxhJySGeILp54LaztGCxJvyfLCSsy8Y9iOhA54NcPKhZZmQbmwNy/eJXGMrnvXXPaPe2DyQSfL55d0xk7gSoPqDkfeHrg5xmst90bXDSwNNExXMrAAxMeATnuD39jQ5OT1Oug1TTSKd/JDc3uqE7lbAl2jjDAAOPbvz7VeXWWugs9wvnPsV7lt2MsoCswHcsuz8jVC8tGTUJrpAJYxI5ZdpIlUsQwYj7pAPf0pgtBJbbLdzJucCJywGc9VOeN2BgfUetFOcovU2nCDivI9U8DakkdwbcNMojyhZgRvIIG0Z5wK7+Z/MhxbybW3fMoP6V8+adrj/arC4UuDald4MnzPgAYCnn1zXsmm6i01qsv2cqrKFznjoa9ehVUo2PEzDCSpyVTuV9R0yOLU7HUoJD5BHlFQR7gKw9Qeh9DjtW9Z5gUyeUwcbWVU+baBwTjv161h6jMG2uArN6iMgsOh46Z6fnV7Slm2JhmZWTIkI+8h9v881pFpSsYSUpU1zPY19TlKeX5amMtwBjJb0AHqfXpVexYSSXEhwViYKvOQTnk5785qnqUtwlsiA+ddTERKUONvYuSOg25PsetSWcTQ2ZiW2lA8zG6MhggHYgcg881cp6nPGCUSYyEFo+AEG4+5PofQVzWtKxb92QzRkufpxk++M10Ezow+UqMjceo6cA1k3MsaXBkGFeNRglgORwRz1+lc1WzjY2oq0rkmkEWth5e2NWhAxzjzTgdPTPb6VBdahHdyKjAeameIzyADndk8g5xyO1QTTRpY3EcEhEcQOTHliMjk857HpVKGe0s50YDzYzJslMI8zG1R0b7pPOOCcd+lcsqjdtdDaVK7c7am3FE3yO207sSFycsc/eJ9/SsbXdMjVFjhlmIlCr5bBSOPmA3EZwOST/OtvPmWk/kxS+ZIdrMWDfKBnauO5Y4/HNYOpavKl7BdW0bGRFUPmFwnmEjjkdAVxUTUUrMKPPe6NHR7RtNgukTmUqSrlcbSMndk+2Dgc4IJxmtNgmVa2jjZ5CAoxnazd/Qd+ewrmrfXX1C/FzIqveCQlk6rs2MGRRx6dTzwMZre82MW7tI5MYhHD8K2OB79fz6Uk4y+HZEShUTvPdgYI5tQgDuqpswfMbJ3ZztAHbofxzV5sicxRIHuMsCqDIYjpjHtnmud0+5luctDayeYjMCUKEBSANxJIIOcdPpWvaXUkRuCtrcJEUHzuVQqw5UKAx3Y9Pf61rGScdjOcWpb7GstxCqgNksBgnf1orPM1/KTI1jErP8xBlGQT/wGiutRqW0X4L/ADMfZr+mdakxkcxsSCRlQPao1YgklWUrnDY+bp09/wCdQJL+9UsRlj98cH6Ht+NJNM6xlZuhG3DHOT/nvUSfc5Yw7DdQeG5tlIYCZOS6jZvx0zisy1nZGfA5PBBAAP8Asn2q4piYqC3L8rg5X04Pf61Uurdo3RZlwQfklTk8ds9xWUr/ABo3p2XusoSN5JmxukLEfdXO3nBBHr6Gqk7MoC4KAEgDGSw79e49DWtOjMqvF8k4UsEzw6/X+lYltM/ntCi7w2chjkgj2POT296xas7HXF31RnIziBW8su3LAEYDjPzAen+OabZ2fnxSThlaGMZxn/V91JI646YqxOYzdM0QzFjbKoP3VPp7g/r9araoBv8AkARSg3bGChu+4emeuP8AGudNLfodTbastLlW7jS6MZkSKJWyzyH+IHr7cVQvoJXvJiqSMFkYhWbZ5ZAwDkdQR19jV/TSY7womHhU4aJxtRx2B/ukgHBP9a0JlGnp9tgQyR7CzeY3zAHKhc/Tj3waa95cz+ZUajhovkcqsUYMqXBGY2QqI+QHz29DgNg1FasOYNQQrmVlZ0G4hSB0A5/4D0PbGKn1W8MWqRXsoMVq8ih3WPcIyUO2QKOvBx7j8qXUpXnljDrFvCBE3RqQSxCg4GM8jg4757VOi+R0wbdr9RIrgafdXF5CPOtuY5ShG5kOD5hT9Mj8eRWfNPAp+0MyeQ7pKzbsKSrHhR0IK5Jbpz9arRSySOZLaMx3sD4aJQSG9Tz0zxnnkk4psIto7RY5lkWzugWjQ/MUjznYwJ7EsBjHTHWmm2XyWeu5UlkmsJ72G5jWZDJ+/jY4Ds65UHByQQefpVRY0XTJLcK8dvexeeodwRG4cBfqOCM9SD7VTNpLd+ZGGzJEjAHPLY6D34rTmvY1L6ZMqLGbWONXKAlH2KxweuCePxqU099DslGzstX1+Rz2ZLS+aOQFJFC5B68qD1r1vwxqckmnIXCsFjAZQx5AHHsK8s11N9zDdt8okt13HjMjjIPH4cmu58DTxpZ+YS+5VBYk9QePoR39a6sFdTcWGLSqULtao7PTbtrqaSHyyBHhnEnUEj7uP611tgfs5EiM2wHewGDsbuwGOhHX8/Wuf0tU3KYyxQA4baNw46E9x061p2Ek6wOlwCsxA/1Z4ZT0I9q9NLU+eq2lokTz7ZAzQyfu2+aPjIDsf5d6tgeUh5G1BztbPf8AXNUoEZrEMBEEDfKyDCnac447j+dTPJHg8fKJOo4yKps5pL3rIZPC0sgO4CPGCG5xXM+JowiwbU3cjcByzD27d67DcJdiRnC53cHI56A1lPA1/OkLhWjB3Hdxxnp+FY14c0bLqXQqOM7voYdtab7PyZWeO2dtm4jDuPp/Dzxz2+vCajGtuttEkgW3YrGyoB8oz3+mSfxxWvMkoi80bvLwwIXAwc8/pWRcKlzeusfkyPEC5xxtA/hI7/h1OK4ZRex2czk7t6Gxakp8hZWGCo5OVOMggjoABxj1rLtd3ngzzSq0QWbk5KgEjaD65zg4x3rRt4mmsw5G2A5YkEgj2HHrgH8ahjs2nMU9wEllDkIcbVVF7L/ntSabsYxkkncRbCJvNkePdElx5iu3ymM4XLZHzE5yODgD06VTv1mgmW5BaaJP3XmNggliANw6AYOQwA5znHWtVpFSGfe0gWPDbUOSwA5GPXjOPx7VJdxrenyWKm3eNkYgAgkAnn1AHGffFEoprTcmnNx1lsJoflfZIjFET5rSAiUgtwMHJ7etaFwvlqG3srrghVPEYPcD3rmtJvZWkVZg7M0aMGTjdIuY2/AbcnHrXSyhblC7xqqqQNgOSSOmPw789quMlKnZf1/W5jUjy1NSWPeUU4cZA4HQfrRVqKMtGjbrYZAPKc0V6cZaL3PwX+RzuSEuVMbbdmEzxKDk/wD6qS82/YduCssZ3LJG2ee+Ppmo78tFcK0bowYggjJUn1PofbpTZZQysCgMxA6nt6rjr9K4G9WioLRMzo4WJOwlMngKxwD1LAVba5fy/wB+EcFQE/2vU47HvVWViA3VpAuY1PAY56k9jS2saybppCGcAZ3nBwT0x7VOq2N3Z6sjlleSfKYE6qczHptwR82f596ofZ11CcqjpGy8sz8+acfc9u+Of6VpX0sdwq4/dyr1dTk8dzWUy+RP5ZMiq+SjjgJnocVm2r+Rcb9NGZl0AuCNsciZOWbBfBOBx39+hzWcbyTy0VE2wu5bIGSvY49QD2rTnJlVmkTcqkIxTqpH6Z/nWaGe11JjKdiDBIX/AJaFSMH/AHutczV3fY742cbMuxxreW6PG4W6Ee6SJQWLqp4xn744B25PfvWQNRKTRS+ZL5BxPvI3Bdx2kj+8oIzjr+VXtSmtvtqyaWoijXd5zk7Srk8HAOASMjAHesDUlWy1JHt0CRY+6MyLKe7Y7AjggelFR2asVQgpLXr/AF/wxYgWWd0jQLE0Tb44kb+ENkYJI6dQTyM8cVTnhMlxJakyRxxO0kZZsqmCMAEdgO4OOAe9LbkyxPAuIJ1dWiLMC0bEHaVPde2PpzQri7jAlimWdpDGMORIG2gMF7EE9scis37y0No3Uhfssy6lJ5bvNcsjmQbtqyj0PuQRg9jgjkVjxRvayx2twnmmV2kiLjDOSMNk9MkryP7yA9zWhaXUNm1t+9aK6tscMuRLgnLZ67OnXkEEVHqd0dVF88aLBcWpjngjTJEqDIeNiTncN2VIOCMjHerTVrrcq8oys1p3MKC4a2vJmgXCqS/zAgqFO0/iSc496r6vKza1PIuPOWZtxxgHHGQB/sjn8auwObuw8wEyTaeCzK2AHj4AYjuy8A+q/QVFr2JLya8UbFuVjmUKMAMy/Nt9sqcVEdj0Ite01Xl+X/DmNq6CKaykm6vEzbExuZRK4OT26Hr/ACxXd+C5Um0tduw7IiCGwSfm7+/X8DXmmqy5ngy5IRMKDyeuTz9T+tdZ8PNQFvNMs0gWJgPlIJ57YwPYDpXRhpqNfXqKvBypSS6M9vsWk+zK3lFOACQMc1bSDzLdtmELMW4IG3nnFVLCVLiwtijSMXHB7dM/qKtwT5AYqQOcgDOeMZ46V7LtdHzCur2HSTgukbySnyxhT1BA4AA7VDCs/wC8VVQxhRlgMcDjn8MVH5DyBioDNgEDoBzVjzTAvlSMyEHaXQdfT61L3ErLYZIHRItkxjmjGRtJKsM9HXoR+R9CKzDqzRxB8gMWeJeOCyk7ufTqR04qTWitvLHi4jEjNjJYAYPp/h1rB1mUhrYA7SszRh5GypJJG7jqOnoOawqzsm+x0Uaak7vqdJBdq8SAkkkgElsj5jnB/LJrLu4Y/NCwoWbzA+89Mjvkdvb3rIstWkvLmWBLdrdEHlCMYJDj7zE/U4H1rdJ+yrt8l5HZ+IwM4JJwD75xj0rk5lURdWk6MrPdl3T1K2r72j2hi22I8sSCRjj6/mamdi8aqhZYkG0KpxnHU+wz0zTbEhr2RpUKPBkiN8AjGM8e/AqdcxRMmxuQDlBzux3z/nihrSxyzY6OB5ZZJHKj5xvUjb25P1GayN7SXv2SSUvaIwClMAZByFyO4JJJ+g7VZiEmUkXJjT5Plz8u7JOe+7gdPXNPuYfNzJD5SSBgiBjgKORz69TkmlKGzCm+W9yK7Z3ljVWLXMG6TBGM7jtYZ+vQ9q2dKZ543MkyBoU+bcQqgD39gayroTmGKeH5ZbfOSy5Ygjk+pHAOPSrloCEQyP5sYYFWR9zAnqM989fSm3aRnKzjY1xPBgY+0fgVoqE2Kk5RIyp6ZznH50V6Co1bf8Ff5HPaJW1GRlkbaADwQ6n5X/DtUNncR4AnQlQcFOm33B7dabcE/MCXDgkyx7eBnuP06VTeZ5lKRyBdhG6RhlhjsO2frXnyk1K50043jYluWKXbPJMq78Ors2QwxjBHcdKZFd75iPLnMbKUBZRjp6981RljSGQMn8B3b84JI/PB+lJZT+dO80Dlsj5oyPzBH4dRU899DZU7q5blvg0sSywyw4GUkVenbBP6VlXV5if7J5m5kUnIH8WTx64/lV/YiSnCKqsdpV2zg9s1V1C1S4/feW77ccoTvXHXB65rOalYcXFSt0IVVJ0c5eORFxknhxjnIrLuJG2qxCunCMgJ3KQf6irFtdlf3MoMm/8A1Fyoxkg9/wDa7ehqC+HnyESDcOXBUZyvQj8Kz5up0pNOzKOtbPNU2SsYrnGVl+Zt2Plwfz/Sq5uJZRHvYshUsojO078nJB7E85H1qezCmaaznIKYBHYMM5DKeoIwKivhcWFzdRxH7Y+wyfuTtyhOWJ7rzgkjvUNt6m8bfA9ytqEUtojPNEZ7XAjGzqiHt6YBz+I6io57lfKguDFGbjCLISxyxDHD47YIweQetSyagZ7WE3ablLcMgIMifdb2zwOvUnNZVkYLa7t4b1xHH8rrIRlHQnB6egxn05pXu7JmkIu15LVFq5u0lsjNLGrXEbhWJAPBP3hjvySR0I+lHhi6hfxXGXCpbrbyQq4bcEiyqDn1Ac8+tVL6ym06+a3y+5I9zsjYDJjIIY8cA4PfuODUNlbXGnXdwy+TvM8MKssmVIaVWK7fTERPUZHtWsbqSfYJxi4Ple/6mVb3U2k61HPBlzt3MpXlhjJB9u9O1lQmnwRqR5aTmMqcAgqCVOO4Ib8MYqpezGe+iljLyfK0UIZucZO0+gwDjHcn0rUeI3mk2sW0rdTJuX0kdMrgf7RTOPU5B5xWdM75SUXGbOJ1XctzGrHax7d66HwJceXdMSrOx27V7u2flXPbJPWsbUNSlsoleMW8ySHDxzwrLGw4IyCMjpxtIPvWv4IutKubtPP0+e3ljAKNaXJZSc8/u5dxzjI4fHPtW8KdqicXqZ1a0o1JU3HTy/yPeNEikXSRD5pZ1AG85+dgOWP1OauHfDNlXARQSVI6fj2qnobGa2gFpeQ3AYglJP3TqRxjB4P1BqzbRTSi8juWTzN7DYHV2A6gkDp261673VjwVo5XJxKLmPC+oC9RmkSK3z5sOULrtzyV/FT3z6YNVYZmim2KqtnkqxxtOfmKn3PUdPT300zJaMq5yk+4rtwMEZ5/76603ruZtcj8jC12SSCSC5O4FEwksCklW65wPm54XHuMZqhqcYurKRJPKF1E5LoWyVYnk5Hoc5x3Fb98ENzFCsnlP1Ur6dse4PIrn5NIV38wqQ2PJUqMFGHfA656c+vtXHVi1e2p1UZLS+lg057W3uIRHEWVVLuirnftGdzY6nDGpr6fddRCJ3htyCULnmRtv6DsD1Gaxr+0nsdQ+2QCVhvUzwYAAU8e/wAuM5+lb4tBJ5YDhWBJBZOn9R0rmUm1Y0rqKtO97ou6WjtAVmyQH8xU5OHJ5Oeuf0q9cMI38uWTfGTuJCZZSDxnnA5/OpNKSNy6u4WSMgEKwJIwent/MVkNMxukWKU+UQYwxziV+pJH6H61clypHAv3kn5F61e5illXGQJMmMHvgZAI69Q3PUUSSf6Vt2DzXyAnB69z9OtCCMmWOFmN0oKFM84K+nbnofb3onEccSMjsHYfMzjOTghv0x+OKUr79CYtdSza3AYRvE2VAx5incc5wCB279aILB7W72wqFDceQcAlc5yG7Z/unj6UWNkjrIXKrEpwN3y55BA/Sr9lLFDeSiZ1Ulc75eASB3zz3FaqPNbmMea1+UnFvKQD5+3P8Pksce2aKXzZm+YXcgB56gUV1KlLz/r5kXff+vuMGYvIvkuuDGNoIPIb1B78U2KIJEylgrgdSPlP196qX17sNuw2sshIjf8AhY+o9CPT1pnnbrZ18x4bpSWVcblYdc157a5jtjB2KVzd77sQrIvGPMHcdsirumKkF2cB12H5iOSAT/niubiUmN55JGaRiCRjBznpj0rVtJ5HgE4OVUeWxA+YEdAx7/WsYye50yp2Vl6GldIN0ksbAHOBnoW/wqCxuWSSMFSN42vk9Mnpjv8AWmTXBuWEvIkx93GSePT1rMt5xvDSArgbAznG1utPms7ozUG1ZkkkIjmWW1UtGG2um7nPQlR2OPzpISiF1aYF92IcLjcO/P8ACfUHrmrs927s04jw3HmoFxx0z71nauIrlmlRY9jDDBSRg+v8qz92OsTS7lZSMW7YI8l1blvM25wRzjoNoPaoJLmSdk1BC43I0TsvyiYY5GPUHaSPSr9ysUscSyNLEkgCpIV+6wHPA6fT61lhrqwufLYmWCQCZCjcKQcHP90kDH5Vk1aX9f1qdlNqS8/0KYcLsuYkVogQu1skZbqnfAPb04qaS1e70sRwyRpcWrNJbwynkg/M3XtjH4gcCrOu/YY7qE2UojgvEVSjA+WkgJIYgevIPHB5FZ1lqHllVuvMi8okDIzJGNuNmD/CDkHuB1ptcr5TSLclzRX9f1cijmiNhbzlWkZE3EOdww4yjdeuN6H2AFXI9kltY2afPLp5Fywf7zop3AkHoVQHg/3sd6wFRrSaVLlYxCkiiRMHYzjnd7AN1A64PrTtM1Mz6gbydVBZJIXAycqy4PPfk5z/APqqlPUc6d721/r/AIcoalbT2Wo3unmOQRC58+MmMjG4kg9M4KY9+K0jO1093aLcbbhiJYAR0mWMNkemcH8QBVfWLOREtrmHYZpbDyCAMfvI38lx7N8oI9dw9ax57tk1Jrm2d1lt5DIpHGNrdv0496fwt3/pG1K1WKtuvzF8dWkdzotpq9oB5d6GMyKMCK5Q/vFA7Agq49ifSs34fKRf2kQZmO4fNnB+ua2b9jqHhLxFaxBRsWO/SEjHzI4R9p7ZST/x0DsK5zwbciHU7R15YnaB0GD1zXRB6xk+5zJtYlxe6Vl6f8Db/hz6V0iNrezXCrtI+YHNbyTx/ZZ3JAGMZzx0rktH1YyaX5ex1O7+Icj6VfubnLYRlZGHzKv3h2/ya9l7nnuhJt8w6BVlMkjlnIAI5+6OvOK1dK+aafLgIzIVcE4K4Pr147VlW6yQ+ROXjAVFcOw65yRnHUe5q/YzH+03ikj3/KJEXOB749e/sBipdial3dBrkiB4wWOCf3bADMfOeOM4PcVDqNxHImLUkqcK2OAT2znvVrUTb/IskqCVB/q0+eQnPHyDJ/kPeudu/thLrFcpHLINqsFy0W8hQeh+Ydc/w+/WuXEKy0FSipW12H2uqxPe3AdvnikNrKShw8ZX5jn1VsYHpk1JaNI0caO6qbQ7JGc7Qy4OCPUEfnVSGzS2Tb5YkRIygBl2gkD6Zz3yevtWfd3kzIkIJeVAA8kgADDopJz178jtXnuTj8R0Spxk7RN2eeQSRpCA0ZTbHGvDYYn+g5+uKvSALDmOEJI7Z3ZO2NeNzfp+NYHh2+WWSW5kRQjxiYsQf3cf3YyOwJwx575PauiiuJCZJgPISQEbXb5lGPXHyD1/LnNVTakrmNVOPu2CBkYzOyM6qAd7Ecc9WI6H2/lV+/vbGKGQJdh0QbgqkNs5+bkcf41yE/nyTRRRfPuC7Q43CJ+pPIGT06/jmtu60wTbh5k8rYLIGIIBJ7Y49e3FWpOzUUZSoxTTky2utWCwAwXcTykbQUOSp65qul1K0EckcSgu22My5bGc8hRwMn37g1HFPDp9uY5YS5Zd3KB/nGRkDt6D61m2+nQqqJewwW7FthCjB57BlGe4546VV5OwqdON2zdS81HYu+QK+ORgDB+m2ip47NBGoM82QB/y8Efpniiu5Rp21f4shyj2/A565nU2oR2MhhYyOvRsdMjsR/k1Sv7gxQJC+FlC/KwPf2/Crc9r5YLrkqudsYXkHr8vqO5BrKlxCNsiqyMMrIPmBB5OR2Irxqkmtz0KSXQlWVYI0V1y8i4jl2ZDZ7fWpzFJcRMyHYyheCcj8fUehrN01ATKEDTwlSwXjp/eA9qtwXXkqpiYFQSNp7g9f/1UlJW1LlG0ny7li1uVS7QM5MyPhnXgIev4kflRq5L3heV8vIuVcjhvX2/Cs6e4h+0AuqK4GSqZd2+ijk1Xl1DzWXJxEBuWJjhlJ9/X26VDn7rX9f1Yfs3zJpGpFf7DHHM3lzQDCO67g/HRh3BqIzK8u+UMtvJtBLEAAnrz3qra2bXewTsXlHyI2enPAJ/xrQnhiBiiQnyUTYqk/wCsbPLEe54A7ChXkv6/rYiooxdijq8LxIsCSI7SqHTa3zP379GH6ismO1lvnkuIoZmNsgZhuwSpyD7fUGr+r7oo1S4+e2bJEkf+s46gD29e1RCd2spoSzpaHmNIeiZ6Mc9T3OaTcefU0pOUaehnXE0V9aGOYI0iqXiliUK24cqW988HPao4pobnUZDc8GUAnJGDIRgNx1B6H1zVFEdb5YSyQlsbx1jY9iM9CT2zjn8Km1AR2q208JcZcoUBz5TFuGXHUE5yD0zSUr6nVyJaLqRX+itb6dcPcT7Sj+Ue5jcHHA7jI/zxWHbRyW93vng2sSMoSQFYHuP7rY2+xI9a6KS/cm60u63B5SCwKjDPwNreoyvUexrDMZXUxZM4jBkdMyD5lLcAMfqBweOKaS+yKMp2fN/SNGWcXfh/cQVNvdxy8H/lkwEb47Z3pG2feuc1m3aKR5pEjiElxKu1GBKsp+bI7A9R9a6O1uDcS2sUuUiu1mguol4WN2H7wfhgOP0NYWtWU8VjdNJB+9glUyyKPukZjcHPqwU/jWktUKjL2U/X9X/mVoHeOO5LK7b7C4PTqBCzDI7rlRWbocMEmsW7IVjV3BZOcAcHIPoRg+3PWrOpfaLXw1eXLSDzp7U20YY7jsxl8e2CF/E46VneCroW97Y3ExG+A79jdcryoPp1xW0Not9xTnzYrTqlb1u1/Xp5Hvnhzy7a4SGbBic5OPmGeqkHvwTWzqCRW9uRCwY4Yv2K8jv9K5TRA/zXFurWk5RZZCMGGQkdWX365BBFbWp3ZfT3WaFl85RGsluPNRsnqDjcBgHqv0z1r1lKy1OaSfPqWtHuXkt8M2UPzeUFBK+iflxWtZvvZY43zHtKtJ951B4Kg+oHcdPrXNaZcKIJ1V2RS4MihWAwMdWIDdCeAO1dVb3ccRwFI8tsRrt+8uPu47AdqpJNI560fedkTvJ5ERtoQqRnkiPgn3//AF1myweYIjbDcqOC69D0br606/bbfZyAwXeuffPGaht4pWEzjd5rqMKeVyORkfgKwq3tsYqKir3HC0WVgRgeeAckcHqMe1YOoSm0+zymV4iWQ7QgYkE7S/sMEH3rqY2S4aC4RxJHnccADBBHygdOD7Vh+I7BWtGjjBV0BlOztjA5Pfg/pXDWi3FuJpTn76UjntODJpW3zdryASvGDxKpOxAMdBwxH+9XXNdySx/ZwCRFhB5XKbiSeueT06+1YEIt4rmJJSrPEdqHBJVxyoPtjp9fat6ZDbRI8GyN2Ul3xtAPf8awpRklc2rtSa09DPELG7S4ttscccgkc8huX6Dk8V0skjWaC3Y7oyGxIvy7O+c/T+VYqTB2kDqIUKAMz85bGSePz/Gq0tzPdaesUSee0WPkQ/f6cn3K9q2UuS/cxlB1LX2Q+O7jn1eMTmSWzGdixjB29yx7EnOPT2pJbmWW7+0RFCFHybiS2Qp5Hbjj5jTYrNZXSRJ9qowVShwxAOdvvz3qxLaJNcRM0XzyyKkYEhBHPI9uuPempOKsy7RTuuxaXR57hRM/ku0nzlvOxknnP3aK2/7KUcNcbWHBBvSMfhmivVXsbaw/8licf1h9/wCvvOW1CSS2W0jILqV2gt654z71HAifaHScfLuJdSMMreo/zzWlHGuo3aJOABL8rbRjPHX61jWG5xqEcjs4tZRGhY8lfQ+vSvElH3rf1od0NYP+tytcQxHVFuEjEU8RBSWNeHPvVfVNOtbiV5UWaKR2xJHvbBZujfSrkbGfVJonH7uYvuUcYwO3pVnQPmeYv8zWxV42PXI5GfUVny8zs+v6Gim6fvLoYduiW95JCsSI0RCl0wMdjz1Ip95btcTGeABPlwyjsw6fgadcDF65B/1kzZ/4EST+tJAzJMJNzHEixlSeGB9fWoS6M3bd+ZdiWzkYweYsZKDAliYY446Hvj0qhPfbZHit97n+I5HysOn149K1ra6kgV0TaVZihBHbqPxqo9tDJc3FuYwqRyBVK/eAYZxn27USi3FNMm8XJ8yIredp4xPI4MoGMsONvakjBEMnmbSpIRhn7rZ4x6A8Y+tOv7aOx0mO5gz5wG/LHPIOOnv3qjHcNc6czSKmEOAoGBg84Prgk49KzejDlTTa2KGrpGyskb7DISI5skbG64I9QRj2qvNM+o2TzbF+2wId8D9CVG0k+/qPfNakyiezUSksHYK/P3uoz9fesOYGDUrq5R2MsNu1ypPQupUcjuCCQR3oSu/U6ae1uqKzyLYzW81oEeFp1KRSHdIjY4BY/wB3dj0PGafcot0Gtrsr9sjURBmH+sK5+Vz2YDILcZwPTJs+IbaO1kjjizsQuFDc4zgfyOPwFVLORpdIuJJCWm+0JP5n8W5YZeM+h2jPritYatkSmklPuVLuWS1Qyur+fG0YYAcLMh+XPGPnjJ960buD7Zta/MVtJLakyo7ESEFQElKj7uSI/vdznoa1fFKx6V4g06OwjEQvI0mkJdmK42jau4nAOST35OCBxWBq58rUIlXnZpqJk8ltsbAE+p+Ra3lHlMI1FVs0t1cxLpor22naSX7OXgEVvbRRlggIIALHGPUnkkknFch4aLQwxsTwXwGHcDGeOvXFdUiL5sigABZCBXMWiCHUbyJPuxyqF9shiaqD5qbSNsSlTq0Zeq/J/oe96HMkEFpMkSlWiDdM4A69f7p6exFbnnSSzxyMT8gLuDySOeh9QBn8aw9IH2nSYRIfu2pkGOPm2EfyUD8TWppTEJaP/E8jBueo5H+H5V60X0M5LRy/rqXbedbe+aOQtudSf3agsOB1B6denet5Eis52ktQJnb5s7xlhg5GehPH+FcyX+0XIhKqiRhTlBgsfmOWPUnjrWzdAWumTzw8P5qADsDgfNj1561d+5zVY3afcsfbPtkyeQj7y5HmEA7iF4Xp36Z9u1T208kkHmYifb0QqABj271z1+rQ3EUKyyGKSZZGXdjlkOemD04rZ047rdYOiRlyD/Eclep/Gs0+a5jVpqKTRX1KO4SWS5iEscshyWWMujLn7rbfukYx0/xpguojPK1+u2GZVRQ4IADKMjkY4J/StiWNVE/XBAyvbnrTgBJqrB+VdEyO3XHH4CuWVPlV4mcqnRr+tDitPLT3Ku829pLto5HYhQShZA347B0966+aCGRSryCQLw2wZzj3OO9czPaxW+pxQxr8ktxNuBOec5z7feNdNZqDbiNssqZxnvg965KO8ommJekZIyYpd959nEbF+T1B3ED5sj09/em6hFIlyjWyxyyS53RhvLbGMggnoewzVxk+y3KXUBKThOG6/e5PH4D8qIStzdx+fHG7SMdzFeTzTV6i+YKXL7y7FfTbpTdzbTsnADNEw2EAYzweDjOP1pdUuFuW8m0Hmbm3MpBYJ7Ajp9T3FRXsZnS4kmkeRomEaFscAuFPb0J/OoSP7Pgu57QsmxY12biVbpyc8989aOb3bPYFFc3N1NeKJDEhMcLHAyS65P6UVopAAijzJDgYyTRXrRjQsrt/gcjk7n//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Ridley, CM, Neill, SM (Eds), The Vulva, 2nd ed, Blackwell Science, Oxford 1999. Copyright &copy; 1999 Blackwell Science.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.blackwell-science.com\">",
"      file://www.blackwell-science.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vulvar lichen sclerosus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 210px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Severely itchy&nbsp;lichen sclerosus&nbsp;in a figure of 8 pattern around vulva and perianal area with loss of clitoris and labia minora. Swollen, irritated hemorrhoidal tags are seen. Typical white shiny&nbsp;lichen sclerosus&nbsp;changes are visible with purpura and erosions from scratching.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: F William Danby, MD, FRCPC, FAAD&nbsp;and Lynne J Margesson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_29_20952=[""].join("\n");
var outline_f20_29_20952=null;
var title_f20_29_20953="Heliotrope eruption in DM";
var content_f20_29_20953=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F73090%7ERHEUM%2F53713&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F73090%7ERHEUM%2F53713&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Heliotrope euption in dermatomyositis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 232px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A reddish-purple eruption on the upper eyelid (the heliotrope eruption), accompanied by swelling of the eyelid in a patient with dermatomyositis (DM). This is the most specific&nbsp;cutaneous eruption&nbsp;in DM, although it is only present in a minority of patients.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John H Stone, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Heliotrope eruption in dermatomyositis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 334px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John H Stone, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_29_20953=[""].join("\n");
var outline_f20_29_20953=null;
var title_f20_29_20954="Clostridium difficile in adults: Treatment";
var content_f20_29_20954=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clostridium difficile in adults: Treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/29/20954/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/29/20954/contributors\">",
"     Ciar&aacute;n P Kelly, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/29/20954/contributors\">",
"     J Thomas LaMont, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/29/20954/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/29/20954/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/29/20954/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/29/20954/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/29/20954/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 26, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clostridium difficile infection (CDI) is one of the most common hospital-acquired (nosocomial) infections, and is an increasingly frequent cause of morbidity and mortality among elderly hospitalized patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/1\">",
"     1",
"    </a>",
"    ]. C. difficile colonizes the human intestinal tract after the normal gut flora has been altered by antibiotic therapy and is the causative organism of antibiotic-associated pseudomembranous colitis.",
"   </p>",
"   <p>",
"    The treatment of CDI, including initial management, management of relapse, and management of severe disease, will be reviewed here [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/2\">",
"     2",
"    </a>",
"    ]. The pathophysiology, epidemiology, clinical manifestations, and diagnosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36137?source=see_link\">",
"     \"Clostridium difficile in adults: Epidemiology, microbiology, and pathophysiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29305?source=see_link\">",
"     \"Clostridium difficile in adults: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL MANAGEMENT PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;An important initial step in the treatment of C. difficile infection (CDI) is cessation of the inciting antibiotic as soon as possible. Treatment with concomitant antibiotics (ie, antibiotics other than those given to treat C. difficile infection) is associated both with significant prolongation of diarrhea and with increased risk of recurrent C. difficile infection [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. If ongoing antibiotics are essential for treatment of the primary infection, it may be prudent, if possible, to select antibiotic therapy that is less frequently implicated in antibiotic-associated CDI, such as parenteral aminoglycosides, sulfonamides, macrolides,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Management must also include implementation of infection control policies. Patients with suspected or proven C. difficile infection should be placed on contact precautions, and healthcare workers should wash hands before and after patient contact. Hand hygiene with soap and water may be more effective than alcohol-based hand sanitizers in removing C. difficile spores, since C. difficile spores are resistant to killing by alcohol. Therefore, use of soap and water is favored over alcohol-based hand sanitization in the setting of a CDI outbreak, although thus far no studies have demonstrated superiority of soap and water in non-outbreak settings [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/57/12184?source=see_link\">",
"     \"Prevention and control of Clostridium difficile in hospital and institutional settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, antimotility agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/53/16214?source=see_link\">",
"     loperamide",
"    </a>",
"    and opiates have traditionally been avoided in CDI, but the evidence that they cause harm is equivocal [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Supportive care with attention to correction of fluid losses and electrolyte imbalances is also important. Patients may have regular diet as tolerated, unless surgery or other procedure is planned.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with typical manifestations of C. difficile (eg, diarrhea, abdominal pain, or nausea and vomiting) and a positive diagnostic assay should receive antibiotics for treatment for C. difficile [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Empiric therapy is appropriate pending results of diagnostic testing if the clinical suspicion is high. Treatment of C. difficile is not indicated in patients who have a positive toxin assay but are asymptomatic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29305?source=see_link\">",
"     \"Clostridium difficile in adults: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2489959\">",
"    <span class=\"h1\">",
"     NON SEVERE DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Initial therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy for non-severe C. difficile infection (CDI) consists of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    or oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef53273 \" href=\"UTD.htm?2/15/2301\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/1,9\">",
"     1,9",
"    </a>",
"    ]. Several randomized trials have demonstrated equivalent efficacy of metronidazole and vancomycin for the treatment of non-severe CDI [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. In one prospective, randomized double-blind trial including 81 patients with mild or moderately severe CDI, metronidazole and vancomycin produced similar rates of clinical cure (90 versus 98 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Guidelines published in the 1990s advocated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    over",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    as first-line therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. Reasons included the lower cost of metronidazole relative to vancomycin and the comparable clinical effectiveness in non-severe disease. In addition, use of metronidazole has been favored over vancomycin to limit the spread of vancomycin-resistant enterococci (VRE), although subsequent data have suggested that the risk of bowel VRE colonization is equivalent with these drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Observational study of C. difficile disease in Canada from 1991 to 2003 preliminarily suggested that patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    for an initial episode of CDI may be at increased risk for relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. However, review of the data through 2006 demonstrated a similar trend in the frequency of recurrences for both metronidazole and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    , suggesting that the rise in recurrence rate during 2003 to 2004 for patients treated with either drug may have corresponded to reinfection during a period when in-hospital exposure to C. difficile spores was very high [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Limitations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    include dose-dependent peripheral neuropathy and side effects of nausea and metallic taste. Although the above studies are limited because of their observational methodologies, the findings raise the possibility that metronidazole may be less effective than oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment of severe disease is discussed below. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Antibiotic dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     Metronidazole",
"    </a>",
"    can be used for initial treatment of non-severe CDI. The recommended regimen is 500 mg three times daily or 250 mg four times daily for 10 to 14 days. As discussed below, intravenous metronidazole at a dose of 500 mg every eight hours may also be used for treatment of CDI in patients in whom oral therapy is not feasible. Fecal concentrations in the therapeutic range are achievable with this regimen because of the drug's biliary excretion and increased exudation across the intestinal mucosa during CDI [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/24-26\">",
"     24-26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    is used, the recommended dose is 125 mg four times daily. Oral vancomycin is not absorbed systemically and achieves predictably high levels in the colon. Dosing regimens of 125 mg four times daily and 500 mg four times daily are equally effective for the treatment of non-severe CDI (",
"    <a class=\"graphic graphic_figure graphicRef70347 \" href=\"UTD.htm?43/12/44237\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/27\">",
"     27",
"    </a>",
"    ]. Intravenous vancomycin has no effect on C. difficile colitis since the antibiotic is not excreted appreciably into the colon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recommended duration of initial antibiotic therapy for non-severe C. difficile diarrhea is 10 to 14 days [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients with an underlying infection requiring prolonged duration of antibiotics should continue CDI treatment throughout the antibiotic course plus an additional week after its completion [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Repeat stool assays are NOT warranted during or following treatment in patients who are recovering or are symptom free. Up to 50 percent of patients have positive stool assays for as long as six weeks after the completion of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Recurrent disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrence is defined by complete abatement of CDI symptoms while on appropriate therapy, followed by subsequent reappearance of diarrhea and other symptoms after treatment has been stopped. Recurrence should be distinguished from persistent diarrhea without resolution during initial therapy, which should prompt an evaluation for other causes. In the absence of an alternative diagnosis, such patients should be considered to have refractory illness.",
"   </p>",
"   <p>",
"    Recurrent CDI often results from reinfection with the same or a different strain of C. difficile [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. Studies using molecular methods have shown that up to one-half of recurrent episodes are reinfections rather than relapses of infection with the original strain [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recurrence occurs in approximately 25 percent of cases treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    , and patients may experience several episodes of recurrent colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/11,16,34-37\">",
"     11,16,34-37",
"    </a>",
"    ]. Most recurrences present within one to three weeks after discontinuing antibiotic therapy, although recurrences rarely can occur as late as two to three months. Recurrences may be mild or severe and may result from an impaired host immune response to C. difficile. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36137?source=see_link\">",
"     \"Clostridium difficile in adults: Epidemiology, microbiology, and pathophysiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Risk factors for recurrence include age &gt;65 years, severe underlying medical disorders, and the need for ongoing therapy with concomitant antibiotics during treatment for CDI [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/3,35,38,39\">",
"     3,35,38,39",
"    </a>",
"    ]. Patients with at least one episode of recurrent C. difficile have a 45 to 65 percent chance of additional episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Pathophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism of CDI recurrence following initial infection is not fully understood. It may be due to persistent spores from the initial infection. C. difficile spores in colonic diverticula, for example, may escape mechanical clearance by peristalsis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Impairment of the host immune response to C. difficile toxins may also be an important mechanism for recurrence. Asymptomatic carriers of C. difficile tend to have high serum antibody levels against C. difficile toxins [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/41\">",
"     41",
"    </a>",
"    ], while patients with recurrent CDI tend to have lower anti-toxin antibody levels than patients with a single, brief episode of diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/38,42-44\">",
"     38,42-44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antibiotic resistance does not appear to be a factor in recurrence. However, treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    for an initial episode of CDI may alter the colonic microenvironment (with regard to flora or other factors), potentially increasing susceptibility to reinfection and recurrence. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Metronidazole failure'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Management of initial recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The signs and symptoms of recurrence are similar to those in the initial episode, usually without progression in severity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/45\">",
"     45",
"    </a>",
"    ]. Because a positive stool toxin assay does not exclude asymptomatic carriage, other causes for diarrhea should be considered, including other infections, inflammatory bowel disease, or irritable bowel syndrome. Colonoscopy should be considered in atypical cases to evaluate for evidence of CDI and to exclude other etiologies.",
"   </p>",
"   <p>",
"    For treatment of an initial episode of CDI,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/28/15812?source=see_link\">",
"     fidaxomicin",
"    </a>",
"    has been associated with a lower incidence of recurrent CDI than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    (15 versus 25 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/46\">",
"     46",
"    </a>",
"    ]. For treatment of initial recurrence of CDI, the initial response to therapy with fidaxomicin and vancomycin has been observed to be comparable, although the likelihood of recurrence four weeks later is lower with fidaxomicin than vancomycin (20 versus 36 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with mild symptoms of recurrence who are otherwise well may be managed conservatively, without further antibiotic therapy. Non-severe initial recurrence following therapy for CDI can be treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    . The decision to administer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    as treatment for a first recurrence should be based upon the presence of markers of severe disease at the time of first recurrence, rather than on previous drug exposure.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/28/15812?source=see_link\">",
"     Fidaxomicin",
"    </a>",
"    is an alternative agent for treatment of an initial recurrence of CDI (",
"    <a class=\"graphic graphic_table graphicRef53273 \" href=\"UTD.htm?2/15/2301\">",
"     table 1",
"    </a>",
"    ). In one study including 128 patients with a first CDI recurrence, the recurrence rate was lower among patients treated with fidaxomicin than among patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    (19 versus 35 percent) (95% CI 30-0.3%; p = 0.045) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15770649\">",
"     'Fidaxomicin'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Management of subsequent recurrences",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with one recurrence have a substantial risk of subsequent CDI episodes after the second course of antibiotic therapy is discontinued. In one study, for example, patients with one or more previous recurrences had a subsequent recurrence rate of 65 percent following standard therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15770611\">",
"    <span class=\"h4\">",
"     Antibiotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no rigorous studies of management for multiple recurrences of CDI. Patients with multiple recurrences may benefit from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    (administered in a pulse tapered fashion),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/28/15812?source=see_link\">",
"     fidaxomicin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/17/37140?source=see_link\">",
"     rifaximin",
"    </a>",
"    , with or without the use of probiotics (",
"    <a class=\"graphic graphic_table graphicRef53273 \" href=\"UTD.htm?2/15/2301\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h5\">",
"     Vancomycin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    in a pulse tapered fashion may be effective for management of recurrent C. difficile infection (",
"    <a class=\"graphic graphic_table graphicRef53273 \" href=\"UTD.htm?2/15/2301\">",
"     table 1",
"    </a>",
"    ). The use of intermittent antibiotic therapy is based upon a theory that relapse may be due to the presence of persistent spores that survive antibiotic therapy. Intermittent therapy may allow the spores to germinate on the days when no antibiotics are administered. Once the spores have converted to the fully functional vegetative, toxin-producing forms, they are susceptible to killing when the antibiotics are readministered.",
"   </p>",
"   <p>",
"    A tapered oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    regimen consists of a stepwise decrease in dose over a period of time. Intermittent (or pulsed) vancomycin therapy consists of administering the drug every few days. Prolonged antibiotic therapy, with or without tapered or intermittent dosing, may also be important for definitive treatment.",
"   </p>",
"   <p>",
"    Intermittent and tapered",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    regimens have been evaluated in observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/28,35\">",
"     28,35",
"    </a>",
"    ]. In one study of 163 CDI cases, for example, 29 patients were treated with a vancomycin tapered regimen and 7 were treated with a vancomycin pulsed regimen; recurrence rates were 31 and 14 percent, respectively, compared with a recurrence rate of 45 percent for other regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2575688\">",
"    <span class=\"h5\">",
"     Rifaximin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small case series have suggested that sequential therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    followed by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/17/37140?source=see_link\">",
"     rifaximin",
"    </a>",
"    may be effective for the treatment of recurrent CDI [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. In one series, eight women with recurrent CDI received a two-week course of rifaximin when they were asymptomatic, immediately after completing their last course of vancomycin. Seven patients had no further recurrence of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Exposure to rifamycins prior the development of CDI is a risk factor for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    resistant C. difficile infection. In such cases, the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/17/37140?source=see_link\">",
"     rifaximin",
"    </a>",
"    for treatment of CDI may be limited [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15770649\">",
"    <span class=\"h5\">",
"     Fidaxomicin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/28/15812?source=see_link\">",
"     Fidaxomicin",
"    </a>",
"    is a macrocyclic antibiotic that is bactericidal against C. difficile (in contrast to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    , which are bacteriostatic) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/51\">",
"     51",
"    </a>",
"    ]. It has a narrower antimicrobial spectrum than metronidazole or vancomycin, leading to less disruption of the normal colonic anaerobic microflora [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/52-56\">",
"     52-56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a phase 3 randomized trial including 629 patients with non-severe C. difficile infection, clinical cure rates with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/28/15812?source=see_link\">",
"     fidaxomicin",
"    </a>",
"    (200 mg orally twice daily) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    (125 mg orally four times daily) were similar, but recurrence of C. difficile infection occurred significantly less often with fidaxomicin than with vancomycin among patients with non-NAP1 strains (10 versus 28 percent in the modified intention-to-treat population) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/46\">",
"     46",
"    </a>",
"    ]. Lower recurrence rates were not seen among patients with the NAP1 strain (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36137?source=see_link&amp;anchor=H11#H11\">",
"     \"Clostridium difficile in adults: Epidemiology, microbiology, and pathophysiology\", section on 'Hypervirulent strain: NAP1/BI/027'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/28/15812?source=see_link\">",
"     Fidaxomicin",
"    </a>",
"    may be an appropriate therapy in patients with recurrent CDI or perhaps as initial therapy in patients at high risk of developing recurrent disease, although parameters for its most appropriate use are still being defined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h4\">",
"     Probiotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies of probiotics are inconclusive regarding treatment benefit. This issue is discussed further separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21015?source=see_link\">",
"     \"Clostridium difficile and probiotics\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16554?source=see_link&amp;anchor=H7#H7\">",
"     \"Probiotics for gastrointestinal diseases\", section on 'Antibiotic-associated diarrhea'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8967771\">",
"    <span class=\"h4\">",
"     Fecal bacteriotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fecal bacteriotherapy may be useful for treatment of patients with recurrent CDI. This issue is discussed further separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/25/23960?source=see_link\">",
"     \"Fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h4\">",
"     Monoclonal antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjunctive use of monoclonal antibodies against C. difficile toxins A and B (in addition to antibiotic therapy) appears to reduce the recurrence rate of C. difficile infection; they are not yet available for routine clinical use. In a study of 200 patients with C. difficile treated with antibiotics (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    ) in addition to monoclonal antibodies or placebo, recurrence rates were 7 versus 25 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/57\">",
"     57",
"    </a>",
"    ]. Studies are needed to confirm these results for recurrent disease, as well as to determine whether monoclonal antibodies are useful in the management of severe disease or whether there is a role for prophylactic passive immunization for patients at highest risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SEVERE DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Definition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with acute C. difficile infection (CDI) may develop signs of systemic toxicity with or without profuse diarrhea warranting admission to an intensive care unit or emergency surgery.",
"   </p>",
"   <p>",
"    There is no consensus definition for severe CDI, nor is there agreement as to the most important clinical indicators that should be used to differentiate severity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/10,20,58\">",
"     10,20,58",
"    </a>",
"    ]. The following illustrate some definitions that have been described in the literature:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Guideline parameters for severe CDI include white blood cell count of &gt;15,000",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      or a serum creatinine level &ge;1.5 times the premorbid level [",
"      <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Clinicians in the setting of the Quebec outbreak identified a white blood cell count &gt;20,000",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      and an elevated serum creatinine as potential indicators of complicated disease [",
"      <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/20\">",
"       20",
"      </a>",
"      ]. Significantly elevated white blood cell counts in the absence of any other evident cause should raise suspicion for C. difficile infection.",
"     </li>",
"     <li>",
"      As part of a randomized trial comparing",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      , a scoring system was devised to identify patients with severe infection [",
"      <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/10\">",
"       10",
"      </a>",
"      ]. One point each was given for age &gt;60 years, temperature &gt;38.3&ordm;C, serum albumin &lt;2.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (25",
"      <span class=\"nowrap\">",
"       g/L),",
"      </span>",
"      or peripheral white blood cell count &gt;15,000",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      within 48 hours of enrollment. Two points were given for endoscopic evidence of pseudomembranous colitis or treatment in the intensive care unit. Patients with two or more points were considered to have severe disease.",
"     </li>",
"     <li>",
"      In a phase 3 trial of tolevamer versus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      , severe disease was defined as &ge;10 bowel movements per day, a peripheral white blood cell count &ge;20,000",
"      <span class=\"nowrap\">",
"       cells/microL,",
"      </span>",
"      or severe abdominal pain [",
"      <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For the purposes of the treatment decisions in the following discussion, determination of disease severity is left to clinician judgment and may include any or all of the criteria mentioned above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data on the incidence of severe CDI are limited, especially given the lack of a consensus definition. The risk of complications during first CDI recurrence in the Quebec outbreak caused by the hypervirulent North American Pulsed Field type 1 (NAP1) strain was 11 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/39\">",
"     39",
"    </a>",
"    ]. Complications included shock, need for colectomy, megacolon, perforation, or death within 30 days. Older age, high leukocyte count, and acute renal failure were strongly associated with a complicated course. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36137?source=see_link\">",
"     \"Clostridium difficile in adults: Epidemiology, microbiology, and pathophysiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with severe CDI (by clinician judgment) should receive antibiotic therapy, supportive care, and close monitoring. Surgery should be considered if the patient's clinical status fails to improve and the serum lactate is above 2.2 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/60\">",
"     60",
"    </a>",
"    ]. Toxic megacolon should be suspected if the patient develops abdominal distention with diminution of diarrhea; this may reflect paralytic ileus resulting from loss of colonic muscular tone [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/30/18920?source=see_link\">",
"     \"Toxic megacolon\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H24\">",
"     'Surgery'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines issued in 2010 by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Disease Society of America (IDSA) recommend oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    as first-line therapy for severe CDI [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/1\">",
"     1",
"    </a>",
"    ]. This is in contrast to previous guidelines published in the 1990s which recommended oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    as initial therapy for both mild and severe C. difficile-associated diarrhea (CDAD) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. This change reflects reports of frequent metronidazole failures in CDI and studies showing the superiority of oral vancomycin in severe disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/10-12,20,59\">",
"     10-12,20,59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The major pharmacologic advantage of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    over",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    is that vancomycin is not absorbed, so maximal concentrations of the drug can act intracolonically at the site of infection. The major advantage of metronidazole over vancomycin is that the cost of metronidazole is substantially lower. With respect to in vitro activity, risk of relapse, and potential for emergence of vancomycin resistant enterococci, the drugs appear to be relatively similar [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/17,22,52,61,62\">",
"     17,22,52,61,62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    is the preferred therapy for severe or refractory cases [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/1,10,39,59,63\">",
"     1,10,39,59,63",
"    </a>",
"    ]. This issue was directly addressed in a prospective, randomized double-blind trial that included 69 patients with severe CDI as defined above [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/10\">",
"     10",
"    </a>",
"    ]. The cure rate was significantly higher with vancomycin (97 versus 76 percent with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Definition'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Although the data are limited, clinical practice is shifting toward using oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    as initial therapy for severe CDI [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/64\">",
"     64",
"    </a>",
"    ]. Many have endorsed vancomycin as the preferred therapy for moderate or severe disease caused by the epidemic strain, and most favor its use for all patients with severe",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    complicated disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/1,22,61,65\">",
"     1,22,61,65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intracolonic administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    via enema (given in combination with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    ) is an option for patients who do not tolerate oral medication, but there is risk of colonic perforation. Therefore, use of intracolonic vancomycin should be restricted to patients who are unresponsive to standard therapies, and the procedure should be performed by personnel with expertise in administering enemas. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Intracolonic antibiotics'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h4\">",
"     Oral antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    (125 mg four times daily) should be initiated promptly for severely ill patients. Some data suggest that levels achieved with higher dosing of vancomycin (500 mg four times daily) may be equivalent to levels with standard dosing [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/27\">",
"     27",
"    </a>",
"    ]. Nevertheless, many clinicians favor higher dosing for severe disease although there is no supportive evidence [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with severe disease who do not demonstrate clinical improvement with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    , administration of therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/28/15812?source=see_link\">",
"     fidaxomicin",
"    </a>",
"    is reasonable. Additional data are needed on the efficacy of fidaxomicin in the setting of severe disease. (See",
"    <a class=\"local\" href=\"#H15770649\">",
"     'Fidaxomicin'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For circumstances in which neither",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    nor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/28/15812?source=see_link\">",
"     fidaxomicin",
"    </a>",
"    is available, oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    (500 mg three times daily or 250 mg four times daily for 14 days) may be administered, although it is less effective than vancomycin [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h4\">",
"     Intravenous antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severely ill patients with ileus may have markedly delayed passage of oral antibiotics from the stomach to the colon. These individuals may benefit from the addition of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    at a dose of 500 mg every eight hours. Fecal concentrations in the therapeutic range can be achieved with this regimen because of biliary and intestinal excretion of the drug [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. However, it is uncertain whether intravenous therapy alone is as effective as oral therapy, so oral therapy should be administered whenever feasible [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    has no effect on C. difficile colitis since vancomycin is not excreted into the colon.",
"   </p>",
"   <p>",
"    Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/7/40053?source=see_link\">",
"     tigecycline",
"    </a>",
"    has been used in a small number of patients with severe CDI that was refractory to standard therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h4\">",
"     Intracolonic antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intracolonic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    (vancomycin enema) may be an effective adjunctive therapy for patients who cannot tolerate the oral preparation, or patients who have megacolon or ileus which would prevent oral vancomycin from reaching the colon [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/68-70\">",
"     68-70",
"    </a>",
"    ]. In a case series of nine patients with refractory symptoms, toxic megacolon, or fulminant colitis, rectal vancomycin was administered in addition to standard antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/68\">",
"     68",
"    </a>",
"    ]. Eight patients had complete resolution of symptoms and one patient died from multisystem organ failure.",
"   </p>",
"   <p>",
"    Intracolonic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    may be useful in the setting of profound ileus that impairs the distal delivery of orally administered drugs. Although the optimal dosing and volume has not been established by clinical trials and case descriptions vary widely, rectal vancomycin is often given as a retention enema containing 500 mg in 100 mL of normal saline every 6 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/1,68,69,71-75\">",
"     1,68,69,71-75",
"    </a>",
"    ]. One report suggests that patients with megacolon may benefit from colonoscopic decompression and placement of a tube in the right colon which can be perfused with a 1",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    solution of vancomycin in normal saline to deliver a total dose of 1 to 2 g per day [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/69\">",
"     69",
"    </a>",
"    ]; however, this requires further confirmation. Dose adjustments may be required depending on individual circumstances including extent of colonic disease and patient weight. It is important to note that vancomycin can be absorbed through inflamed colonic mucosa and cause toxicity if it accumulates in patients with renal failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/47/15096?source=see_link\">",
"     \"Vancomycin dosing and serum concentration monitoring in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h4\">",
"     Antibiotic recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend that patients with severe disease be treated with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    (125 mg four times daily). For patients with severe disease who do not demonstrate clinical improvement, we suggest increasing the dose of oral vancomycin to 500 mg four times daily.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/28/15812?source=see_link\">",
"     Fidaxomicin",
"    </a>",
"    may be considered in patients who cannot tolerate vancomycin, although more data are needed. In the setting of ileus, addition of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    (500 mg every eight hours) is appropriate. Intracolonic vancomycin may be considered in patients with profound ileus.",
"   </p>",
"   <p>",
"    The standard duration of antibiotic therapy for C. difficile diarrhea is 10 to 14 days; the antibiotic course should be tailored to clinical circumstances for patients with severe disease. Those with an underlying infection requiring prolonged duration of antibiotics should continue CDI treatment throughout the antibiotic course plus one additional week after its completion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some severely ill patients with CDI require surgical intervention as a result of toxic megacolon, perforation or impending perforation, necrotizing colitis or rapidly progressive",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    refractory disease with systemic inflammatory response syndrome leading to multiorgan system failure [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. The optimal timing of surgery remains uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h4\">",
"     Timing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Literature written prior to the emergence of the hypervirulent strain suggested surgery for CDI patients with severe disease unresponsive to medical therapy within 48 hours, bowel perforation, or multiorgan system failure [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/78\">",
"     78",
"    </a>",
"    ]. However, in the setting of CDI due to the hypervirulent strain, some patients progressed from severe disease to death in less than 48 hours. Furthermore, some patients with severe disease cannot receive enteral therapy due to ileus or severe nausea and vomiting.",
"   </p>",
"   <p>",
"    Data from the Canadian outbreak with the hypervirulent strain have been used to try to standardize criteria for surgical intervention. In a retrospective review, colectomy was most beneficial for immunocompetent patients aged &ge;65 years with a white blood cell count &ge;20,000",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a plasma lactate between 2.2 and 4.9",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We favor early surgery for patients with the above criteria. In addition, surgical intervention is advisable in the setting of peritoneal signs, severe ileus, or toxic megacolon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26275430\">",
"    <span class=\"h4\">",
"     Procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two surgical approaches for management of CDI have been described: subtotal colectomy (removal of the entire colon with ileostomy, without removal of the rectum), and diverting loop ileostomy with colonic lavage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h5\">",
"     Subtotal colectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subtotal colectomy is the procedure for which there is greatest experience in the setting of emergency surgical intervention for CDI [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/60,79-81\">",
"     60,79-81",
"    </a>",
"    ]. In a retrospective review of 14 patients who underwent surgery for severe CDI, nine patients survived, of whom eight had subtotal colectomy and one had a right hemicolectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/79\">",
"     79",
"    </a>",
"    ]. Four of the five patients who died had undergone left hemicolectomy.",
"   </p>",
"   <p>",
"    Primary anastomosis is not feasible acutely due to the pancolitis associated with severe disease. However, after colonic inflammation has subsided, closure of the ileostomy and ileorectal anastomosis can be created.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26275469\">",
"    <span class=\"h5\">",
"     Diverting loop ileostomy and colonic lavage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diverting loop ileostomy and colonic lavage may be a potential alternative procedure to colectomy in the treatment of severe, complicated CDI. In one study including 42 patients with severe CDI, reduced mortality was observed among patients who underwent loop ileostomy and colonic lavage, compared with the historical controls who underwent colectomy (19 versus 50 percent; odds ratio, 0.24; P = 0.006) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/82\">",
"     82",
"    </a>",
"    ]. The surgical approach involved creation of a loop ileostomy, intraoperative colonic lavage with warmed polyethylene glycol solution via the ileostomy, and postoperative antegrade instillation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    flushes via the ileostomy. Preservation of the colon was achieved in 93 percent of patients. This surgical approach is potentially promising, but further data from prospective, randomized controlled trials are needed to validate this preliminary study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     METRONIDAZOLE FAILURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reasons for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    failure are poorly understood [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/83\">",
"     83",
"    </a>",
"    ]. Stool metronidazole concentrations in patients receiving the drug orally are higher in watery stools at the beginning of C. difficile infection (CDI) treatment than in semiformed stools a few days later [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/24\">",
"     24",
"    </a>",
"    ]. Thus, stool metronidazole levels decrease as colonic inflammation subsides. In contrast, oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    maintains high stool concentrations (1000 to 3000",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    throughout the course of therapy) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/24,84\">",
"     24,84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given these observations, even a modest increase in an organism's minimum inhibitory concentration for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    might lead to insufficient stool levels after a few days of treatment. Although some metronidazole resistance in C. difficile has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/85-89\">",
"     85-89",
"    </a>",
"    ], resistance rates are low and do not appear to be increasing in the setting of the rising rates of treatment failure [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/36,90-92\">",
"     36,90-92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Risk factors associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    failure include recent cephalosporin use, C. difficile on admission and transfer from another hospital [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     ALTERNATIVE THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other therapeutic options for C. difficile infection (CDI) are being developed, and drugs used for other infections are being studied as alternatives to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Probiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies of probiotics are inconclusive regarding benefit. The data are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21015?source=see_link\">",
"     \"Clostridium difficile and probiotics\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8967983\">",
"    <span class=\"h2\">",
"     Fecal bacteriotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fecal bacteriotherapy may be useful for treatment of patients with recurrent CDI. This issue is discussed further separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/25/23960?source=see_link\">",
"     \"Fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Alternative antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of 12 studies including 1157 participants evaluated eight different antibiotics for the treatment of CDI:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/9/21651?source=see_link\">",
"     fusidic acid",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/24/5508?source=see_link\">",
"     nitazoxanide",
"    </a>",
"    , teicoplanin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/17/37140?source=see_link\">",
"     rifaximin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/20/6469?source=see_link\">",
"     bacitracin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/7\">",
"     7",
"    </a>",
"    ]. In paired comparisons, no single antibiotic was clearly superior to others. Combination therapy has been tried without success [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/24/5508?source=see_link\">",
"     Nitazoxanide",
"    </a>",
"    may be as effective as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    (as suggested by a randomized trial of 50 CDI patients), although the small sample precluded conclusions about noninferiority of nitazoxanide to vancomycin [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Teicoplanin may be at least as effective as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    , although it is costly and is not available in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/11,97\">",
"     11,97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/28/15812?source=see_link\">",
"     Fidaxomicin",
"    </a>",
"    was approved by the United States Food and Drug Administration (FDA) in 2011. (See",
"    <a class=\"local\" href=\"#H15770649\">",
"     'Fidaxomicin'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Anion-binding resins",
"    </span>",
"    &nbsp;&mdash;&nbsp;The importance of toxin production in the pathophysiology of C. difficile diarrhea has prompted consideration of anion-binding resins as a possible alternative to antimicrobial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/98\">",
"     98",
"    </a>",
"    ]. An advantage of resin therapy is that the bowel flora is not altered, as occurs with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    . This may allow more rapid reconstitution of the normal colonic flora.",
"   </p>",
"   <p>",
"    The anion-binding resins",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/26/12710?source=see_link\">",
"     colestipol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36374?source=see_link\">",
"     cholestyramine",
"    </a>",
"    are not effective as primary therapy for C. difficile colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/99,100\">",
"     99,100",
"    </a>",
"    ], although they may be beneficial as adjunctive therapy for relapsing infection [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/101\">",
"     101",
"    </a>",
"    ]. In a series of 11 patients with relapsing CDI, the administration of colestipol with tapered",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    led to sustained resolution in all patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Anion-exchange resins bind",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    as well as toxins; thus, the resin must be taken at least two or three hours apart from the vancomycin [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/98\">",
"     98",
"    </a>",
"    ]. Suggested regimens are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/26/12710?source=see_link\">",
"     colestipol",
"    </a>",
"    (5 g every 12 hours) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36374?source=see_link\">",
"     cholestyramine",
"    </a>",
"    (4 g three or four times daily) for one to two weeks, usually with vancomycin.",
"   </p>",
"   <p>",
"    Tolevamer is a C. difficile toxin binding resin developed specifically for CDI [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/59,102\">",
"     59,102",
"    </a>",
"    ]. Preliminary studies with tolevamer showed promising results. However, two large multicenter trials found that it was inferior to both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    as primary therapy for CDI [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Intravenous immunoglobulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous immunoglobulin (IVIG) contains C. difficile antitoxin and has been used in some patients with relapsing or severe C. difficile colitis. Although there are case reports suggesting IVIG may be a useful addition to antibiotic therapy for refractory CDI [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/42,103,104\">",
"     42,103,104",
"    </a>",
"    ], a retrospective review of 18 patients who received IVIG demonstrated no significant difference in clinical outcomes compared with 18 matched control cases [",
"    <a class=\"abstract\" href=\"UTD.htm?20/29/20954/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/47/28402?source=see_link\">",
"       \"Patient information: Antibiotic-associated diarrhea (C. difficile infection) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?18/52/19267?source=see_link\">",
"       \"Patient information: Antibiotic-associated diarrhea caused by Clostridium difficile (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The initial step in the treatment of Clostridium difficile infection (CDI) is cessation of the inciting antibiotic as soon as possible. Infection control practices must be implemented, including contact precautions and hand hygiene. Hand hygiene with soap and water may be more effective than alcohol-based hand sanitizers in removing C. difficile spores, since C. difficile spores are resistant to killing by alcohol. Therefore, use of soap and water is favored over alcohol-based hand sanitization in the setting of a CDI outbreak, although thus far no studies have demonstrated superiority of soap and water in non-outbreak settings. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General management principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For initial treatment of non-severe CDI, we suggest oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Initial therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For treatment of severe CDI we recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      125 mg four times daily for 10 to 14 days (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). For patients with severe disease who do not demonstrate clinical improvement, we suggest treatment with oral vancomycin 500 mg four times daily (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      );",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/28/15812?source=see_link\">",
"       fidaxomicin",
"      </a>",
"      may be considered in patients who cannot tolerate vancomycin, although more data are needed. In critically ill patients with fulminant or refractory disease, we suggest oral vancomycin 500 mg four times daily and intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      500 mg every eight hours (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ); fidaxomicin may be considered in patients who cannot tolerate vancomycin, although more data are needed. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For treatment of severe disease in patients with profound ileus, we suggest intracolonic",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ), but there is risk of colonic perforation. Therefore, use of intracolonic vancomycin should be restricted to patients who are not responsive to oral therapy, and the procedure should be performed by personnel with expertise in administering enemas. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For treatment of a non-severe initial recurrence of CDI, we suggest oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). Alternatives include oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/28/15812?source=see_link\">",
"       fidaxomicin",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Management of initial recurrence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For treatment of a second recurrence of CDI, we suggest intermittent and tapering",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      therapy or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/28/15812?source=see_link\">",
"       fidaxomicin",
"      </a>",
"      (",
"      <a class=\"graphic graphic_table graphicRef53273 \" href=\"UTD.htm?2/15/2301\">",
"       table 1",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). For treatment of subsequent recurrences of CDI, we suggest administering either fidaxomicin or vancomycin followed by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/17/37140?source=see_link\">",
"       rifaximin",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Management of subsequent recurrences'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend urgent surgical evaluation for patients with a white blood cell count &ge;20,000",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a plasma lactate between 2.2 and 4.9",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). In addition, surgical intervention should be strongly considered",
"      <strong>",
"      </strong>",
"      in the setting of peritoneal signs, severe ileus, or toxic megacolon. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Potential alternative therapies requiring further investigation prior to routine use include new antibiotic agents, binding resins, intravenous immunoglobulin, and fecal bacteriotherapy. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Alternative therapies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/1\">",
"      Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/2\">",
"      Kelly CP, LaMont JT. Clostridium difficile--more difficult than ever. N Engl J Med 2008; 359:1932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/3\">",
"      Hu MY, Katchar K, Kyne L, et al. Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection. Gastroenterology 2009; 136:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/4\">",
"      Mullane KM, Miller MA, Weiss K, et al. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin Infect Dis 2011; 53:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/5\">",
"      Wilcox MH, Howe R. Diarrhoea caused by Clostridium difficile: response time for treatment with metronidazole and vancomycin. J Antimicrob Chemother 1995; 36:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/6\">",
"      Koo HL, Koo DC, Musher DM, DuPont HL. Antimotility agents for the treatment of Clostridium difficile diarrhea and colitis. Clin Infect Dis 2009; 48:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/7\">",
"      Nelson R. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev 2007; :CD004610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/8\">",
"      Drekonja DM, Butler M, MacDonald R, et al. Comparative effectiveness of Clostridium difficile treatments: a systematic review. Ann Intern Med 2011; 155:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/9\">",
"      Leffler DA, Lamont JT. Treatment of Clostridium difficile-associated disease. Gastroenterology 2009; 136:1899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/10\">",
"      Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/11\">",
"      Wenisch C, Parschalk B, Hasenh&uuml;ndl M, et al. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis 1996; 22:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/12\">",
"      Teasley DG, Gerding DN, Olson MM, et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis. Lancet 1983; 2:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/13\">",
"      Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). Am J Infect Control 1995; 23:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/14\">",
"      Hospital Infection Control Practices Advisory Committee (HICPAC). Recommendations for preventing the spread of vancomycin resistance. Infect Control Hosp Epidemiol 1995; 16:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/15\">",
"      ASHP therapeutic position statement on the preferential use of metronidazole for the treatment of Clostridium difficile-associated disease. Am J Health Syst Pharm 1998; 55:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/16\">",
"      Fekety R. Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 1997; 92:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/17\">",
"      Carmeli Y, Eliopoulos GM, Samore MH. Antecedent treatment with different antibiotic agents as a risk factor for vancomycin-resistant Enterococcus. Emerg Infect Dis 2002; 8:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/18\">",
"      Al-Nassir WN, Sethi AK, Li Y, et al. Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease. Antimicrob Agents Chemother 2008; 52:2403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/19\">",
"      Pepin J, Alary ME, Valiquette L, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005; 40:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/20\">",
"      P&eacute;pin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004; 171:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/21\">",
"      P&eacute;pin J, Valiquette L, Gagnon S, et al. Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027. Am J Gastroenterol 2007; 102:2781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/22\">",
"      Pepin J. Vancomycin for the treatment of Clostridium difficile Infection: for whom is this expensive bullet really magic? Clin Infect Dis 2008; 46:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/23\">",
"      Borody TJ, Warren EF, Leis SM, et al. Bacteriotherapy using fecal flora: toying with human motions. J Clin Gastroenterol 2004; 38:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/24\">",
"      Bolton RP, Culshaw MA. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut 1986; 27:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/25\">",
"      Kleinfeld DI, Sharpe RJ, Donta ST. Parenteral therapy for antibiotic-associated pseudomembranous colitis. J Infect Dis 1988; 157:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/26\">",
"      Friedenberg F, Fernandez A, Kaul V, et al. Intravenous metronidazole for the treatment of Clostridium difficile colitis. Dis Colon Rectum 2001; 44:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/27\">",
"      Fekety R, Silva J, Kauffman C, et al. Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. Am J Med 1989; 86:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/28\">",
"      McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002; 97:1769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/29\">",
"      Walters BA, Roberts R, Stafford R, Seneviratne E. Relapse of antibiotic associated colitis: endogenous persistence of Clostridium difficile during vancomycin therapy. Gut 1983; 24:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/30\">",
"      Young G, McDonald M. Antibiotic-associated colitis: why do patients relapse? Gastroenterology 1986; 90:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/31\">",
"      Wilcox MH, Fawley WN, Settle CD, Davidson A. Recurrence of symptoms in Clostridium difficile infection--relapse or reinfection? J Hosp Infect 1998; 38:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/32\">",
"      Barbut F, Richard A, Hamadi K, et al. Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea. J Clin Microbiol 2000; 38:2386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/33\">",
"      Nor&eacute;n T, Akerlund T, B&auml;ck E, et al. Molecular epidemiology of hospital-associated and community-acquired Clostridium difficile infection in a Swedish county. J Clin Microbiol 2004; 42:3635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/34\">",
"      Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med 1994; 330:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/35\">",
"      Tedesco FJ, Gordon D, Fortson WC. Approach to patients with multiple relapses of antibiotic-associated pseudomembranous colitis. Am J Gastroenterol 1985; 80:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/36\">",
"      Bartlett JG, Tedesco FJ, Shull S, et al. Symptomatic relapse after oral vancomycin therapy of antibiotic-associated pseudomembranous colitis. Gastroenterology 1980; 78:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/37\">",
"      McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994; 271:1913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/38\">",
"      Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001; 357:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/39\">",
"      P&eacute;pin J, Routhier S, Gagnon S, Brazeau I. Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada. Clin Infect Dis 2006; 42:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/40\">",
"      McFarland LV. Alternative treatments for Clostridium difficile disease: what really works? J Med Microbiol 2005; 54:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/41\">",
"      Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000; 342:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/42\">",
"      Leung DY, Kelly CP, Boguniewicz M, et al. Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr 1991; 118:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/43\">",
"      Aboudola S, Kotloff KL, Kyne L, et al. Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A. Infect Immun 2003; 71:1608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/44\">",
"      Kelly CP. Immune response to Clostridium difficile infection. Eur J Gastroenterol Hepatol 1996; 8:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/45\">",
"      Fekety R, McFarland LV, Surawicz CM, et al. Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin Infect Dis 1997; 24:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/46\">",
"      Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/47\">",
"      Cornely OA, Miller MA, Louie TJ, et al. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. Clin Infect Dis 2012; 55 Suppl 2:S154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/48\">",
"      Johnson S, Schriever C, Galang M, et al. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis 2007; 44:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/49\">",
"      Garey KW, Ghantoji SS, Shah DN, et al. A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. J Antimicrob Chemother 2011; 66:2850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/50\">",
"      Curry SR, Marsh JW, Shutt KA, et al. High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital. Clin Infect Dis 2009; 48:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/51\">",
"      Venugopal AA, Johnson S. Fidaxomicin: a novel macrocyclic antibiotic approved for treatment of Clostridium difficile infection. Clin Infect Dis 2012; 54:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/52\">",
"      Hecht DW, Galang MA, Sambol SP, et al. In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother 2007; 51:2716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/53\">",
"      Ackermann G, L&ouml;ffler B, Adler D, Rodloff AC. In vitro activity of OPT-80 against Clostridium difficile. Antimicrob Agents Chemother 2004; 48:2280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/54\">",
"      Finegold SM, Molitoris D, Vaisanen ML, et al. In vitro activities of OPT-80 and comparator drugs against intestinal bacteria. Antimicrob Agents Chemother 2004; 48:4898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/55\">",
"      Credito KL, Appelbaum PC. Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species. Antimicrob Agents Chemother 2004; 48:4430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/56\">",
"      Tannock GW, Munro K, Taylor C, et al. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. Microbiology 2010; 156:3354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/57\">",
"      Lowy I, Molrine DC, Leav BA, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010; 362:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/58\">",
"      Rubin MS, Bodenstein LE, Kent KC. Severe Clostridium difficile colitis. Dis Colon Rectum 1995; 38:350.",
"     </a>",
"    </li>",
"    <li>",
"     Louie T, Gerson M, Grimard D, et al. Results of a phase III trial comparing tolevamer, vancomycin and metronidazole in Clostridium difficile-associated diarrhea (CDAD) [abstract K-425a]. In: Program and abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago, IL). Washington, DC: American Society for Microbiology, 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/60\">",
"      Lamontagne F, Labb&eacute; AC, Haeck O, et al. Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain. Ann Surg 2007; 245:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/61\">",
"      Bartlett JG. The case for vancomycin as the preferred drug for treatment of Clostridium difficile infection. Clin Infect Dis 2008; 46:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/62\">",
"      Gerding DN. Is there a relationship between vancomycin-resistant enterococcal infection and Clostridium difficile infection? Clin Infect Dis 1997; 25 Suppl 2:S206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/63\">",
"      Bartlett JG, Perl TM. The new Clostridium difficile--what does it mean? N Engl J Med 2005; 353:2503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/64\">",
"      Nielsen ND, Layton BA, McDonald LC, et al. Changing epidemiology of Clostridium difficile-associated disease. Infect Dis Clin Pract 2006; 14:296.",
"     </a>",
"    </li>",
"    <li>",
"     Institut National de Sant&eacute; du Qu&eacute;bec. Pr&eacute;vention et contr&ocirc;le de la diarrh&eacute;e nosocomiale associ&eacute;e au Clostridium difficile au Qu&eacute;bec [in French]. 3rd ed. Quebec City, Quebec, Canada: Institut National de Sant&eacute; du Qu&eacute;bec, 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/66\">",
"      Wenisch JM, Schmid D, Tucek G, et al. A prospective cohort study on hospital mortality due to Clostridium difficile infection. Infection 2012; 40:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/67\">",
"      Herpers BL, Vlaminckx B, Burkhardt O, et al. Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection. Clin Infect Dis 2009; 48:1732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/68\">",
"      Apisarnthanarak A, Razavi B, Mundy LM. Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: case series and review of the literature. Clin Infect Dis 2002; 35:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/69\">",
"      Shetler K, Nieuwenhuis R, Wren SM, Triadafilopoulos G. Decompressive colonoscopy with intracolonic vancomycin administration for the treatment of severe pseudomembranous colitis. Surg Endosc 2001; 15:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/70\">",
"      Nathanson DR, Sheahan M, Chao L, Wallack MK. Intracolonic use of vancomycin for treatment of clostridium difficile colitis in a patient with a diverted colon: report of a case. Dis Colon Rectum 2001; 44:1871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/71\">",
"      Halsey J. Current and future treatment modalities for Clostridium difficile-associated disease. Am J Health Syst Pharm 2008; 65:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/72\">",
"      Apisarnthanarak A, Khoury H, Reinus WR, et al. Severe Clostridium difficile colitis: the role of intracolonic vancomycin? Am J Med 2002; 112:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/73\">",
"      Goodpasture HC, Dolan PJ Jr, Jacobs ER, Meredith WT. Pseudomembranous colitis &amp; antibiotics. Kans Med 1986; 87:133, 146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/74\">",
"      Silva J Jr. Update on pseudomembranous colitis. West J Med 1989; 151:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/75\">",
"      McMaster-Baxter NL, Musher DM. Clostridium difficile: recent epidemiologic findings and advances in therapy. Pharmacotherapy 2007; 27:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/76\">",
"      Sailhamer EA, Carson K, Chang Y, et al. Fulminant Clostridium difficile colitis: patterns of care and predictors of mortality. Arch Surg 2009; 144:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/77\">",
"      Miller MA. Clinical management of Clostridium difficile-associated disease. Clin Infect Dis 2007; 45 Suppl 2:S122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/78\">",
"      Dallal RM, Harbrecht BG, Boujoukas AJ, et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg 2002; 235:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/79\">",
"      Koss K, Clark MA, Sanders DS, et al. The outcome of surgery in fulminant Clostridium difficile colitis. Colorectal Dis 2006; 8:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/80\">",
"      Morris JB, Zollinger RM Jr, Stellato TA. Role of surgery in antibiotic-induced pseudomembranous enterocolitis. Am J Surg 1990; 160:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/81\">",
"      Longo WE, Mazuski JE, Virgo KS, et al. Outcome after colectomy for Clostridium difficile colitis. Dis Colon Rectum 2004; 47:1620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/82\">",
"      Neal MD, Alverdy JC, Hall DE, et al. Diverting loop ileostomy and colonic lavage: an alternative to total abdominal colectomy for the treatment of severe, complicated Clostridium difficile associated disease. Ann Surg 2011; 254:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/83\">",
"      Gerding DN. Metronidazole for Clostridium difficile-associated disease: is it okay for Mom? Clin Infect Dis 2005; 40:1598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/84\">",
"      Johnson S, Homann SR, Bettin KM, et al. Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial. Ann Intern Med 1992; 117:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/85\">",
"      Olsson-Liljequist B, Nord CE. In vitro susceptibility of anaerobic bacteria to nitroimidazoles. Scand J Infect Dis Suppl 1981; 26:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/86\">",
"      Brazier JS, Fawley W, Freeman J, Wilcox MH. Reduced susceptibility of Clostridium difficile to metronidazole. J Antimicrob Chemother 2001; 48:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/87\">",
"      Wong SS, Woo PC, Luk WK, Yuen KY. Susceptibility testing of Clostridium difficile against metronidazole and vancomycin by disk diffusion and Etest. Diagn Microbiol Infect Dis 1999; 34:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/88\">",
"      Barbut F, Decr&eacute; D, Burghoffer B, et al. Antimicrobial susceptibilities and serogroups of clinical strains of Clostridium difficile isolated in France in 1991 and 1997. Antimicrob Agents Chemother 1999; 43:2607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/89\">",
"      Baines SD, O'Connor R, Freeman J, et al. Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J Antimicrob Chemother 2008; 62:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/90\">",
"      Pel&aacute;ez T, Alcal&aacute; L, Alonso R, et al. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob Agents Chemother 2002; 46:1647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/91\">",
"      McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005; 353:2433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/92\">",
"      Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353:2442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/93\">",
"      Hu MY, Maroo S, Kyne L, et al. A prospective study of risk factors and historical trends in metronidazole failure for Clostridium difficile infection. Clin Gastroenterol Hepatol 2008; 6:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/94\">",
"      Treatment of Clostridium difficile-associated disease (CDAD). Med Lett Drugs Ther 2006; 48:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/95\">",
"      Lagrotteria D, Holmes S, Smieja M, et al. Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile-associated diarrhea. Clin Infect Dis 2006; 43:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/96\">",
"      Musher DM, Logan N, Bressler AM, et al. Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study. Clin Infect Dis 2009; 48:e41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/97\">",
"      de Lalla F, Nicolin R, Rinaldi E, et al. Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea. Antimicrob Agents Chemother 1992; 36:2192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/98\">",
"      Taylor NS, Bartlett JG. Binding of Clostridium difficile cytotoxin and vancomycin by anion-exchange resins. J Infect Dis 1980; 141:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/99\">",
"      Mogg GA, Arabi Y, Youngs D, et al. Therapeutic trials of antibiotic associated colitis. Scand J Infect Dis Suppl 1980; :41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/100\">",
"      Kreutzer EW, Milligan FD. Treatment of antibiotic-associated pseudomembranous colitis with cholestyramine resin. Johns Hopkins Med J 1978; 143:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/101\">",
"      Tedesco FJ. Treatment of recurrent antibiotic-associated pseudomembranous colitis. Am J Gastroenterol 1982; 77:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/102\">",
"      Louie TJ, Peppe J, Watt CK, et al. Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea. Clin Infect Dis 2006; 43:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/103\">",
"      Salcedo J, Keates S, Pothoulakis C, et al. Intravenous immunoglobulin therapy for severe Clostridium difficile colitis. Gut 1997; 41:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/104\">",
"      Warny M, Denie C, Delm&eacute;e M, Lefebvre C. Gamma globulin administration in relapsing Clostridium difficile-induced pseudomembranous colitis with a defective antibody response to toxin A. Acta Clin Belg 1995; 50:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/29/20954/abstract/105\">",
"      Juang P, Skledar SJ, Zgheib NK, et al. Clinical outcomes of intravenous immune globulin in severe clostridium difficile-associated diarrhea. Am J Infect Control 2007; 35:131.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2698 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.66.252.144-2A34E2F131-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_29_20954=[""].join("\n");
var outline_f20_29_20954=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H35\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL MANAGEMENT PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INDICATIONS FOR TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2489959\">",
"      NON SEVERE DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Initial therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Antibiotic dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Recurrent disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Management of initial recurrence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Management of subsequent recurrences",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15770611\">",
"      Antibiotic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Vancomycin",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H2575688\">",
"      - Rifaximin",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H15770649\">",
"      - Fidaxomicin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Probiotic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8967771\">",
"      Fecal bacteriotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Monoclonal antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SEVERE DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Definition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Oral antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Intravenous antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Intracolonic antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Antibiotic recommendations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Timing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H26275430\">",
"      Procedure",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Subtotal colectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H26275469\">",
"      - Diverting loop ileostomy and colonic lavage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      METRONIDAZOLE FAILURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      ALTERNATIVE THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Probiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8967983\">",
"      Fecal bacteriotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Alternative antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Anion-binding resins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Intravenous immunoglobulin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2698\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2698|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/12/44237\" title=\"figure 1\">",
"      Vancomycin dose C diff diarrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2698|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/15/2301\" title=\"table 1\">",
"      Rx CDAD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21015?source=related_link\">",
"      Clostridium difficile and probiotics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29305?source=related_link\">",
"      Clostridium difficile in adults: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36137?source=related_link\">",
"      Clostridium difficile in adults: Epidemiology, microbiology, and pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/25/23960?source=related_link\">",
"      Fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/47/28402?source=related_link\">",
"      Patient information: Antibiotic-associated diarrhea (C. difficile infection) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/52/19267?source=related_link\">",
"      Patient information: Antibiotic-associated diarrhea caused by Clostridium difficile (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/57/12184?source=related_link\">",
"      Prevention and control of Clostridium difficile in hospital and institutional settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16554?source=related_link\">",
"      Probiotics for gastrointestinal diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/30/18920?source=related_link\">",
"      Toxic megacolon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/47/15096?source=related_link\">",
"      Vancomycin dosing and serum concentration monitoring in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_29_20955="Treatment diarrhea pts on IFL";
var content_f20_29_20955=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F62912&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F62912&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations of an independent panel for management of diarrhea in patients receiving the IFL regimen",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Clinical presentation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Intervention",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diarrhea, any grade",
"       </td>",
"       <td>",
"        Oral loperamide (2 mg every two hours) until diarrhea-free for &ge;12 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diarrhea persists on loperamide &gt;24 hours",
"       </td>",
"       <td>",
"        Oral fluoroquinolone for seven days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diarrhea persists on loperamide &gt;48 hours",
"       </td>",
"       <td>",
"        Stop loperamide; hospitalize the patient, adminsiter IV fluids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neutropenic (ANC &lt;500 microL), even in the absence of fever or diarrhea",
"       </td>",
"       <td>",
"        Oral fluoroquinolone, continue until resolution of neutropenia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fever with persistent diarrhea, even in absence of neutropenia",
"       </td>",
"       <td>",
"        Oral fluoroquinolone, continue until resolution of fever and diarrhea",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IFL: irinotecan, 5-fluorouracil, leucovorin; ANC: absolute neutrophil count.",
"    </div>",
"    <div class=\"reference\">",
"     Rothenberg ML, et al. J Clin Oncol 2001; 19:3801.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_29_20955=[""].join("\n");
var outline_f20_29_20955=null;
var title_f20_29_20956="MD responsibility sleep apnea";
var content_f20_29_20956=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F52085&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F52085&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Summary of the responsibilities of clinicians who care for patients with sleep apnea",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td colspan=\"1\">",
"        Consult an attorney to",
"learn about applicable laws and regulations in your state. Laws",
"regarding impaired drivers, including those with sleep apnea, vary",
"widely from state to state. For example, some states require reporting",
"based on diagnosis alone, while some states permit reporting but do not",
"require it. Other states have no pertinent statute(s) at all. Whether",
"or not a statutory reporting duty exists, physicians may be liable for",
"damages if a patient with sleep apnea injures himself or someone else",
"while driving.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        Be alert for excessive",
"sleepiness or other symptoms of sleep apnea in any patient who operates",
"a motor vehicle. Be especially alert to these symptoms in those",
"patients who drive a bus or who are otherwise occupationally",
"responsible for driving.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        Carefully diagnose and",
"treat any patient whom you suspect of having sleep apnea. Document the",
"effectiveness of your treatment. If in doubt about the diagnosis or",
"treatment, consult a sleep disorders specialist.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        Assess the risk of",
"impaired driving in any patient with sleep apnea. The risk of a crash",
"is increased if the patient has had any recent accidents or multiple",
"\"near miss\" incidents while driving, if the patient's sleep apnea is",
"severe, or if there is other documented evidence of severe sleepiness",
"or impaired driving performance.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        Warn any patient with",
"sleep apnea that driving while sleepy is very dangerous. Depending on",
"the severity of the patient's condition and other risk factors,",
"additional counseling should be undertaken, including the exploration",
"of alternatives to driving. It is advisable to put the warning and any",
"specific clinical recommendations in writing. This reinforces the",
"seriousness of the warning in the patient's mind and reduces the risk",
"of legal liability.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        If a severely sleepy",
"driver with sleep apnea presents a clear danger of impaired driving,",
"the name of the patient should be reported to the appropriate state",
"authority. Reporting is strongly advisable, both to provide good",
"clinical care and to reduce legal risk, if a sleepy patient has had any",
"motor vehicular crashes due to falling asleep, or if the patient is a",
"driver of a bus or truck or is otherwise occupationally responsible for",
"driving. (As noted above, however, an attorney should be consulted",
"before any report is made to assure that the disclosure is legally",
"permissible in the particular state). A diagnosis of sleep apnea,",
"without any additional risk factors, would not ordinarily warrant such",
"a report, unless the law of the particular state requires one.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Findley L, Levinson M, Bonnie R, Clin Chest Med 1992; 13:427.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_29_20956=[""].join("\n");
var outline_f20_29_20956=null;
var title_f20_29_20957="Immunologic sys drug rxns";
var content_f20_29_20957=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F77196&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F77196&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comparison of systemic immunologic drug reactions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"6\" width=\"16%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Type of immunologic drug reaction",
"       </td>",
"       <td class=\"subtitle1\">",
"        Incidence",
"       </td>",
"       <td class=\"subtitle1\">",
"        Signs and symptoms",
"       </td>",
"       <td class=\"subtitle1\">",
"        Timing",
"       </td>",
"       <td class=\"subtitle1\">",
"        Common culprit drugs",
"       </td>",
"       <td class=\"subtitle1\">",
"        Diagnostic testing available?",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <p>",
"         IgE, mast cell and basophil mediated",
"        </p>",
"        <p>",
"         Type I Gell and Coombs",
"        </p>",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"       <td>",
"        Urticaria/angioedema, bronchospasm, laryngeal edema, nausea, vomiting, hypotension, shock",
"       </td>",
"       <td>",
"        <p>",
"         Immediate: Seconds to 1 hour after last dose",
"        </p>",
"        <p>",
"         May be slightly more delayed if drug slowly absorbed",
"        </p>",
"        <p>",
"         Faster and more severe upon re-exposure",
"        </p>",
"       </td>",
"       <td>",
"        Beta-lactam antibiotics (penicillins and cephalosporins), muscle relaxants, foreign proteins (eg, cetuximab, rituximab), platinum-based chemotherapy (eg, carboplatin, cisplatin)",
"       </td>",
"       <td>",
"        <p>",
"         YES",
"        </p>",
"        <p>",
"         At time of reaction: Serum tryptase",
"        </p>",
"        <p>",
"         Later: Skin prick and intradermal testing",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <p>",
"         Antibody-mediated (IgG and IgM) cell destruction",
"        </p>",
"        <p>",
"         Type II Gell and Coombs",
"        </p>",
"       </td>",
"       <td>",
"        Uncommon",
"       </td>",
"       <td>",
"        <p>",
"         Hemolytic anemia",
"        </p>",
"        <p>",
"         Thrombocytopenia",
"        </p>",
"        <p>",
"         Neutropenia or agranulocytosis",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Delayed: Days to weeks after beginning therapy",
"        </p>",
"        <p>",
"         May occur months into long-term treatments",
"        </p>",
"        <p>",
"         Faster upon re-exposure",
"        </p>",
"       </td>",
"       <td>",
"        Beta-lactam antibiotics, NSAIDs, quinidine, methyldopa, ticlopidine",
"       </td>",
"       <td>",
"        <p>",
"         YES",
"        </p>",
"        <p>",
"         Direct Coombs",
"        </p>",
"        <p>",
"         Tests for anti-platelet antibodies",
"        </p>",
"        <p>",
"         Tests for anti-neutrophil antibodies",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <p>",
"         Immune complex-mediated tissue damage",
"        </p>",
"        <p>",
"         Type III Gell and Coombs",
"        </p>",
"       </td>",
"       <td>",
"        Uncommon",
"       </td>",
"       <td>",
"        <p>",
"         Serum sickness, serum-sickness like reactions",
"        </p>",
"        <p>",
"         Vasculitis (eg, cutaneous)",
"        </p>",
"        <p>",
"         Drug fever",
"        </p>",
"        <p>",
"         Acute glomerulonephritis",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Delayed: Weeks to months after beginning therapy",
"        </p>",
"        <p>",
"         Faster on re-exposure",
"        </p>",
"       </td>",
"       <td>",
"        Beta-lactam antibiotics, sulfonamide antibiotics, sirolimus/tacrolimus",
"       </td>",
"       <td>",
"        <p>",
"         No direct diagnostic testing available. Diagnosis is based on patterns of clinical and laboratory findings.",
"        </p>",
"        <p>",
"         Biopsy of affected tissue is sometimes helpful",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <p>",
"         Mediated by T cells",
"        </p>",
"        <p>",
"         +/- other cell types (esp eosinophils, neutrophils)",
"        </p>",
"        <p>",
"         Type IV Gell and Coombs",
"        </p>",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"       <td>",
"        <p>",
"         Prominent skin findings +/- other organ involvement: Exanthematous (morbilliform) eruption",
"        </p>",
"        <p>",
"         DRESS/DiHS",
"        </p>",
"        <p>",
"         Acute generalized exanthematous pustulosis (AGEP)",
"        </p>",
"        <p>",
"         Exfoliative dermatoses (SJS/TEN)",
"        </p>",
"       </td>",
"       <td>",
"        Delayed at least 24 to 48 hours after beginning therapy and may begin weeks to months after treatment began",
"       </td>",
"       <td>",
"        Beta-lactam antibiotics, sulfonamide antibiotics and sulfasalazine, minocycline, phenytoin, carbamazepine, lamotrigine, allopurinol, abacavir, nevirapine",
"       </td>",
"       <td>",
"        <p>",
"         VARIABLE",
"        </p>",
"        <p>",
"         Although testing is not standardized and is considered investigational in most cases, some centers perform skin and in vitro testing for type IV reactions. For example, DiHS/DRESS reactions can be evaluated with in vitro lymphocyte activation, and tests have good specificity.",
"        </p>",
"        <p>",
"         ANY form of re-exposure to the culprit drug is CONTRAINDICATED in patients with past severe or exfoliative reactions, including DRESS/DiHS and SJS/TEN",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unclassified",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         Drug-induced lupus",
"        </p>",
"        <p>",
"         Fixed drug eruption",
"        </p>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Patch testing at affected area may be useful in fixed drug eruption",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     DRESS/DiHS: drug rash with eosinophilia and systemic symptoms/drug-induced hypersensitivity syndrome.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_29_20957=[""].join("\n");
var outline_f20_29_20957=null;
var title_f20_29_20958="Laser coagulation TTTS";
var content_f20_29_20958=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/64395/ttts_conv.mp4?title=Laser+coagulation+TTTS\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Laser coagulation twin-twin transfusion syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_29_20958=[""].join("\n");
var outline_f20_29_20958=null;
var title_f20_29_20959="Elastic tape method";
var content_f20_29_20959=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F56186&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F56186&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Elastic tape (or string wrap) method",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 307px; height: 243px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Apply a blood pressure cuff to the affected extremity and inflate it to the patient's systolic blood pressure plus 100 mmHg. Tightly wrap a Penrose drain or 1 inch elastic band (eg, intravenous tourniquet) from the tip of the digit proximally and elevate the extremity above the heart for 15 minutes. Assess for reduction of edema and reapply the elastic wrap, if necessary. Keep the blood pressure cuff inflated while attempting manual removal. Total tourniquet time should not exceed two hours.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fuchs SM. Ring removal. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_29_20959=[""].join("\n");
var outline_f20_29_20959=null;
